St. Jude Medical (STJ) Inactive 10-K26 Feb 142013 FY Annual reportFinancial data

Company Profile

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
In Billions, except Share data, unless otherwise specified	Dec. 28, 2013	Feb. 21, 2014	Jun. 28, 2013
Document And Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	28-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Entity Registrant Name	'ST JUDE MEDICAL INC	'	'
Entity Central Index Key	'0000203077	'	'
Current Fiscal Year End Date	'--12-28	'	'
Entity Filer Category	'Large Accelerated Filer	'	'
Entity Common Stock, Shares Outstanding	'	283,804,872	'
Entity Voluntary Filers	'No	'	'
Entity Public Float	'	'	$13
Entity Well-known Seasoned Issuer	'Yes	'	'
Entity Current Reporting Status	'Yes	'	'

Consolidated_Statements_Of_Ear

Consolidated Statements Of Earnings (USD $)	12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Income Statement [Abstract]	'	'	'
Net sales	$5,501	$5,503	$5,612
Cost of sales:	'	'	'
Cost of sales before special charges	1,529	1,445	1,486
Special charges	45	93	47
Total cost of sales	1,574	1,538	1,533
Gross profit	3,927	3,965	4,079
Selling, general and administrative expense	1,884	1,891	2,084
Research and development expense	691	676	705
Purchased in-process research and development charges	0	0	4
Special charges	301	298	171
Operating profit	1,051	1,100	1,115
Other expense, net	267	95	96
Earnings before income taxes and noncontrolling interest	784	1,005	1,019
Income tax expense	92	253	193
Net earnings before noncontrolling interest	692	752	826
Net loss attributable to noncontrolling interest	-31	0	0
Net earnings attributable to St. Jude Medical, Inc.	$723	$752	$826
Net earnings per share attributable to St. Jude Medical, Inc.:	'	'	'
Basic net earnings per share	$2.52	$2.40	$2.55
Diluted net earnings per share	$2.49	$2.39	$2.52
Cash dividends declared per share:	$1	$0.92	$0.84
Weighted average shares outstanding:	'	'	'
Basic	287	313.3	324.3
Diluted	290.6	314.8	327.1

Consolidated_Statements_Of_Com

Consolidated Statements Of Comprehensive Income (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Statement of Comprehensive Income [Abstract]	'	'	'
Net earnings before noncontrolling interest	$692	$752	$826
Other comprehensive income (loss), net of tax:	'	'	'
Unrealized gain on available-for-sale securities, net of taxes of $2 million, $1 million and $2 million, respectively	5	10	3
Reclassification of realized gain on available-for-sale securities, net of taxes of $5 million and $6 million, respectively	-8	-8	0
Unrealized gain on derivative financial instruments, net of taxes	3	0	0
Foreign currency translation adjustment, net of taxes	0	28	-71
Other comprehensive income (loss)	0	30	-68
Total comprehensive income before noncontrolling interest	692	782	758
Total comprehensive loss attributable to noncontrolling interest	-31	0	0
Total comprehensive income attributable to St. Jude Medical, Inc.	$723	$782	$758

Consolidated_Statements_Of_Com1

Consolidated Statements Of Comprehensive Income (Parentheticals) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Statement of Comprehensive Income [Abstract]	'	'	'
Unrealized gain on available-for-sale securities, taxes	$2	$1	$2
Reclassification of realized gain on available-for-sale securities, taxes	5	6	0
Unrealized gain on derivative financial instruments, taxes	$0	$0	$0

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 28, 2013	Dec. 29, 2012
In Millions, unless otherwise specified	Dec. 28, 2013	Dec. 29, 2012
ASSETS	'	'
Cash and cash equivalents	$1,373	$1,194
Accounts receivable, less allowance for doubtful accounts	1,422	1,349
Inventories	708	610
Deferred income taxes, net	229	220
Other current assets	178	178
Total current assets	3,910	3,551
Land, buildings and improvements	651	602
Machinery and equipment	1,674	1,603
Diagnostic equipment	474	424
Property, plant and equipment at cost	2,799	2,629
Less accumulated depreciation	-1,389	-1,204
Net property, plant and equipment	1,410	1,425
Goodwill	3,524	2,961
Intangible assets, net	911	804
Deferred income taxes, net	116	130
Other assets	377	400
TOTAL ASSETS	10,248	9,271
LIABILITIES AND SHAREHOLDERS' EQUITY	'	'
Current debt obligations	62	530
Accounts payable	247	254
Dividends payable	72	68
Income taxes payable	32	142
Employee compensation and related benefits	312	299
Other current liabilities	655	482
Total current liabilities	1,380	1,775
Long-term debt	3,518	2,550
Deferred income taxes, net	240	323
Other liabilities	706	529
Total liabilities	5,844	5,177
Commitments and Contingencies (Note 5)	0	0
Shareholders' Equity	'	'
Preferred stock ($1.00 par value, 25,000,000 shares authorized; none outstanding)	0	0
Common stock ($0.10 par value; 500,000,000 shares authorized; 289,117,352 and 295,648,327 shares issued and outstanding at December 28, 2013 and December 29, 2012, respectively)	29	30
Additional paid-in capital	220	0
Retained earnings	3,936	4,018
Accumulated Other Comprehensive Income	46	46
Total shareholders' equity before noncontrolling interest	4,231	4,094
Noncontrolling Interest	173	0
Total shareholders' equity	4,404	4,094
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$10,248	$9,271

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 28, 2013	Dec. 29, 2012
In Millions, except Share data, unless otherwise specified	Dec. 28, 2013	Dec. 29, 2012
Statement of Financial Position [Abstract]	'	'
Accounts receivable, less allowance for doubtful accounts	$45	$47
Preferred stock, par value	$1	$1
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred Stock, Shares Outstanding	0	0
Common stock, par value	$0.10	$0.10
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	289,117,352	295,648,327
Common stock, shares outstanding	289,117,352	295,648,327

Consolidated_Statements_of_Sha

Consolidated Statements of Shareholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Noncontrolling Interest [Member]
In Millions, except Share data, unless otherwise specified	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Noncontrolling Interest [Member]
Balance at Jan. 01, 2011	$4,372	$33	$156	$4,099	$84	$0
Balance, shares at Jan. 01, 2011	'	329,018,166	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Net earnings	826	'	'	826	'	0
Other comprehensive income (loss)	-68	'	'	'	-68	0
Cash dividends declared	-272	'	'	-272	'	'
Repurchases of commmon stock, shares	'	-18,314,774	'	'	'	'
Repurchases of common stock, value	-775	-2	-504	-269	'	'
Stock-based compensation	76	'	76	'	'	'
Common stock issued under stock plans and other, net - shares	'	8,912,573	'	'	'	'
Common stock issued under stock plans and other, net - value	303	1	302	'	'	'
Tax benefit (shortfall) from stock plans	13	'	13	'	'	'
Balance at Dec. 31, 2011	4,475	32	43	4,384	16	0
Balance, shares at Dec. 31, 2011	'	319,615,965	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Net earnings	752	'	'	752	'	0
Other comprehensive income (loss)	30	'	'	'	30	0
Cash dividends declared	-284	'	'	-284	'	'
Repurchases of commmon stock, shares	'	-27,670,874	'	'	'	'
Repurchases of common stock, value	-1,058	-3	-221	-834	'	'
Stock-based compensation	69	'	69	'	'	'
Common stock issued under stock plans and other, net - shares	'	3,703,236	'	'	'	'
Common stock issued under stock plans and other, net - value	119	1	118	'	'	'
Tax benefit (shortfall) from stock plans	-9	'	-9	'	'	'
Balance at Dec. 29, 2012	4,094	30	0	4,018	46	0
Balance, shares at Dec. 29, 2012	295,648,327	295,648,327	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Net earnings	692	'	'	723	'	-31
Other comprehensive income (loss)	0	'	'	'	'	0
Cash dividends declared	-286	'	'	-286	'	'
Repurchases of commmon stock, shares	'	-18,385,436	'	'	'	'
Repurchases of common stock, value	-808	-2	-287	-519	'	'
Stock-based compensation	65	'	65	'	'	'
Common stock issued under stock plans and other, net - shares	'	11,854,461	'	'	'	'
Common stock issued under stock plans and other, net - value	443	1	442	'	'	'
Additions in noncontrolling ownership interests	204	'	'	'	'	204
Balance at Dec. 28, 2013	$4,404	$29	$220	$3,936	$46	$173
Balance, shares at Dec. 28, 2013	289,117,352	289,117,352	'	'	'	'

Consolidated_Statements_Of_Cas

Consolidated Statements Of Cash Flows (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
OPERATING ACTIVITIES	'	'	'
Net earnings	$692	$752	$826
Adjustments to reconcile net earnings to net cash from operating activities:	'	'	'
Depreciation and amortization	297	284	296
Amortization of debt premium, net	-6	-11	-5
Inventory step-up amortization	4	0	30
Contingent consideration fair value adjustment, net	1	0	0
Stock-based compensation	65	69	76
Excess tax benefits from stock-based compensation	-15	-1	-9
Gain on sale of investment	-13	-14	0
Loss on retirement of long-term debt	161	0	0
Purchased in-process research and development charges	0	0	4
Deferred income taxes	-124	-77	-65
Other, net	75	106	78
Changes in operating assets and liabilities, net of business acquisitions:	'	'	'
Accounts receivable	-100	13	-55
Inventories	-99	13	10
Other current assets	13	4	48
Accounts payable and accrued expenses	31	29	39
Income taxes payable	-21	168	14
Net cash provided by operating activities	961	1,335	1,287
INVESTING ACTIVITIES	'	'	'
Purchases of property, plant and equipment	-222	-280	-307
Business acquisition payments, net of cash acquired	-292	0	0
Proceeds from sale of investments	10	19	0
Other investing activities, net	-18	-52	-30
Net cash used in investing activities	-522	-313	-337
FINANCING ACTIVITIES	'	'	'
Proceeds from exercise of stock options and stock issued, net	443	119	302
Excess tax benefits from stock issued under employee stock plans	15	1	9
Common stock repurchased, including related costs	-833	-992	-809
Dividends paid	-282	-284	-205
Issuances (payments) of commercial paper borrowings, net	121	321	247
Borrowings under debt facilities	2,092	0	78
Payments under debt facilities	-1,659	0	-78
Other financing activities, net	-154	22	0
Net cash used in financing activities	-257	-813	-456
Effect of currency exchange rate changes on cash and cash equivalents	-3	-1	-8
Net increase in cash and cash equivalents	179	208	486
Cash and cash equivalents at beginning of period	1,194	986	500
Cash and cash equivalents at end of period	1,373	1,194	986
Supplemental Cash Flow Information	'	'	'
Income Taxes Paid	246	177	203
Interest Paid	95	69	68
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]	'	'	'
Additions in noncontrolling ownership interests	204	0	0
Fair value of acquisition contingent consideration	$188	$0	$0

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 28, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Company Overview: St. Jude Medical, Inc., together with its subsidiaries (St. Jude Medical or the Company) develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas and implantable neurostimulation devices for the management of chronic pain. On August 30, 2012, the Company announced the realignment of its product divisions into two new business units (or divisions): the Implantable Electronic Systems Division (combining its legacy Cardiac Rhythm Management and Neuromodulation product divisions) and the Cardiovascular and Ablation Technologies Division (combining its legacy Cardiovascular and Atrial Fibrillation product divisions). In addition, the Company centralized certain support functions, including information technology, human resources, legal, business development and certain marketing functions. The organizational changes were part of a comprehensive plan to accelerate its growth, reduce costs and leverage economies of scale. The Company began reporting under the new organizational structure as of the beginning of fiscal year 2013.
	The Company's principal products in each division are as follows: Implantable Electronic Systems Division (IESD) – tachycardia implantable cardioverter defibrillator systems (ICDs), bradycardia pacemaker systems (pacemakers) and neurostimulation products (spinal cord and deep brain stimulation devices); and Cardiovascular and Ablation Technologies Division (CATD) – vascular products (vascular closure products, pressure measurement guidewires, optical coherence tomography (OCT) imaging products, vascular plugs and other vascular accessories), structural heart products (heart valve replacement and repair products and structural heart defect devices) and atrial fibrillation (AF) products (EP introducers and catheters, advanced cardiac mapping, navigation and recording systems and ablation systems). The Company markets and sells its products primarily through a direct sales force. The principal geographic markets for the Company's products are the United States, Europe, Japan and Asia Pacific.
	On January 28, 2014, the Company announced further organizational changes to combine its IESD and CATD operating divisions, resulting in an integrated research and development organization and a consolidation of manufacturing and supply chain operations worldwide. The integration will be conducted in a phased approach throughout 2014. The Company's continuing global restructuring efforts are focused on streamlining its organization to improve productivity, reduce costs and leverage its scale to drive additional growth. The Company will continue to report under the existing reportable segment structure for internal management financial forecasting and reporting purposes into fiscal year 2014 until the organizational changes and the related financial reporting structure is finalized.
	Principles of Consolidation: The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries and entities for which St. Jude Medical has a controlling financial interest. Intercompany transactions and balances have been eliminated in consolidation. For variable interest entities (VIEs), the Company assesses the terms of its interest in the entity to determine if St. Jude Medical is the primary beneficiary. Variable interests are ownership, contractual or other interests in an entity that change with increases or decreases in the fair value of the VIE's net assets exclusive of variable interests. The entity that consolidates the VIE is considered the primary beneficiary, and is defined as the party with (1) the power to direct activities of the VIE that most significantly affect the VIE's economic performance and (2) the obligation to absorb losses of the VIE or the right to receive benefits from the VIE. In the first quarter of 2013, the Company determined that CardioMEMS, Inc. (CardioMEMS) was a VIE for which the Company is the primary beneficiary and began consolidating their results effective February 27, 2013. Additionally, during the second quarter of 2013, the Company entered into a $40 million equity investment, contingent acquisition agreement and exclusive distribution agreement with Spinal Modulation, Inc. (Spinal Modulation) and determined it also was a VIE for which the Company is the primary beneficiary. The Company began consolidating Spinal Modulation's results effective June 7, 2013 (see Note 2).
	Fiscal Year: The Company utilizes a 52/53-week fiscal year ending on the Saturday nearest December 31st. Fiscal year 2013, 2012 and 2011 consisted of 52 weeks and ended on December 28, 2013, December 29, 2012 and December 31, 2011, respectively.
	Reclassifications: Certain prior period amounts have been reclassified to conform to current year presentation (see Note 15).
	Use of Estimates: Preparation of the Company's consolidated financial statements in conformity with accounting principles generally accepted in the United States (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.
	Cash Equivalents: The Company considers highly liquid investments with an original maturity of three months or less to be cash equivalents. Cash equivalents are stated at cost, which approximates fair value. The Company's cash equivalents include bank certificates of deposit, money market funds and instruments and commercial paper investments. The Company performs periodic evaluations of the relative credit standing of the financial institutions and issuers of its cash equivalents and limits the amount of credit exposure with any one issuer.
	Marketable Securities: Marketable securities consist of publicly-traded equity securities that are classified as available-for-sale securities and investments in mutual funds that are classified as trading securities. On the balance sheet, available-for-sale securities and trading securities are classified as other current assets and other assets, respectively.
	The following table summarizes the components of the balance of the Company's available-for-sale securities at December 28, 2013 and December 29, 2012 (in millions):


		December 28, 2013				December 29, 2012
	Adjusted cost	$	7			$	9

	Gross unrealized gains	28				32

	Fair value	$	35			$	41


	Available-for-sale securities are reported at fair value based upon quoted market prices (see Note 13). Unrealized gains and losses, net of related incomes taxes, are recognized in accumulated other comprehensive income in shareholders' equity. Upon the sale of an available-for-sale security, the unrealized gain (loss) is reclassified out of accumulated other comprehensive income and reflected as a realized gain (loss) in net earnings. Realized gains (losses) are computed using the specific identification method and recognized as other expense, net. During both 2013 and 2012, the Company sold available-for-sale securities, recognizing pre-tax gains of $13 million and $14 million, respectively (see Note 10). There were no realized gains (losses) from the sale of available-for-sale securities recorded during fiscal year 2011. Additionally, when the fair value of an available-for-sale security falls below its original cost and the Company determines that the corresponding unrealized loss is other-than-temporary, it recognizes an impairment loss to net earnings in that period. There were no available-for-sale impairment losses recognized in fiscal years 2013, 2012 or 2011.

	The Company's investments in mutual funds are reported at fair market value based upon quoted market prices (see Note 13) and are held in a rabbi trust, which is not available for general corporate purposes and is subject to creditor claims in the event of insolvency. These investments are specifically designated as available to the Company solely for the purpose of paying benefits under the Company's deferred compensation plan (see Note 12).
	Accounts Receivable: The Company grants credit to customers in the normal course of business, but generally does not require collateral or any other security to support its receivables. The Company maintains an allowance for doubtful accounts for potential credit losses. During 2013, the Company recognized a $9 million accounts receivable allowance charge in connection with a distributor termination in Europe. During 2011, the Company recognized a $57 million accounts receivable allowance charge with a distributor in the Greece market. In February 2012, an agreement was reached between the Greek government and the European Union and International Monetary Fund whereby creditors would swap existing Greek government bonds for new bonds with a significant reduction in face value, a longer term and lower interest rates. This agreement, among other macroeconomic and factors specific to the distributor, negatively impacted the solvency and liquidity of the Company's Greece distributor, raising significant doubt regarding the collectability of the Company's outstanding receivable balance. As a result, the Company recognized the $57 million accounts receivable allowance charge in the consolidated financial statements for the fiscal year ended December 31, 2011, which was subsequently written off during 2012. The Company also recognized an additional $9 million accounts receivable allowance charge in 2011 for increased collection risk associated with a customer in Europe. No significant accounts receivable allowance charges were recognized in 2012. The Company's total allowance for doubtful accounts was $45 million and $47 million at December 28, 2013 and December 29, 2012, respectively.
	Inventories: Inventories are stated at the lower of cost or market with cost determined using the first-in, first-out method. Inventories consisted of the following (in millions):



		December 28, 2013				December 29, 2012
	Finished goods	$	494			$	416

	Work in process	52				50

	Raw materials	162				144

		$	708			$	610


	Property, Plant and Equipment: Property, plant and equipment are recorded at cost and are depreciated using the straight-line method over their estimated useful lives, ranging from 15 years to 39 years for buildings and improvements, three to 15 years for machinery and equipment, including capitalized development costs for internal-use software, and three to seven years for diagnostic equipment. Diagnostic equipment primarily consists of programmers that are used by physicians and healthcare professionals to program and analyze data from ICDs and pacemakers. Diagnostic equipment also includes other capital equipment provided by us to customers for use in diagnostic and surgical procedures. The estimated useful lives of this equipment are based on anticipated usage by physicians and healthcare professionals and the timing and impact of expected new technology platforms and rollouts by the Company. Property, plant and equipment are depreciated using accelerated methods for income tax purposes. During 2013, 2012 and 2011, depreciation expense was $218 million, $196 million, and $203 million, respectively.
	Goodwill: Goodwill represents the excess of cost over the fair value of identifiable net assets of a business acquired. Goodwill for each reporting unit is reviewed for impairment at least annually. The Company assesses goodwill impairment by considering qualitative factors such as macroeconomic conditions, industry and market considerations, cost factors, financial performance, entity specific events, changes in net assets and sustained decrease in share price. If the qualitative assessment results in a determination that the fair value of a reporting unit is more-likely-than-not ("likely" meaning having a likelihood of more than 50%) greater than its carrying amount, no additional testing is considered necessary. However, if the Company determines the fair value is more-likely-than-not below the carrying value of a reporting unit, the Company performs the two-step goodwill impairment test required by the Financial Accounting Standards Board's (FASB) Accounting Standards Codification (ASC) Topic 350, Intangibles - Goodwill and Other. In the first step, the Company compares the fair value of each reporting unit, as computed primarily by present value cash flow calculations, to its book carrying value, including goodwill. If the carrying value exceeds the fair value, the goodwill of the reporting unit is potentially impaired and the Company would complete step 2 in order to measure the potential impairment loss. In step 2, the Company calculates the implied fair value of goodwill by deducting the fair value of all tangible and intangible net assets (including unrecognized intangible assets) of the reporting unit from the fair value of the reporting unit (as determined in step 1). If the implied fair value of goodwill is less than the carrying value of goodwill, the Company would recognize an impairment loss equal to the difference. During the fourth quarters of 2013, 2012 and 2011, the Company concluded that it was more-likely-than-not that the fair value was more than its carry value based on its qualitative assessment.
	Other Intangible Assets: Other intangible assets consist of purchased technology and patents, in-process research and development (IPR&D) acquired in a business acquisition, customer lists and relationships, trademarks and tradenames, licenses and distribution agreements. Definite-lived intangible assets are amortized on a straight-line basis over the estimated useful life ranging from three to 20 years. Certain trademark assets are considered indefinite-lived intangible assets and are not amortized.
	The Company's policy defines IPR&D as the value of technology acquired for which the related products have not yet reached technological feasibility and have no future alternative use. The primary basis for determining the technological feasibility of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. IPR&D acquired in a business acquisition is subject to ASC Topic 805, Business Combinations (ASC Topic 805), which requires the fair value of IPR&D to be capitalized as an indefinite-lived intangible asset until completion of the IPR&D project or abandonment. Upon completion of the development project (generally when regulatory approval to market the product is obtained), the IPR&D is amortized over its estimated useful life. If the IPR&D projects are abandoned, the related IPR&D assets would likely be impaired and written down to fair value. The purchase of certain intellectual property assets relate to technology or products without regulatory approval is considered a purchase of assets rather than the acquisition of a business. For such purchases, rather than being capitalized, any IPR&D acquired in such asset purchases is expensed immediately.
	The Company also reviews its indefinite-lived intangible assets for impairment regularly to determine if any adverse conditions exist that would indicate impairment or when impairment indicators exist. The Company assesses its indefinite-lived intangible assets for impairment similar to goodwill by considering qualitative factors such as macroeconomic conditions, industry and market considerations, cost factors, financial performance, entity specific events and project-based performance toward regulatory approvals. Similar to the goodwill impairment analysis, if the qualitative assessment results in a determination that the fair value of an indefinite-lived intangible asset is more-likely-than-not ("likely" meaning having a likelihood of more than 50%) greater than its carrying amount, no additional testing is considered necessary. However, if the Company determines the fair value of its indefinite-lived intangible assets is more-likely-than-not below the carrying value, impairment indicators exist. During 2013, the Company performed a qualitative assessment of its indefinite-lived intangible assets by considering many of the above factors and subsequently determined that a quantitative impairment analysis was further necessary for certain CATD indefinite-lived tradename and IPR&D assets. The Company utilized a discounted cash flow model for each individual asset level under scrutiny and recognized an impairment charge of $29 million to write-down the related assets to fair value. The impairments were due primarily to the Company's revised expectations, including an increase in the cost and length of time to bring the related products to market through U.S. regulatory approval. The Company recognized no impairment charges on its indefinite-lived intangible assets during fiscal year 2012 or 2011.
	The Company also reviews its definite-lived intangible assets for impairment when impairment indicators exist. When impairment indicators exist, the Company determines if the carrying value of its definite-lived intangible assets exceeds the related undiscounted future cash flows. In cases where the carrying value exceeds the undiscounted cash flows, the carrying value is written down to fair value, which the Company determines using present value cash flow calculations. During 2012, the Company recognized impairment charges of $31 million associated with purchased technology assets in the Company's IESD and CATD segments, as their future expected discounted cash flows did not exceed the carrying value of the related assets. Additionally, during 2013, 2012 and 2011, the Company recognized $13 million, $2 million and $52 million, respectively, of intangible asset impairments primarily associated with customer relationship intangible assets acquired in connection with legacy acquisitions of businesses involved in the distribution of the Company's products. Due to the changing dynamics of the U.S. healthcare market, specifically as it relates to hospital purchasing practices, these intangible assets were determined to have no future discrete cash flows and were fully impaired in the respective periods. See Note 9 for further detail regarding the intangible asset impairments recognized during fiscal years 2013, 2012 and 2011.
	Contingent Consideration: In connection with certain business combinations or purchases of intellectual property the Company may agree to provide future contingent consideration payments. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels, achieving product development targets or receiving regulatory approvals to market products. Contingent consideration is recognized on the acquisition date at the estimated fair value of the contingent milestone payment(s). The acquisition date fair value is measured based on the consideration expected to be transferred (probability-weighted), discounted back to present value. The discount rate used is determined at the time of measurement in accordance with accepted valuation methods. The fair value of the contingent consideration is remeasured to its estimated fair value at each reporting period with the change in fair value recognized in selling, general and administrative expense in the Company's Consolidated Statements of Earnings.
	Product Warranties: The Company offers a warranty on various products, the most significant of which relate to pacemaker and ICD systems. The Company estimates the costs it expects to incur under its warranties and records a liability for such costs at the time the product is sold. Factors that affect the Company's warranty liability include the number of units sold, historical and anticipated rates of warranty claims and cost per claim. The Company regularly assesses the adequacy of its warranty liabilities and adjusts the amounts as necessary.

	Changes in the Company's product warranty liability during fiscal years 2013 and 2012 were as follows (in millions):


		2013				2012
	Balance at beginning of period	$	38			$	36

	Warranty expense recognized	3				5

	Warranty credits issued	(4		)		(3		)
	Balance at end of period	$	37			$	38


	Product Liability: Based on historical loss trends and anticipated loss on products sold, the Company accrues for product liability claims through its self-insurance program in effort to adequately cover future losses. Additionally, the Company accrues for product liability claims when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Receivables for insurance recoveries from prior product liability insurance coverage are recognized when it is probable that a recovery will be realized. We are currently the subject of product liability litigation proceedings and other proceedings described in more detail at Note 5.

	Litigation: The Company accrues a liability for costs related to litigation, including future legal costs, settlements and judgments where it has assessed that such costs are probable and an amount can be reasonably estimated.
Revenue Recognition: The Company sells its products to hospitals primarily through a direct sales force. In certain international markets, the Company sells its products through independent distributors. The Company recognizes revenue when persuasive evidence of a sales arrangement exists, delivery of goods occurs through the transfer of title and risks and rewards of ownership, the selling price is fixed or determinable and collectability is reasonably assured. A portion of the Company's inventory is held by field sales representatives or consigned at hospitals. For such product inventory, revenue is recognized at the time the Company is notified that the inventory has been implanted or used by the customer. For products that are not consigned, revenue recognition occurs upon shipment to the hospital or, in the case of distributors, when title transfers under the contract assuming all other revenue recognition criteria are met. The Company offers sales rebates and discounts to certain customers. The Company records such rebates and discounts as a reduction of net sales in the same period revenue is recognized. The Company estimates rebates based on customers' contracted terms and historical sales experience.
Excise Taxes: The Company incurs certain excise taxes in the distribution of its products, including a medical device excise tax assessed on U.S sales and an excise tax assessed on purchases from the Company's Puerto Rico manufacturing subsidiary. The U.S. medical device excise tax is imposed on the first sale in the U.S. by the manufacturer, producer or importer of a medical device to either a third party or an affiliated distribution entity. The Company capitalizes the assessment of these excise taxes as part of inventory, which is then recognized as cost of sales when the related inventory is sold to a third party customer.
Research and Development: Research and development costs are expensed as incurred. Research and development costs include costs of all basic research activities, including engineering and technical effort required to develop a new product or make significant improvements to an existing product or manufacturing process. Research and development costs also include pre-approval regulatory costs and clinical research expenses.
Stock-Based Compensation: The Company accounts for stock-based compensation in accordance with ASC Topic 718, Compensation - Stock Compensation (ASC Topic 718). Under the fair value recognition provisions of ASC Topic 718, the Company measures stock-based compensation cost at the grant date fair value and recognizes the compensation expense over the requisite service period, which is the vesting period, using a straight-line attribution method.
The amount of stock-based compensation expense recognized during a period is based on the portion of the awards that are ultimately expected to vest. The Company estimates pre-vesting award forfeitures at the time of grant by analyzing historical data and revises those estimates in subsequent periods if actual forfeitures differ from those estimates. Ultimately, the total expense recognized over the vesting period will only be for those awards that vest. The Company's awards are not eligible to vest early in the event of retirement, however, the majority of the Company's awards vest early in the event of a change in control. See Note 8 for further detail on the Company's stock compensation plans.
Net Earnings Per Share Attributable to St. Jude Medical, Inc.: Basic net earnings per share is computed by dividing net earnings by the weighted average number of outstanding common shares during the period, exclusive of dilutive securities. Diluted net earnings per share is computed by dividing net earnings by the weighted average number of outstanding common shares and dilutive securities.
The following table sets forth the computation of basic and diluted net earnings per share for fiscal years 2013, 2012 and 2011 (in millions, except per share amounts):


	2013				2012				2011
Numerator:

Net earnings attributable to St. Jude Medical, Inc.	$	723			$	752			$	826

Denominator:

Basic weighted average shares outstanding	287				313.3				324.3

Effect of dilutive securities:

Stock options	3.2				1.3				2.6

Restricted stock units	0.4				0.2				0.2

Diluted weighted average shares outstanding	290.6				314.8				327.1

Basic net earnings per share	$	2.52			$	2.4			$	2.55

Diluted net earnings per share	$	2.49			$	2.39			$	2.52

Approximately 4.8 million, 18.9 million and 11.5 million shares of common stock subject to stock options and restricted stock units were excluded from the diluted net earnings per share computation because they were not dilutive during fiscal years 2013, 2012 and 2011, respectively.
Foreign Currency Translation: Sales and expenses denominated in foreign currencies are translated at average exchange rates in effect throughout the year. Assets and liabilities of foreign operations are translated at period-end exchange rates with the impacts of foreign currency translation recognized to cumulative translation adjustment, a component of accumulated other comprehensive income (loss). Foreign currency transaction gains and losses are included in other expense, net.
Derivative Financial Instruments: The Company follows the provisions of ASC Topic 815, Derivatives and Hedging (ASC Topic 815) to account for its derivative instruments and hedging activities. ASC Topic 815 requires all derivative financial instruments to be recognized on the balance sheet at fair value. Changes in the fair value of derivatives are recognized in net earnings or other comprehensive income depending on whether the derivative is designated as part of a qualifying hedge transaction.
The Company uses forward contracts to manage foreign currency exposures primarily related to intercompany receivables and payables arising from intercompany purchases of manufactured products. These forward contracts are not designated as qualifying hedges and therefore, the changes in the fair values of these derivatives are recognized in net earnings and classified in other expense, net. The gains and losses on these forward contracts largely offset the losses or gains on the foreign currency exposures being managed. See Note 14 for further detail on the Company's use of its derivative financial instruments.
New Accounting Pronouncements: In February 2013, the FASB issued Accounting Standards Update (ASU) 2013-02: Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (ASU 2013-02), an update to Comprehensive Income (Topic 220). ASU 2013-02 requires an entity to present either on the face of the statement where net income is presented or in the notes to the financial statements, significant amounts reclassified out of accumulated other comprehensive income by the respective line items in the statement presenting net income. Additionally, disclosures about the changes in each component of accumulated other comprehensive income are also required. ASU 2013-02 requires prospective application and is effective for all fiscal years and interim periods beginning after December 15, 2012. The Company adopted ASU 2013-02 in the first quarter of 2013 and includes the required disclosures in Note 7.

Business_Combinations

Business Combinations	12 Months Ended
	Dec. 28, 2013
Business Combinations [Abstract]	'
Business Combination Disclosure [Text Block]	'
	BUSINESS COMBINATIONS
	Endosense S.A.: On August 19, 2013, the Company acquired all the outstanding shares of Endosense S.A. (Endosense) for the equivalent of $171 million (160 million Swiss Francs) in net cash consideration using available cash from outside the United States (U.S.). Endosense is based in Geneva, Switzerland and develops, manufactures and markets the TactiCath® irrigated ablation catheter to provide physicians a real-time, objective measure of the force to apply to the heart wall during a catheter ablation procedure. The Endosense force-sensing technology is CE Mark-approved for atrial fibrillation and supra ventricular tachycarida ablation. Under the terms of the acquisition agreement, the Company is obligated to make an additional cash payment of up to 150 million Swiss Francs (approximately $167 million at December 28, 2013), contingent upon both the achievement and timing of U.S. Food and Drug Administration (FDA) approval.

	Consistent with the provisions of ASC Topic 805, the Company accrued the contingent payment on the date of acquisition after determining its fair value of $132 million in arriving at $303 million of total consideration, net of cash acquired. The contingent consideration liability is reflected in other current liabilities as of December 28, 2013 and continues to be remeasured to fair value at each reporting period with changes in fair value reflected in the Consolidated Statements of Earnings.

	The goodwill recorded as a result of the Endosense acquisition is not deductible for income tax purposes and was entirely allocated to the CATD reportable segment. The goodwill represents the strategic opportunities for growing the Company's atrial fibrillation product portfolio and the expected revenue growth from increased market penetration from future products and customers. The Company now has the potential to integrate the force-sensing technology to offer a MediGuide™-enabled force-sensing ablation catheter and incorporate force-sensing data into its EnSite Velocity™ Mapping System. In connection with the acquisition of Endosense, the Company recognized $20 million of developed technology intangible assets that have an estimated useful life of 7 years and $33 million of IPR&D that was capitalized as an indefinite-lived intangible asset. Upon completion of the related development projects (when U.S. regulatory approval to market the product is obtained), the IPR&D will be amortized over its estimated useful life.

	The results of Endosense since the date of acquisition and pro forma disclosures of the consolidated results of the Company with the full year effects of Endosense have not been separately presented since the impact to the Company's results of operations was not material.

	Nanostim, Inc.: On October 11, 2013, the Company exercised its exclusive purchase option and acquired all the outstanding shares of Nanostim, Inc. (Nanostim) for $121 million in net cash consideration. The Company previously held an investment in Nanostim, which provided the Company with an 18% voting equity interest. Nanostim is based in Sunnyvale, California and has developed the first leadless, miniaturized cardiac pacemaker system, which received CE Mark approval in August 2013. The Nanostim™ leadless pacemaker also received FDA conditional approval in September 2013 for its Investigational Device Exemption application and pivotal clinical trial protocol to begin evaluating the technology in the U.S. The terms of the Company’s original investment agreement with Nanostim included an exclusive fixed price purchase option to acquire the remaining 82% equity interest in Nanostim. In accordance with ASC Topic 810, Consolidations (ASC Topic 810), the Company previously concluded that Nanostim was a VIE, but that St. Jude Medical was not the primary beneficiary as it did not retain power to direct the activities of Nanostim that most significantly impacted its economic performance. The Company previously reflected its investment in Nanostim as a cost method investment in other assets.

	At the time of acquisition, the Company's 18% voting equity interest in Nanostim was remeasured to fair value of $33 million, which approximated its carrying value, and the related remeasurement gain was not material. Under the terms of the acquisition agreement, the Company is obligated to make additional cash payments of up to $65 million, contingent upon the achievement and timing of certain revenue-based milestones. Consistent with the provisions of ASC Topic 805, the Company accrued the contingent payment after determining its fair value of $56 million in arriving at $210 million of total consideration, net of cash acquired. The contingent consideration accrual is reflected in other liabilities as of December 28, 2013 and will be remeasured to fair value at each reporting period with changes in fair value reflected in the Consolidated Statements of Earnings. The purchase price allocation is preliminary subject to finalization of the fair value valuation.

	The goodwill recorded as a result of the Nanostim acquisition is not deductible for income tax purposes and was entirely allocated to the IESD reportable segment. The goodwill represents the strategic opportunities for growing the Company's cardiac rhythm management business through expected revenue growth from increased market penetration and consumer preference for a miniaturized, leadless pacemaker as well as the potential for future product indications. In connection with the acquisition of Nanostim, the Company recognized $34 million of developed technology intangible assets that have an estimated useful life of 10 years and $27 million of IPR&D that was capitalized as an indefinite-lived intangible asset. Upon completion of the related development projects, the IPR&D will be amortized over its estimated useful life.

	The results of Nanostim since the date of acquisition and pro forma disclosures of the consolidated results of the Company with the full year effects of Nanostim have not been separately presented since the impact to the Company's results of operations was not material.

	The following table summarizes the purchase price allocation of the estimated fair values of net assets acquired and liabilities assumed as a result of the Company's acquisitions of Endosense and Nanostim during fiscal year 2013 as follows (in millions):



			Endosense			Nanostim			Total
	Assets acquired:
	Current assets		$	2		$	1		$	3

	Goodwill		258			149			407

	IPR&D		33			27			60

	Other intangible assets		20			34			54

	Other long-term assets		1			1			2

	Total assets acquired		314			212			526


	Liabilities assumed:
	Current liabilities		11			2			13

	Net assets acquired		303			210			513


	Cash paid		180			124			304

	Cash acquired		(9		)	(3		)	(12		)
	Net cash consideration		171			121			292

	Contingent consideration		132			56			188

	Fair value of St. Jude Medical, Inc.'s previously held interest		—			33			33

	Total purchase consideration		$	303		$	210		$	513


	Spinal Modulation, Inc.: On June 7, 2013, the Company made an equity investment of $40 million in Spinal Modulation, a privately-held company that is focused on the development of an intraspinal neuromodulation therapy that delivers spinal cord stimulation targeting the dorsal root ganglion to manage chronic pain. The investment agreement resulted in a 19% voting equity interest and provided the Company with the exclusive right, but not the obligation, to acquire Spinal Modulation for payments of up to $300 million during the period that extends through the completion of certain regulatory milestones. Additionally, in connection with the investment and contingent acquisition agreement, the Company also entered into an exclusive international distribution agreement, and obtained significant decision-making rights over Spinal Modulation's operations and economic performance. The Company also committed to providing additional debt financing to Spinal Modulation of up to $15 million. Accordingly, effective June 7, 2013, the Company determined that Spinal Modulation was a VIE for which St. Jude Medical is the primary beneficiary. Therefore, as of June 7, 2013, the financial condition and results of operations of Spinal Modulation were included in St. Jude Medical's consolidated financial statements. The Company has a 19% voting equity interest in Spinal Modulation and allocates the losses attributable to Spinal Modulation's noncontrolling shareholders to noncontrolling interest in St. Jude Medical's Consolidated Statements of Earnings and Consolidated Balance sheets.

	The initial consolidation of a VIE that is determined to be a business is accounted for as a business combination. The following table summarizes the estimated fair values of Spinal Modulation’s assets and liabilities included in St. Jude Medical's consolidated balance sheets as of the June 7, 2013 consolidation date, and as of December 28, 2013 after elimination of all intercompany balances and transactions (in millions):



			7-Jun-13			28-Dec-13
	Cash and cash equivalents		$	41		$	25

Other current assets		9			5

Goodwill		82			82

IPR&D		45			45

Other intangible assets		7			7

Other long-term assets		1			1

Total assets		185			165


Current liabilities		6			5

Deferred income taxes, net		19			19

Total liabilities		25			24


Non-controlling interest		$	120		$	104


The initial allocation of Spinal Modulation’s assets and liabilities included in the Company’s consolidated balance sheet is based upon preliminary valuations, and the estimated fair values of assets and liabilities are subject to change as the valuations are finalized within the initial measurement period. During the third quarter of 2013, the Company reflected a preliminary fair value adjustment and recorded a $35 million decrease to goodwill, a $5 million decrease to acquired IPR&D, a $3 million decrease to purchased technology intangible assets, a $3 million decrease to liabilities and a $40 million reduction to noncontrolling interest. These changes have been reflected retrospectively in the June 7, 2013 balances presented in the previous table.

The cash and cash equivalents balance of Spinal Modulation at June 7, 2013 includes $40 million of the Company’s equity investment proceeds. Assets recorded as a result of consolidating Spinal Modulation into the Company's consolidated balance sheet do not represent additional assets that could be used to satisfy claims against the Company's general assets. The creditors of Spinal Modulation do not have any recourse to the general credit of St. Jude Medical.

The goodwill recognized in connection with the Spinal Modulation transaction was not deductible for income tax purposes and was allocated entirely to the Company's IESD segment. The goodwill represents the strategic opportunities for growing the Company's neuromodulation chronic pain portfolio as well as the expected revenue growth from increased market penetration. The Company recognized $45 million of indefinite-lived IPR&D intangible assets. Upon completion of the related development project (generally when regulatory approval to market the product is obtained), the IPR&D will be amortized over its estimated useful life. The Company also recognized $7 million of purchased technology intangible assets with an estimated useful life of 12 years.

If the Company acquires Spinal Modulation, the contingent acquisition agreement also provides for additional consideration payments contingent upon the achievement of certain revenue-based milestones. In the event the Company acquires the noncontrolling interest of Spinal Modulation, the contingent payments would be recognized at the then-current fair value as an equity transaction.

CardioMEMS, Inc.: During 2010, the Company made an equity investment of $60 million in CardioMEMS, a privately-held company that is focused on the development of a wireless monitoring technology that can be placed directly into the pulmonary artery to assess cardiac performance via measurement of pulmonary artery pressure. The investment agreement resulted in a 19% voting equity interest and provided the Company with the exclusive right, but not the obligation, to acquire CardioMEMS for an additional payment of $375 million less any net debt payable to St. Jude Medical under a separate loan agreement entered into between CardioMEMS and the Company.

In the first quarter of 2013, the Company obtained significant decision-making rights over CardioMEMS' operations and provided debt financing of $28 million to CardioMEMS which was collateralized by substantially all the assets of CardioMEMS including its intellectual property. In July 2013, the Company provided $9 million of additional debt financing to CardioMEMS. In accordance with ASC Topic 810, the Company reconsidered its arrangements with CardioMEMS and determined that effective February 27, 2013 CardioMEMS was a VIE for which St. Jude Medical is the primary beneficiary. As a result, as of February 27, 2013, the financial condition and results of operations of CardioMEMS were included in St. Jude Medical's consolidated financial statements. The Company recognized a $29 million loss associated with a fair value remeasurement adjustment to other expense (see Note 10) to adjust the carrying value of its equity investment and fixed price purchase option. The Company continues to hold a 19% voting equity interest in CardioMEMS and allocates the losses attributable to CardioMEMS' noncontrolling shareholders to noncontrolling interest in St. Jude Medical's Consolidated Statements of Earnings and Consolidated Balance Sheets.

The initial consolidation of a VIE that is determined to be a business is accounted for as a business combination. The following table summarizes the estimated fair values of CardioMEMS’ assets and liabilities included in St. Jude Medical's consolidated balance sheets as of the February 27, 2013 consolidation date, and as of December 28, 2013 after elimination of all intercompany balances and transactions (in millions):



		27-Feb-13			28-Dec-13
Cash and cash equivalents		$	33		$	14

Other current assets		2			6

Goodwill		83			83

IPR&D		63			63

Other long-term assets		2			2

Total assets		183			168


Current liabilities		13			7

Deferred income taxes, net		23			23

Other liabilities		5			4

Total liabilities		41			34


Noncontrolling interest		$	84		$	68

The initial allocation of CardioMEMS’ assets and liabilities included in the Company’s consolidated balance sheet was based upon preliminary valuations, and the estimated fair values of assets and liabilities were subject to change as the valuations were finalized within the initial measurement period. During the third quarter of 2013, the Company finalized the valuations and allocation of the estimated fair values of CardioMEMS’ assets and liabilities and recorded a $1 million decrease to goodwill, a $6 million decrease to IPR&D, a $2 million decrease to liabilities and a $5 million reduction to noncontrolling interest. These changes have been reflected retrospectively in the February 27, 2013 balances presented in the previous table.

The cash and cash equivalents balance of CardioMEMS at February 27, 2013 includes $28 million of the Company’s debt financing proceeds. Assets recorded as a result of consolidating CardioMEMS into the Company's consolidated balance sheet do not represent additional assets that could be used to satisfy claims against the Company's general assets. The other creditors of CardioMEMS do not have any recourse to the general credit of St. Jude Medical.

The goodwill recognized in connection with the CardioMEMS transaction was not deductible for income tax purposes and was allocated entirely to the Company's IESD segment. The goodwill represents the strategic opportunities for growing the Company's cardiac rhythm management and heart failure therapy product portfolio as well as the expected revenue growth from increased market penetration. The Company recognized $63 million of indefinite-lived IPR&D intangible assets. Upon completion of the related development projects (generally when regulatory approval to market the product is obtained), the IPR&D will be amortized over its estimated useful life.

Goodwill_And_Other_Intangible_

Goodwill And Other Intangible Assets	12 Months Ended
	Dec. 28, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill And Other Intangible Assets	'
	GOODWILL AND OTHER INTANGIBLE ASSETS
	The changes in the carrying amount of goodwill for each of the Company’s reportable segments (see Note 15) for the fiscal years ended December 28, 2013 and December 29, 2012 were as follows (in millions):



		IESD			CATD		Total
	Balance at December 31, 2011	$	1,235		$	1,718	$	2,953

	Foreign currency translation and other	(6		)	14		8

	Balance at December 29, 2012	1,229			1,732		2,961

	Endosense S.A.	—			258		258

	Nanostim, Inc.	149			—		149

	Spinal Modulation, Inc.	82			—		82

	CardioMEMS, Inc.	83			—		83

	Foreign currency translation and other	(17		)	8		(9		)

	Balance at December 28, 2013	$	1,526		$	1,998	$	3,524


	The following table provides the gross carrying amount of other intangible assets and related accumulated amortization (in millions):


		December 28, 2013					December 29, 2012
		Gross			Accumulated		Gross			Accumulated
		Carrying			Amortization		Carrying			Amortization
		Amount					Amount
	Definite-lived intangible assets:

	Purchased technology and patents	$	986		$	393	$	947		$	336

	Customer lists and relationships	20			13		57			36

	Trademarks and tradenames	22			11		22			10

	Licenses, distribution agreements and other	4			1		6			4

		$	1,032		$	418	$	1,032		$	386

	Indefinite-lived intangible assets:

	Acquired IPR&D	$	262				$	109

	Trademarks and tradenames	35					49

		$	297				$	158


	During 2013, the Company recognized impairment charges of $29 million associated with its indefinite-lived tradename and IPR&D assets in the Company's CATD segment. Additionally, the Company recognized a $13 million impairment charge primarily associated with customer relationship intangible assets. See Note 9 for further details discussing these charges. The gross carrying amounts and related accumulated amortization amounts for these impairment charges were written off accordingly.

	Amortization expense was $79 million, $88 million and $93 million during fiscal years 2013, 2012 and 2011, respectively. The following table presents expected future amortization expense including amortization expense of expected indefinite-lived IPR&D amortization based on anticipated regulatory product approvals. Actual amounts of amortization expense may differ due to actual timing of regulatory approvals, additional intangible assets acquired and foreign currency translation impacts (in millions):


														After
		2014			2015		2016			2017		2018		2018
	Amortization expense	$	90		$	95	$	101		$	93	$	87	$	410

Debt

Debt	12 Months Ended
	Dec. 28, 2013
Debt Disclosure [Abstract]	'
Debt	'
	DEBT
	The Company’s debt consisted of the following, including discounts and premiums (in millions):


		December 28, 2013		December 29, 2012
	Term loan due 2015	$	500	$	—

	2.50% senior notes due 2016	512		518

	3.25% senior notes due 2023	896		—

	4.75% senior notes due 2043	696		—

	3.75% senior notes due 2014 (redeemed May 2013)	—		699

	4.875% senior notes due 2019 (redeemed May 2013)	—		496

	2.20% senior notes due 2013 (retired September 2013)	—		454

	1.58% Yen-denominated senior notes due 2017	78		95

	2.04% Yen-denominated senior notes due 2020	122		149

	Yen-denominated credit facilities	62		76

	Commercial paper borrowings	714		593

	Total debt	3,580		3,080

	Less: current debt obligations	62		530

	Long-term debt	$	3,518	$	2,550

	Expected future minimum principal payments under the Company’s debt obligations are as follows: $62 million in 2014; $500 million in 2015; $500 million in 2016; $78 million in 2017; $714 million in 2018; and $1,722 million in years thereafter.
	Term Loan Due 2015: In June 2013, the Company entered into a 2-year, $500 million unsecured term loan that matures in June 2015, the proceeds of which were used for general corporate purposes including the repayment of outstanding commercial paper borrowings of the Company. These borrowings bear interest at LIBOR plus 0.5%, subject to adjustment in the event of a change in the Company's credit ratings. The Company may make principal payments on the outstanding borrowings any time after June 26, 2014.
	Senior Notes Due 2016: On December 1, 2010, the Company issued $500 million principal amount of 5-year, 2.50% unsecured senior notes (2016 Senior Notes) that mature in January 2016. The majority of the net proceeds from the issuance of the 2016 Senior Notes was used for general corporate purposes including the repurchase of the Company’s common stock. Interest payments are required on a semi-annual basis. The 2016 Senior Notes were issued at a discount, yielding an effective interest rate of 2.54% at issuance. The debt discount is being amortized as interest expense through maturity. The Company may redeem the 2016 Senior Notes at any time at the applicable redemption price.
	Concurrent with the issuance of the 2016 Senior Notes, the Company entered into a 5-year, $500 million notional amount interest rate swap designated as a fair value hedge of the changes in fair value of the Company’s fixed-rate 2016 Senior Notes. On June 7, 2012, the Company terminated the interest rate swap and received a cash payment of $24 million. The gain from terminating the interest rate swap agreement has been reflected as an increase to the carrying value of the debt and is being amortized as a reduction of interest expense resulting in a net average interest rate of 1.3% that will be recognized over the remaining term of the 2016 Senior Notes.
	Senior Notes Due 2023: In April 2013, the Company issued $900 million principal amount of 10-year, 3.25% unsecured senior notes (2023 Senior Notes) that mature in April 2023. Interest payments are required on a semi-annual basis. The 2023 Senior Notes were issued at a discount, yielding an effective interest rate of 3.31% at issuance. The debt discount is being amortized as interest expense through maturity. The Company may redeem the 2023 Senior Notes at any time at the applicable redemption price.
	Senior Notes Due 2043: In April 2013, the Company issued $700 million principal amount of 30-year, 4.75% unsecured senior notes (2043 Senior Notes) that mature in April 2043. Interest payments are required on a semi-annual basis. The 2043 Senior Notes were issued at a discount, yielding an effective interest rate of 4.79% at issuance. The debt discount is being amortized as interest expense through maturity. The Company may redeem the 2043 Senior Notes at any time at the applicable redemption price.

	In May 2013, the Company used the majority of the proceeds from the issuance of its 2023 Senior Notes and 2043 Senior Notes to redeem both $700 million principal amount of 5-year, 3.75% unsecured senior notes originally due in 2014 (2014 Senior Notes) and $500 million principal amount of 10-year, 4.875% unsecured senior notes originally due in 2019 (2019 Senior Notes). In connection with the redemption of these senior notes, the Company recognized an aggregate $161 million debt retirement charge in the second quarter of 2013 primarily associated with required make-whole redemption payments to noteholders from the senior notes being retired prior to their scheduled maturity as well as the write-off of unamortized debt issuance costs.
	Senior Notes Due 2013: On March 10, 2010, the Company issued $450 million principal amount of 3-year, 2.20% unsecured senior notes (2013 Senior Notes) that matured on September 15, 2013, which the Company paid in full utilizing commercial paper borrowings and cash generated from operations.
	1.58% Yen-Denominated Senior Notes Due 2017: On April 28, 2010, the Company issued 7-year, 1.58% unsecured senior notes in Japan (1.58% Yen Notes) totaling 8.1 billion Japanese Yen (the equivalent of $78 million at December 28, 2013 and $95 million at December 29, 2012). The principal amount of the 1.58% Yen Notes recorded on the balance sheet fluctuates based on the effects of foreign currency translation. Interest payments are required on a semi-annual basis and the entire principal balance is due on April 28, 2017.
	2.04% Yen-Denominated Senior Notes Due 2020: On April 28, 2010, the Company issued 10-year, 2.04% unsecured senior notes in Japan (2.04% Yen Notes) totaling 12.8 billion Japanese Yen (the equivalent of $122 million at December 28, 2013 and $149 million at December 29, 2012). The principal amount of the 2.04% Yen Notes recorded on the balance sheet fluctuates based on the effects of foreign currency translation. Interest payments are required on a semi-annual basis and the entire principal balance is due on April 28, 2020.
	Yen–Denominated Credit Facilities: In March 2011, the Company borrowed 6.5 billion Japanese Yen (the equivalent of $62 million at December 28, 2013 and $76 million at December 29, 2012) under uncommitted credit facilities with two commercial Japanese banks that provide for borrowings up to a maximum of 11.25 billion Japanese Yen. The principal amount reflected on the balance sheet fluctuates based on the effects of foreign currency translation. Half of the borrowings bear interest at Yen LIBOR plus 0.25% and mature in March 2014 and the other half of the borrowings bear interest at Yen LIBOR plus 0.275% and mature in June 2014. The maturity dates of each credit facility automatically extend for a one-year period, unless the Company elects to terminate the credit facility.
	Other Available Borrowings: In May 2013, the Company entered into a $1.5 billion unsecured committed credit facility (Credit Facility) that it may draw on for general corporate purposes and to support its commercial paper program. The Credit Facility expires in May 2018. Borrowings under the Credit Facility bear interest initially at LIBOR plus 0.8%, subject to adjustment in the event of a change in the Company’s credit ratings. The Credit Facility replaces the Company's previous $1.5 billion credit facility that was scheduled to expire in February 2015. As of December 28, 2013 and December 29, 2012, the Company had no outstanding borrowings under either credit facility.
	The Company’s commercial paper program provides for the issuance of short-term, unsecured commercial paper with maturities up to 270 days. As of December 28, 2013 and December 29, 2012, the Company's commercial paper borrowings were $714 million and $593 million, respectively. During 2013, the Company’s weighted average effective interest rate on its commercial paper borrowings was approximately 0.24%. Any future commercial paper borrowings would bear interest at the applicable then-current market rates. The Company classifies all of its commercial paper borrowings as long-term debt, as the Company has the ability to repay any short-term maturity with available cash from its existing long-term, committed Credit Facility.

Commitments_And_Contingencies

Commitments And Contingencies	12 Months Ended
Commitments And Contingencies	Dec. 28, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments And Contingencies	'
	COMMITMENTS AND CONTINGENCIES
	Leases
	The Company leases various facilities and equipment under non-cancelable operating lease arrangements. Future minimum lease payments under these leases are as follows: $30 million in 2014; $22 million in 2015; $15 million in 2016; $15 million in 2017; $10 million in 2018; and $4 million in years thereafter. Rent expense under all operating leases was $36 million, $44 million and $45 million in fiscal years 2013, 2012 and 2011, respectively.
	Product Liability Litigation
	Riata® Litigation: In April 2013, a lawsuit seeking a class action was filed against the Company in the U.S. District Court for the Western District of Washington by plaintiffs alleging they suffered injuries caused by Riata® and Riata® ST Silicone Defibrillation Leads. This matter has been resolved and the case has been dismissed.

	As of February 21, 2014, the Company is aware of 44 lawsuits from plaintiffs alleging injuries caused by, and asserting product liability claims concerning, Riata® and Riata® ST Silicone Defibrillation Leads. Most of the lawsuits have been brought by single plaintiffs, but some of them name multiple individuals as plaintiffs. Five separate multi-plaintiff lawsuits have been initiated against the Company that involve more than one unrelated plaintiff: a multi-plaintiff lawsuit joining 29 unrelated claimants was filed in the Superior Court of California for the city and county of Los Angeles on April 4, 2013; a multi-plaintiff lawsuit joining two unrelated claimants was filed in the Superior Court of California for the city and county of Los Angeles on April 4, 2013; a multi-plaintiff lawsuit joining two claimants was filed in the United States District Court for the Central District of California on April 4, 2013; a multi-plaintiff lawsuit joining three unrelated claimants was filed in the Superior Court of California for the city and county of Los Angeles on April 29, 2013; and a multi-plaintiff lawsuit joining 21 unrelated claimants was filed in the Superior Court of California for the city and county of Los Angeles on July 15, 2013. Of the 44 lawsuits, 18 cases are pending in federal courts, including three in the U.S. District Court for the District of Minnesota, nine in the U.S. District Court for the Central District of California, one in the U.S. District Court for the District of South Carolina, one in the U.S. District Court for the Northern District of New York, one in the U.S. District Court for the Western District of New York, one in the U.S. District Court for the Middle District of Florida, one in the U.S. District Court for the Western District of Kentucky and one in the U.S. District Court for the Southern District of West Virginia. The remaining 26 lawsuits are pending in state courts across the country, including seven in Minnesota, sixteen in California, one in Indiana, one in Georgia and one in Kentucky.

	In November 2013, an amended claim was filed in a Canadian proposed class proceeding alleging that Riata® leads were prone to insulation abrasion and breach, failure to warn and conspiracy. The plaintiffs took no action between their 2008 filing and the amended claim they filed in November 2013. The Company has filed its statement of intent to defend in response to the amended claims, and the plaintiffs have not taken any further action.

	Although some of the claimants in the aforementioned suits allege no specific injuries, the majority of the claimants allege bodily injuries as a result of surgical revision or removal and replacement of Riata® leads, or other complications, which they attribute to the leads. The majority of the claimants who seek recovery for implantation and/or surgical removal of Riata® leads are seeking compensatory damages in unspecified amounts, and declaratory judgments that the Company is liable to the claimants for any past, present and future evaluative monitoring, and corrective medical, surgical and incidental expenses and losses. Several claimants also seek punitive damages. The Company is responsible for legal costs incurred in defense of the Riata product liability claims including any potential settlements, judgments and other legal defense costs.
	Silzone® Litigation and Insurance Receivables: The Company has been sued in various jurisdictions beginning in March 2000 by some patients who received a heart valve product with Silzone® coating, which the Company stopped selling in January 2000. The Company's outstanding Silzone cases consist of one class action in Ontario and one individual case in Ontario. In June 2012, the Ontario Court ruled in the Company's favor on all nine common class issues in a class action involving Silzone patients, and the case was dismissed. In September 2012, counsel for the class filed an appeal with the Court of Appeal for the Province of Ontario. The oral argument concerning the appeal was expected to be heard in November 2013, but that hearing date was adjourned and no new hearing date has been scheduled. The individual case in Ontario requests damages in excess of $1 million (claiming unspecified special damages, health care costs and interest). Based on the Company’s historical experience, the amount ultimately paid, if any, often does not bear any relationship to the amount claimed. To the extent that the Company’s future Silzone costs (inclusive of settlements, judgments, legal fees and other related defense costs) exceed its remaining historical insurance coverage of approximately $10 million, the Company would be responsible for such costs.
	The Company intends to vigorously defend against the claims that have been asserted. The Company has not recorded an expense related to any potential damages in connection with these product liability litigation matters because any potential loss is not probable or reasonably estimable. Other than disclosed above, the Company cannot reasonably estimate a loss or range of loss, if any, that may result from these litigation matters.
	Patent and Other Intellectual Property Litigation
	Volcano Corporation & LightLab Imaging Litigation: The Company's subsidiary, LightLab Imaging, has pending litigation with Volcano Corporation (Volcano) and Axsun Technologies, Inc. (Axsun), a subsidiary of Volcano, in the Massachusetts state court and in state court in Delaware. LightLab Imaging makes and sells optical coherence tomography (OCT) imaging systems. Volcano is a LightLab Imaging competitor in medical imaging. Axsun makes and sells lasers and is a supplier of lasers to LightLab Imaging for use in OCT imaging systems. The lawsuits arise out of Volcano's acquisition of Axsun in December 2008. Before Volcano acquired Axsun, LightLab Imaging and Axsun had worked together to develop a tunable laser for use in OCT imaging systems. While the laser was in development, LightLab Imaging and Axsun entered into an agreement pursuant to which Axsun agreed to sell its tunable lasers exclusively to LightLab in the field of human coronary artery imaging for a certain period of time.
	After Volcano acquired Axsun in December 2008, LightLab Imaging sued Axsun and Volcano in Massachusetts, asserting a number of claims arising out of Volcano's acquisition of Axsun. In January 2011, the Court ruled that Axsun's and Volcano's conduct constituted knowing and willful violations of a statute which prohibits unfair or deceptive acts or practices or acts of unfair competition, entitling LightLab Imaging to double damages, and furthermore, that LightLab Imaging was entitled to recover attorneys' fees. In February 2011, Volcano and Axsun were ordered to pay the Company for reimbursement of attorneys' fees and double damages, which Volcano paid to the Company in July 2011. The Court also issued certain injunctions and declaratory relief against Volcano. The Company has also appealed certain rulings relating to the trial court's exclusion of certain expert testimony and its refusal to enter permanent injunctions. In January 2013, the Supreme Judicial Court for Massachusetts granted the Company's request to bypass the intermediary appellate court and accepted the matter for its direct review. Oral argument occurred on December 2, 2013, and a decision is expected in 2014.
	In May 2011, LightLab Imaging initiated a lawsuit against Volcano and Axsun in the Delaware state court. The suit seeks to enforce LightLab Imaging's exclusive contract with Axsun, and also alleges claims to prevent Volcano from interfering with that contract and to bar Axsun and Volcano from using LightLab Imaging confidential information and trade secrets, and to prevent Volcano and Axsun from violating a Massachusetts statute prohibiting unfair methods of competition and unfair or deceptive acts or practices relating to LightLab Imaging's tunable laser technology. In May 2012, the Court granted Volcano's motion to stay the proceedings until Volcano provides notice of its intent to begin clinical trials or engage in other public activities with an OCT imaging system that uses a type of light source that is in dispute in the lawsuit. Volcano is under an order to provide such a notice at least 45 days before beginning such trials or engaging in such activities. In April 2013, the Court denied a motion by the Company to lift the stay. On November 4, 2013 Volcano announced that it was discontinuing its OCT development program effective September 30, 2013. Accordingly, Volcano has filed a motion to dismiss without prejudice in the Delaware state court litigation. The Court has not ruled on Volcano’s motion.

	Volcano Corporation & St. Jude Medical Patent Litigation: In July 2010, the Company filed a lawsuit in federal district court in Delaware against Volcano for patent infringement. In the suit, the Company asserted certain patents against Volcano and seeks injunctive relief and monetary damages. The infringed patents are part of the St. Jude Medical PressureWire® technology platform, which was acquired as part of St. Jude Medical's purchase of Radi Medical Systems in December 2008. On October 19, 2012 a jury ruled in favor of Volcano finding that certain Volcano patents did not infringe the Company's patents and that certain St. Jude Medical patents were invalid. The Company filed a motion for judgment as a matter of law which the Court denied. The Company intends to appeal to the federal circuit court and raise challenges to various issues related to the trial that resulted in the October 19, 2012 jury decision. Volcano also filed counterclaims against the Company in this case, alleging certain St. Jude Medical patent claims are unenforceable and that certain St. Jude Medical products infringe certain Volcano patents. On October 25, 2012, a jury ruled that the Company did not infringe certain Volcano patents and the Court entered judgment on both October jury verdicts in January 2013. The parties are moving forward with other post-trial proceedings.

	On April 16, 2013, Volcano filed a lawsuit in federal district court in Delaware against the Company alleging that the Company is infringing two U.S. patents owned by Volcano which were issued that same day. The allegations relate to the Company's PressureWire® technology (Fractional Flow Reserve) FFR Platforms, including ILUMIENTM PCI Optimization System and QuantienTM Integrated FFR platforms. In its complaint, Volcano sought both injunctive relief and monetary damages. On January 29, 2014, the Court issued a claims construction ruling favorable to the Company. Based on that ruling, the parties filed a stipulation with the Court on February 14, 2014, agreeing that the Company's products do not infringe the two patents Volcano has asserted.

	The Company has not recorded an expense related to any potential damages in connection with these litigation matter because any potential loss is not probable or reasonably estimable. Other than disclosed above, the Company cannot reasonably estimate a loss or range of loss, if any, that may result from these litigation matters.
	Securities and Other Shareholder Litigation
	March 2010 Securities Class Action Litigation: In March 2010, a securities lawsuit seeking class action status was filed in federal district court in Minnesota against the Company and certain officers (collectively, the defendants) on behalf of purchasers of St. Jude Medical common stock between April 22, 2009 and October 6, 2009. The lawsuit relates to the Company's earnings announcements for the first, second and third quarters of 2009, as well as a preliminary earnings release dated October 6, 2009. The complaint, which seeks unspecified damages and other relief as well as attorneys' fees, alleges that the defendants failed to disclose that it was experiencing a slowdown in demand for its products and was not receiving anticipated orders for cardiac rhythm management devices. Class members allege that the defendant's failure to disclose the above information resulted in the class purchasing St. Jude Medical stock at an artificially inflated price. In December 2011, the Court issued a decision denying a motion to dismiss filed by the defendants in October 2010. In October 2012, the Court granted plaintiffs' motion to certify the case as a class action and the discovery phase of the case closed in September 2013. On October 15, 2013, the defendants filed a motion for summary judgment. A hearing concerning that motion took place with the Court in January 2014 and a ruling is expected later in 2014. Subject to the outcome of this hearing, the trial of this class action matter is presently scheduled for October 2014. The defendants intend to continue to vigorously defend against the claims asserted in this lawsuit.
	December 2012 Securities Class Action Litigation: On December 7, 2012, a securities class action lawsuit was filed
	in federal district court in Minnesota against the Company and an officer (collectively, the defendants) for alleged violations of the federal securities laws, on behalf of all purchasers of the publicly traded securities of the defendants between October 17, 2012 and November 20, 2012. The complaint, which seeks unspecified damages and other relief as well as attorneys' fees, challenges the Company’s disclosures concerning its high voltage cardiac rhythm lead products during the purported class period. On December 10, 2012, a second securities class action lawsuit was filed in federal district court in Minnesota against the Company and certain officers for alleged violations of the federal securities laws, on behalf of all purchasers of the publicly traded securities of the Company between October 19, 2011 and November 20, 2012. The second complaint pursues similar claims and seeks unspecified damages and other relief as well as attorneys’ fees. In March 2013, the Court consolidated the two cases and appointed a lead counsel and lead plaintiff. In September 2013, the defendants filed a motion to dismiss the consolidated and amended complaint. Oral argument concerning this motion to dismiss occurred in January 2014, and a ruling is expected later in 2014. The Company intends to vigorously defend against the claims asserted in this matter.

	December 2012 Derivative Litigation: In December 2012, a shareholder derivative action was initiated in Minnesota state court in Ramsey County, on behalf of the Company, against members of St. Jude Medical’s Board of Directors as well as certain officers of the Company (collectively, the defendants). The plaintiffs in this action allege breach of fiduciary duty, waste of corporate assets and unjust enrichment. The claims center around and involve the Company’s high voltage cardiac rhythm lead products and related activities and events. No damages are sought against the Company. The defendants intend to vigorously defend against the claims asserted in this matter. In March 2013, the defendants filed a motion to dismiss the plaintiffs' complaint. The matter was transferred to a new judge effective July 31, 2013 and at a scheduling conference in February 2014 the judge scheduled an oral hearing on the motion to dismiss for April 2014.

	The Company has not recorded an expense related to any potential damages in connection with these securities and other shareholder litigation matters because any potential loss is not probable or reasonably estimable. The Company cannot reasonably estimate a loss or range of loss, if any, that may result from these matters.
	Governmental Investigations
	In March 2010, the Company received a Civil Investigative Demand (CID) from the Civil Division of the Department of Justice (DOJ). The CID requests documents and sets forth interrogatories related to communications by and within the Company on various indications for tachycardia implantable cardioverter defibrillator systems (ICDs) and a National Coverage Decision issued by Centers for Medicare and Medicaid Services. Similar requests were made of the Company's major competitors. The Company provided its response to the DOJ in June 2010.
	On September 20, 2012, the Office of Inspector General for the Department of Health and Human Services (OIG) issued a subpoena requiring the Company to produce certain documents related to payments made by the Company to healthcare professionals practicing in California, Florida, and Arizona, as well as policies and procedures related to payments made by the Company to non-employee healthcare professionals. The Company has provided its response to the OIG.
	The Company is cooperating with the two open investigations and is responding to these requests. However, the Company cannot predict when these investigations will be resolved, the outcome of these investigations or their impact on the Company. The Company has not recorded an expense related to any potential damages in connection with these governmental matters because any potential loss is not probable or reasonably estimable. The Company cannot reasonably estimate a loss or range of loss, if any, that may result from these matters.
	Regulatory Matters
	In late September 2012, the FDA commenced an inspection of the Company's Sylmar, California facility, and, following such inspection, issued eleven observations on a Form 483, which the Company disclosed on a Form 8-K filed on October 24, 2012 along with an exhibit containing a redacted version of the Form 483. The FDA subsequently released its own redacted version of the 483 Letter on November 20, 2012. The redacted version of the Form 483 that was released by the FDA on November 20, 2012 and included in its website at that time is attached as Exhibit 99.1 to the Company's Quarterly Report on Form 10-Q for the period ended June 29, 2013. In early November 2012, the Company provided written responses to the FDA on the Form 483 detailing proposed corrective actions and immediately initiated efforts to address the FDA's inspectional observations. The Company subsequently received a warning letter dated January 10, 2013 from the FDA relating to these inspectional observations with respect to its Sylmar, California facility. The warning letter does not identify any specific concerns regarding the performance of, or indicate the need for any field or other action regarding, any particular St. Jude Medical product. In July 2013, the FDA inspected the Company's Sylmar, California facility for progress made remediating the warning letter and Form 483 observations. No additional observations on Form 483 were issued following the July inspection. The Sylmar, California facility will continue to manufacture cardiac rhythm management devices while the Company works with the FDA to address its concerns.

	The FDA inspected the Company's Plano, Texas manufacturing facility at various times between March 5 and April 6, 2009. On April 6, 2009, the FDA issued a Form 483 identifying certain inspectional observations with current Good Manufacturing Practice (cGMP). Following the receipt of the Form 483, the Company provided written responses to the FDA detailing proposed corrective actions and immediately initiated efforts to address the FDA's inspectional observations. The Company subsequently received a warning letter dated June 26, 2009 from the FDA relating to these inspectional observations with respect to its legacy Neuromodulation division's Plano, Texas and Hackettstown, New Jersey facilities.
	With respect to both of these warning letters, the FDA notes that it will not grant requests for exportation certificates to foreign governments or approve pre-market approval applications for Class III devices to which the quality system regulation deviations are reasonably related until the violations have been corrected. The Company is working cooperatively with the FDA to resolve all of its concerns.
	Customer orders have not been and are not expected to be impacted while the Company works to resolve the FDA's concerns. The Company is working diligently to respond timely and fully to the FDA's observations and requests. While the Company believes the issues raised by the FDA can be resolved without a material impact on the Company's financial results, the FDA has recently been increasing its scrutiny of the medical device industry and raising the threshold for compliance. The government is expected to continue to scrutinize the industry closely with inspections, and possibly enforcement actions, by the FDA or other agencies. The Company is regularly monitoring, assessing and improving its internal compliance systems and procedures to ensure that its activities are consistent with applicable laws, regulations and requirements, including those of the FDA.

Shareholders_Equity

Shareholders' Equity	12 Months Ended
Shareholders' Equity	Dec. 28, 2013
Shareholders' Equity [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	SHAREHOLDERS' EQUITY

	Share Repurchases: On December 9, 2013, the Company's Board of Directors authorized a share repurchase program of up to $700 million of its outstanding common stock. The Company began repurchasing shares on December 11, 2013 and completed the repurchases under the program on January 17, 2014, repurchasing 11.1 million shares for $700 million at an average repurchase price of $63.07 per share. From December 11, 2013 through December 28, 2013, the Company repurchased 4.4 million shares for $266 million at an average repurchase price of $60.18 per share.

	On November 29, 2012, the Company's Board of Directors authorized a share repurchase program of up to $1.0 billion of its outstanding common stock. The Company began repurchasing shares on December 5, 2012 and completed the repurchases under the program on February 1, 2013, repurchasing 26.8 million shares for $1.0 billion at an average repurchase price of $37.27 per share. From December 5, 2012 through December 29, 2012, the Company repurchased 12.9 million shares for $458 million at an average repurchase price of $35.60 per share. From December 30, 2012 through February 1, 2013, the Company repurchased 13.9 million shares for $542 million at an average repurchase price of $38.83 per share.

	On October 17, 2012, the Company's Board of Directors authorized a share repurchase program of up to $300 million of its outstanding common stock. The Company began repurchasing shares on October 19, 2012 and completed the repurchases under the program on November 6, 2012, repurchasing 7.7 million shares for $300 million at an average repurchase price of $38.97 per share.

	On December 12, 2011, the Company's Board of Directors authorized a share repurchase program of up to $300 million of the Company's outstanding common stock. The Company began repurchasing shares on January 27, 2012 and completed the repurchases under the program on February 8, 2012, repurchasing 7.1 million shares for $300 million at an average repurchase price of $42.14 per share.

	On August 2, 2011, the Company's Board of Directors authorized a share repurchase program of up to $500 million of the Company's outstanding common stock. The Company completed the repurchases under the program on August 29, 2011, repurchasing 11.7 million shares for $500 million at an average repurchase price of $42.79 per share.

	On October 15, 2010, the Company's Board of Directors authorized a share repurchase program of up to $600 million of the Company's outstanding common stock. On October 21, 2010, the Company's Board of Directors authorized an additional $300 million of share repurchases as part of this share repurchase program. The Company began repurchasing shares on November 18, 2010 and completed the repurchases under the programs on January 20, 2011, repurchasing a total of 22.0 million shares for $900 million at an average repurchase price of $40.87 per share. From January 2, 2011 through January 20, 2011, the Company repurchased 6.6 million shares for $275 million at an average repurchase price of $41.44 per share.

	Dividends: During 2013, the Company's Board of Directors authorized four quarterly cash dividend payments of $0.25 per share paid on April 30, 2013, July 31, 2013, October 31, 2013 and January 31, 2014. During 2012, the Company's Board of Directors authorized four quarterly cash dividend payments of $0.23 per share paid on April 30, 2012, July 31, 2012, October 31, 2012 and January 31, 2013. During 2011, the Company's Board of Directors authorized four quarterly cash dividend payments of $0.21 per share paid on April 29, 2011, July 29, 2011, October 31, 2011 and January 31, 2012.

	On February 22, 2014, the Company's Board of Directors authorized a cash dividend of $0.27 per share payable on April 30, 2014 to shareholders of record as of March 31, 2014.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income	12 Months Ended
	Dec. 28, 2013
Accumulated Other Comprehensive Income [Abstract]	'
Comprehensive Income (Loss) Note [Text Block]	'
	ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
	The table below presents the changes in each component of accumulated other comprehensive income, including other comprehensive income and the reclassifications out of accumulated other comprehensive income into net earnings for fiscal years 2013, 2012 and 2011 (in millions):



		Unrealized			Unrealized			Foreign			Accumulated
		Gain (Loss) On			Gain (Loss) On			Currency			Other
		Available-for-sale			Derivative			Translation			Comprehensive
		Securities			Instruments			Adjustment			Income
	Accumulated other comprehensive income (loss), net of tax, at January 1, 2011	$	15		$	—		$	69		$	84

	Other comprehensive income (loss) before reclassifications	3			—			(71		)	(68		)

	Amounts reclassified to net earnings from accumulated other comprehensive income	—			—			—			—

	Other comprehensive income (loss)	3			—			(71		)	(68		)

	Accumulated other comprehensive income (loss), net of tax, at December 31, 2011	18			—			(2		)	16

	Other comprehensive income (loss) before reclassifications	10			—			28			38

	Amounts reclassified to net earnings from accumulated other comprehensive income	(8		)	—			—			(8		)

	Other comprehensive income (loss)	2			—			28			30

	Accumulated other comprehensive income (loss), net of tax, at December 29, 2012	20			—			26			46

	Other comprehensive income (loss) before reclassifications	5			3			—			8

	Amounts reclassified to net earnings from accumulated other comprehensive income	(8		)	—			—			(8		)

	Other comprehensive income (loss)	(3		)	3			—			—

	Accumulated other comprehensive income (loss), net of tax, at December 28, 2013	$	17		$	3		$	26		$	46


	The table below provides details about reclassifications out of accumulated other comprehensive income and the line items impacted in the Company's Consolidated Statements of Earnings for fiscal years 2013, 2012 and 2011 (in millions):



		Amounts reclassified from accumulated other comprehensive income
		2013			2012			2011			Statements of Earnings Classification
	Unrealized gain on available-for-sale securities:
	Gain on sale of available-for-sale securities	$	13		$	14		$	—		Other expense, net

		(5		)	(6		)	—			Income tax expense

		8			8			—			Net earnings before noncontrolling interest

		$	8		$	8		$	—		Net earnings attributable to St. Jude Medical, Inc.

Stockbased_Compensation

Stock-based Compensation	12 Months Ended
	Dec. 28, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	STOCK-BASED COMPENSATION

	Stock Compensation Plans
	The Company's stock compensation plans provide for the issuance of stock-based awards, such as stock options, restricted stock units and restricted stock awards, to directors, officers, employees and consultants. Since 2000, all stock option awards granted under these plans have an exercise price equal to the closing stock price on the date of grant, an eight-year contractual life and generally, vest annually over a four-year vesting term. Restricted stock units and restricted stock awards under these plans also generally vest annually over a four-year period. Restricted stock awards are considered issued and outstanding at the grant date and have the same dividend and voting rights as other common stock. Directors can elect to receive half of their entire annual retainer in the form of a restricted stock award with a six-month vesting term. Restricted stock units are not issued and outstanding at the grant date; instead, upon vesting the recipient receives one share of the Company's common stock for each vested restricted stock unit. At December 28, 2013, the Company had 15.7 million shares of common stock available for stock option grants under its stock compensation plans. The Company has the ability to grant a portion of the available shares in the form of restricted stock awards or units. Specifically, in lieu of granting up to 13.9 million stock options under these plans, the Company may grant up to 6.2 million restricted stock awards or units (for certain grants of restricted stock units or awards, the number of shares available are reduced by 2.25 shares). Additionally, in lieu of granting up to 0.1 million stock options under these plans, the Company may grant up to 0.1 million restricted stock awards (for certain grants of restricted stock awards, the number of shares available are reduced by one share). The remaining 1.7 million shares of common stock are available only for stock option grants. At December 28, 2013, there was $149 million of total unrecognized stock-based compensation expense, adjusted for estimated forfeitures, which is expected to be recognized over a weighted average period of approximately 2.9 years and will be adjusted for any future changes in estimated forfeitures.
	The Company also has an Employee Stock Purchase Plan (ESPP) that allows participating employees to purchase newly issued shares of the Company's common stock at a discount through payroll deductions. The ESPP consists of a 12-month offering period whereby employees can purchase shares at 85% of the market value at either the beginning of the offering period or the end of the offering period, whichever price is lower. Employees purchased 0.9 million shares each year in fiscal years 2013, 2012 and 2011. At December 28, 2013, 5.8 million shares of common stock were available for future purchases under the ESPP.
	The Company's total stock compensation expense for fiscal years 2013, 2012 and 2011 by income statement line item was as follows (in millions):


		2013				2012				2011
	Selling, general and administrative expense	$	45			$	49			$	55

	Research and development expense	15				15				15

	Cost of sales	5				5				6

	Total stock compensation expense	$	65			$	69			$	76


	Valuation Assumptions

	The Company uses the Black-Scholes standard option pricing model (Black-Scholes model) to determine the fair value of stock options and ESPP purchase rights. The determination of the fair value of the awards on the date of grant using the Black-Scholes model is affected by the Company's stock price as well as assumptions of other variables, including projected employee stock option exercise behaviors, risk-free interest rate, expected volatility of the Company's stock price in future periods and expected dividend yield. The fair value of both restricted stock and restricted stock units is based on the Company's closing stock price on the date of grant. The weighted average fair value of restricted stock awards granted during fiscal years 2013, 2012 and 2011 was $42.26, $37.63 and $49.77, respectively. The weighted average fair value of the restricted stock units granted during fiscal years 2013, 2012 and 2011 was $59.04, $35.39 and $35.14, respectively. The weighted average fair value of ESPP purchase rights granted to employees during fiscal years 2013, 2012 and 2011 was $13.06, $9.39 and $10.86, respectively.
	The following table provides the weighted average fair value of stock options granted to employees during fiscal years 2013, 2012 and 2011 and the related weighted average assumptions used in the Black-Scholes model:


		2013				2012				2011
	Fair value of options granted	$	13.83			$	7.71			$	9.17

	Assumptions:
	Expected life (years)	5.4				5.4				5.5

	Risk-free interest rate	1.6		%		0.7		%		0.9		%
	Volatility	28.6		%		31.2		%		33.9		%
	Dividend yield	1.8		%		2.5		%		2		%

	Expected Life: The Company analyzes historical employee exercise and termination data to estimate the expected life assumption. Annually, the Company updates these assumptions unless circumstances would indicate a more frequent update is necessary.
	Risk-free Interest Rate: The rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity equal to or approximating the expected life of the options.
	Volatility: The Company calculates its expected volatility assumption by blending the historical and implied volatility. The historical volatility is based on the daily closing prices of the Company's common stock over a period equal to the expected term of the option. Market-based implied volatility is based on utilizing market data of actively traded options on the Company's stock, from options at- or near-the-money, at a point in time as close to the grant date of the employee options as reasonably practical and with similar terms to the employee share option, or a remaining maturity of at least six months if no similar terms are available. The historical volatility of the Company's common stock price over the expected term of the option is a strong indicator of the expected future volatility. In addition, implied volatility takes into consideration market expectations of how future volatility will differ from historical volatility. The Company does not believe that one estimate is more reliable than the other, and as a result, the Company uses an equal weighting of historical volatility and market-based implied volatility.
	Dividend Yield: Beginning in fiscal year 2011, the Company began paying cash dividends. The Company's dividend yield assumption is based on the expected annual dividend yield on the grant date.

	Stock Compensation Activity

	The following table summarizes stock option activity under all stock compensation plans during the fiscal year ended December 28, 2013:


									Weighted
					Weighted				Average		Aggregate
					Average				Remaining		Intrinsic
		Options			Exercise				Contractual		Value
		(in millions)			Price				Term (in years)		(in millions)
	Outstanding at December 29, 2012	28.2			$	38.05

	Granted	2.7			59.16

	Exercised	(10.6	)		39.83

	Canceled	(1.4	)		40.05

	Outstanding at December 28, 2013	18.9			$	39.94			5.3		$	422

	Vested and expected to vest	18.2			$	39.7			5.2		$	409

	Exercisable at December 28, 2013	10.6			$	37.07			4.1		$	267


The aggregate intrinsic value of options outstanding and options exercisable is based on the Company's closing stock price on the last trading day of the fiscal year for in-the-money options. The aggregate intrinsic value represents the cumulative difference between the fair market value of the underlying common stock and the option exercise prices. The total intrinsic value of options exercised during fiscal years 2013, 2012 and 2011 was $125 million, $14 million and $96 million, respectively.
The following table summarizes activity for restricted stock awards and restricted stock units under all stock compensation plans during the fiscal year ended December 28, 2013:


				Weighted Average
	Restricted Stock			Grant Date
	(in millions)			Fair Value
Unvested balance at December 29, 2012	1.6			$	36.61

Granted	0.7			58.32

Vested	(0.5	)		37.45

Canceled	(0.2	)		36.96

Unvested balance at December 28, 2013	1.6			$	45.98

The total aggregate grant date fair value of restricted stock awards and restricted stock units vested during fiscal years 2013, 2012 and 2011 was $18 million, $11 million and $7 million, respectively.

Special_Charges

Special Charges	12 Months Ended
	Dec. 28, 2013
Special Charges [Abstract]	'
Special Charges	'
	PURCHASED IN-PROCESS RESEARCH AND DEVELOPMENT (IPR&D) AND SPECIAL CHARGES
	IPR&D Charges
	During 2011, the Company recorded IPR&D charges of $4 million in connection with the purchase of cardiac rhythm management-related intellectual property. As the related technological feasibility had not yet been reached and such technology had no future alternative use, the intellectual property asset purchase was expensed as IPR&D.
	Special Charges
	The Company recognizes certain transactions and events as special charges in its consolidated financial statements. These charges (such as restructuring charges, impairment charges and certain settlement or litigation charges) result from facts and circumstances that vary in frequency and impact on the Company's results of operations. In order to enhance segment comparability and reflect management's focus on the ongoing operations of the Company, special charges are not reflected in the individual reportable segments' operating results.
	2012 Business Realignment Plan
	During 2012, the Company incurred charges of $185 million resulting from the realignment of its product divisions into two new operating divisions: Implantable Electronic Systems Division (combining its legacy Cardiac Rhythm Management and Neuromodulation product divisions) and the Cardiovascular and Ablation Technologies Division (combining its legacy Cardiovascular and Atrial Fibrillation product divisions). In addition, the Company centralized certain support functions, including information technology, human resources, legal, business development and certain marketing functions. The organizational changes are part of a comprehensive plan to accelerate the Company's growth, reduce costs and leverage economies of scale. In connection with the realignment, the Company recognized $109 million of severance costs and other termination benefits after management determined that such severance and benefit costs were probable and estimable, in accordance with ASC Topic 712, Nonretirement Postemployment Benefits (ASC Topic 712). The 2012 business realignment plan reduced the Company's workforce by approximately 5%. The Company also recognized $17 million of inventory write-offs associated with discontinued CATD product lines and $41 million of incremental depreciation charges and fixed asset write-offs, primarily associated with information technology assets no longer expected to be utilized or with a limited remaining useful life. Additionally, the Company recognized $18 million of other restructuring costs which included $7 million of contract termination costs and $11 million of other costs.
	During 2013, the Company incurred additional charges totaling $220 million related to the realignment plan initiated during 2012. The Company also recognized severance costs and other termination benefits of $75 million after management determined that such severance and benefit costs were probable and estimable, in accordance with ASC Topic 712. Additionally, we recorded $30 million of inventory write-offs primarily associated with discontinued CATD product lines, $13 million of fixed asset write-offs primarily related to information technology assets no longer expected to be utilized and $102 million of other restructuring costs. Of the $102 million in other restructuring costs, $64 million was associated with distributor and other contract termination costs and office consolidation costs, including a $23 million charge related to the termination of a research agreement, and $38 million was associated with other costs, all as part of the Company's continued integration efforts.
	A summary of the activity related to the 2012 business realignment plan accrual is as follows (in millions):


		Employee				Inventory				Fixed				Other Restructuring Costs				Total
		Termination				Charges				Asset
		Costs								Charges
	Balance at December 31, 2011	$	—			$	—			$	—			$	—			$	—

	Cost of sales special charges	5				17				—				2				24

	Special charges	104				—				41				16				161

	Non-cash charges used	—				(17		)		(41		)		(3		)		(61		)

	Cash payments	(52		)		—				—				(7		)		(59		)

	Foreign exchange rate impact	1				—				—				—				1

	Balance at December 29, 2012	58				—				—				8				66

	Cost of sales special charges	—				30				—				5				35

	Special charges	75				—				13				97				185

	Non-cash charges used	—				(30		)		(13		)		(4		)		(47		)

	Cash payments	(79		)		—				—				(73		)		(152		)

	Foreign exchange rate impact	—				—				—				—				—

	Balance at December 28, 2013	$	54			$	—			$	—			$	33			$	87

	2011 Restructuring Plan
	During 2011, the Company incurred charges totaling $162 million related to restructuring actions to realign certain activities in the Company's legacy cardiac rhythm management business and sales and selling support organizations. The restructuring actions included phasing out cardiac rhythm management manufacturing and R&D operations in Sweden, reductions in the Company's workforce and rationalizing product lines. In connection with the staged phase-out of the manufacturing and R&D operations in Sweden, the Company began recognizing severance costs and other termination benefits for over 650 employees in accordance with ASC Topic 420, Exit or Disposal Cost Obligations whereby certain employee termination costs are recognized over the employees’ remaining future service period. Additionally, during 2011, the Company recognized certain severance costs for 550 employees after management determined that such severance and benefit costs were probable and estimable, in accordance with ASC Topic 712. The total charge for employee termination costs recognized during 2011 was $82 million. Additionally, the Company recognized $20 million of inventory obsolescence charges primarily associated with the rationalization of product lines across its business. The Company also recorded $26 million of impairment and incremental depreciation charges, of which $12 million related to an impairment charge to write-down the Company's manufacturing facility in Sweden to its fair value. Additionally, the Company recognized $34 million of other restructuring charges primarily associated with the cardiac rhythm management restructuring actions ($13 million of pension settlement charges associated with the termination of Sweden's defined benefit pension plan and $4 million of idle facility costs related to transitioning manufacturing operations out of Sweden) as well as $7 million of contract termination costs and $10 million of other costs.

	During 2012, the Company incurred additional charges totaling $102 million related to the restructuring actions initiated during 2011. The Company recognized severance costs and other termination benefits of $38 million for an additional 100 employees after management determined that such severance and benefit costs were probable and estimable, in accordance with ASC Topic 712. The Company also recognized $13 million of inventory obsolescence charges primarily related with the rationalization of product lines in its IESD segment. Additionally, the Company recognized $51 million of other restructuring charges which included $37 million of restructuring related charges associated with the Company's legacy cardiac rhythm management business and sales and selling support organizations (of which $13 million primarily related to idle facility costs in Sweden). The remaining charges included $8 million of contract termination costs and $6 million of other costs.
	During 2013, the Company recognized additional charges totaling $24 million related to the restructuring actions initiated during 2011. Of the $24 million recorded as special charges, the Company recognized severance costs and other termination benefits of $5 million after management determined that such severance and benefit costs were probable and estimable, in accordance with ASC Topic 712. The Company also recognized $1 million of fixed write-offs and $18 million of other restructuring costs, primarily associated with idle facility costs in Sweden.
	A summary of the activity related to the 2011 restructuring plan accrual is as follows (in millions):


		Employee				Inventory				Fixed				Other Restructuring Costs				Total
		Termination				Charges				Asset
		Costs								Charges
	Balance at January 1, 2011	$	—			$	—			$	—			$	—			$	—

	Cost of sales special charges	9				20				9				9				47

	Special charges	73				—				17				25				115

	Non-cash charges used	—				(20		)		(26		)		(1		)		(47		)

	Cash payments	(27		)		—				—				(15		)		(42		)

	Foreign exchange rate impact	(1		)		—				—				—				(1		)

Balance at December 31, 2011	54				—				—				18				72

Cost of sales special charges	11				13				—				20				44

Special charges	27				—				—				31				58

Non-cash charges used	—				(13		)		—				(4		)		(17		)

Cash payments	(68		)		—				—				(47		)		(115		)

Foreign exchange rate impact	1				—				—				(1		)		—

Balance at December 29, 2012	25				—				—				17				42

Cost of sales special charges	—				—				—				—				—

Special charges	5				—				1				18				24

Non-cash charges used	—				—				(1		)		—				(1		)

Cash payments	(21		)		—				—				(29		)		(50		)

Foreign exchange rate impact	—				—				—				—				—

Balance at December 28, 2013	$	9			$	—			$	—			$	6			$	15

Other Special Charges
Intangible asset impairment charges: During 2013, the Company recognized impairment charges of $29 million to write-down certain CATD indefinite-lived tradename and IPR&D assets to fair value. The impairments were due primarily to the Company's revised expectations, including an increase in the cost and length of time to bring the related products to market through U.S. regulatory approval. During 2012, the Company recognized a $23 million impairment charge for certain developed technology intangible assets, as the Company's updated expectations for the future cash flows of the related neuromodulation product lines decreased, ultimately resulting in the related assets' fair value falling below carrying value. Additionally, the Company discontinued certain CATD product lines and recognized $8 million of impairment charges to fully impair the related developed technology intangible assets. During 2013, 2012 and 2011, the Company also recognized $13 million, $2 million and $52 million, respectively, of impairments primarily associated with customer relationship intangible assets recognized in connection with legacy acquisitions involved in the distribution of the Company's products. Due to the changing dynamics of the U.S. healthcare market, specifically as it relates to hospital purchasing practices, the Company determined that these intangible assets had no future discrete cash flows and were fully impaired.
Settlement charges: During 2013, the Company agreed to settle a dispute on licensed technology associated with certain CATD product lines. In connection with the settlement, which resolved all disputed claims, the Company recognized a $22 million settlement expense. During 2012, the Company agreed to settle a dispute on licensed technology for the Company's Angio-Seal™ vascular closure devices. In connection with this settlement, which resolved all disputed claims and included a fully-paid perpetual license, the Company recognized a $28 million settlement expense which it classified as a special charge and also recognized a $12 million licensed technology intangible asset to be amortized over the technology's remaining patent life. During 2011, the Company recognized a $4 million legal settlement charge after reaching an agreement with the Office of Inspector General of the Department of Health and Human Services to settle a previously disclosed investigation initiated in December 2008 related to allegations that the Company failed to properly apply certain warranty credits.
Litigation charges: During 2013, the Company recognized $28 million of litigation charges for future probable and estimable legal costs related to outstanding matters associated with the Company's IESD field actions. Previously during 2012, the Company also recognized $16 million of litigation charges for future probable and estimable legal costs related to these same IESD field actions.
Field action charges: During 2013, the Company recognized special charges of $10 million, which was recorded to cost of sales, for additional costs related to the voluntary field action initiated in late 2012 associated with certain neuromodulation implantable pulse generator charging systems. During 2012, the Company recognized special charges of $27 million, of which $25 million was charged to cost of sales, for costs primarily related to the neuromodulation 2012 field action.

Other_Expense_Net

Other Expense, Net	12 Months Ended
	Dec. 28, 2013
Other Nonoperating Income (Expense) [Abstract]	'
Other Expense, Net	'
	OTHER EXPENSE, NET
	The Company’s other expense, net consisted of the following (in millions):


		2013			2012			2011
	Interest income	$	(5	)	$	(5	)	$	(4	)
	Interest expense	81			73			70

	Other	191			27			30

	Other expense, net	$	267		$	95		$	96

	During 2013, the Company redeemed the full $700 million principal amount of the 2014 Senior Notes and the full $500 million principal amount of the 2019 Senior Notes. In connection with the redemption of these notes, prior to their scheduled maturities, the Company recognized a $161 million debt retirement charge to other expense primarily associated with make-whole redemption payments and the write-off of unamortized debt issuance costs (see Note 4). Additionally, in connection with the initial February 2013 consolidation of CardioMEMS, the Company recognized a $29 million loss associated with a fair value remeasurement adjustment to other expense to adjust the carrying value of its equity investment and fixed price purchase option (see Note 2).
	The Company classifies realized gains or losses from the sale of investments to other income or expense. The Company recognized $13 million and $14 million of realized gains during 2013 and 2012, respectively, associated with the sale of available-for-sale securities. No realized gains or losses were recognized during 2011.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 28, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	INCOME TAXES
	The Company's earnings before income taxes as generated from its U.S. and international operations are as follows (in millions):


		2013				2012				2011
	U.S.	$	(17	)		$	316			$	502

	International	801				689				517

	Earnings before income taxes and noncontrolling interest	$	784			$	1,005			$	1,019


	Income tax expense consisted of the following (in millions):


		2013				2012				2011
	Current:
	U.S. federal	$	101			$	236			$	180

	U.S. state and other	7				16				13

	International	108				78				65

	Total current	216				330				258

	Deferred	(124		)		(77		)		(65		)
	Income tax expense	$	92			$	253			$	193


	Deferred income taxes result from temporary differences between the amount of assets and liabilities recognized for financial reporting and tax purposes. The components of deferred tax assets and liabilities are as follows (in millions):


		2013				2012
	Deferred income tax assets:
	Net operating and capital loss carryforwards	$	402			$	236

	Tax credit carryforwards	75				70

	Inventories	136				148

	Stock-based compensation	47				78

	Compensation and benefits	123				113

	R&D expenditures, capitalized for tax	112				—

	Accrued liabilities and other	130				133

		1,025				778

	Less: valuation allowance	(368		)		(228		)
	Deferred income tax assets	657				550

	Deferred income tax liabilities:
	Unrealized gain on available-for-sale securities	(11		)		(12		)
	Property, plant and equipment	(189		)		(204		)
	Intangible assets	(352		)		(307		)
	Deferred income tax liabilities	(552		)		(523		)
	Net deferred income tax assets (liabilities)	$	105			$	27


	At December 28, 2013, the Company had U.S. federal net operating loss carryforwards, the tax effect of which was $22 million and U.S. tax credit carryforwards, the tax effect of which was $4 million that will expire from 2017 through 2032 if not utilized. The Company also has state tax carryforwards, the tax effect of which was $71 million, that have an unlimited carryforward period. These amounts are subject to annual usage limitations. In addition, the Company had foreign tax net operating loss carryforwards, the tax effect of which was $380 million as of December 28, 2013. These tax attributes have an unlimited carryforward period.
	The Company establishes valuation allowances for deferred tax assets when, after consideration of all positive and negative evidence, it is considered more-likely-than-not that a portion of the deferred tax assets will not be realized. The Company's valuation allowances of $368 million and $228 million at December 28, 2013 and December 29, 2012, respectively, reduce the carrying value of deferred tax assets associated with certain net operating loss and tax credit carryforwards.
A reconciliation of the U.S. federal statutory income tax rate to the Company's effective income tax rate is as follows:


	2013			2012			2011
U.S. federal statutory tax rate	35	%		35	%		35	%
Increase (decrease) in tax rate resulting from:
U.S. state income taxes, net of federal tax benefit	0.6			0.5			1.2

International taxes at lower rates	(13.6	)		(12.1	)		(11.6	)
Tax benefits from domestic manufacturer's deduction	(1.9	)		(2.2	)		(2.0	)
Research and development credits	(4.6	)		(1.1	)		(2.7	)
Puerto Rico excise tax	(3.0	)		(1.8	)		(1.7	)
Tax settlements	(1.9	)		4.6			—

Noncontrolling interest	3.6			—			—

Other	(2.5	)		2.3			0.8

Effective income tax rate	11.7	%		25.2	%		19	%
The Company's effective income tax rate is favorably impacted by tax incentive grants, which result in Puerto Rico and Costa Rica earnings being partially tax exempt through the year 2023.

The Company has not recorded U.S. deferred income taxes on approximately $3.6 billion of its non-U.S. subsidiaries' undistributed earnings because such amounts are intended to be reinvested outside the United States indefinitely. If these earnings were repatriated to the United States, the Company would be required to accrue and pay U.S. federal income taxes and foreign withholding taxes, as adjusted for foreign tax credits. Determination of the amount of any unrecognized deferred income tax liability on these earnings is not practicable.

The Company recognizes all income tax liabilities in accordance with ASC Topic 740, Income Taxes, including liabilities for unrecognized tax benefits that require application of accounting estimates that are subject to the inherent uncertainties associated with the tax audit process, and therefore include certain contingencies. The Company recognizes interest and penalties related to income tax matters in income tax expense. The Company recognized interest and penalties, net of tax benefit, of $2 million, $22 million and $1 million during fiscal years 2013, 2012 and 2011, respectively. The Company's accrued liability for gross interest and penalties was $37 million, $69 million and $35 million at December 28, 2013, December 29, 2012 and December 31, 2011, respectively.
The following table summarizes the activity related to the Company's unrecognized tax benefits (in millions):


	2013				2012				2011
Balance at beginning of year	$	314			$	205			$	163

Increases related to current year tax positions	74				38				33

Increases related to prior year tax positions	33				90				16

Reductions related to prior year tax positions	(16		)		(18		)		(1		)
Reductions related to settlements / payments	(90		)		(1		)		(2		)
Expiration of the statute of limitations for the assessment of taxes	—				—				(4		)

Balance at end of year	$	315			$	314			$	205

The Company is subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. The Company has substantially concluded all material U.S. federal, state, foreign and local income tax matters for all tax years through 2004. The U.S. Internal Revenue Service (IRS) is currently auditing the Company’s 2008 and 2009 tax returns and an audit report is expected to be issued in 2014. The Company does not expect its unrecognized tax benefits to change significantly over the next 12 months.

Retirement_Plans

Retirement Plans	12 Months Ended
Retirement Plans	Dec. 28, 2013
Retirement Plans [Abstract]	'
Pension and Other Postretirement Benefits Disclosure [Text Block]	'
	RETIREMENT PLANS
	Defined Contribution Plans: The Company has a 401(k) profit sharing plan that provides retirement benefits to substantially all full-time U.S. employees. Eligible employees may contribute a percentage of their annual compensation, subject to IRS limitations, with the Company matching a portion of the employees' contributions at the discretion of the Company's Board of Directors. In addition, the Company has defined contribution programs for employees in certain countries outside the United States. Company contributions under all defined contribution plans totaled $26 million, $26 million and $23 million in 2013, 2012 and 2011, respectively.
	The Company also has a non-qualified deferred compensation plan that provides certain officers and employees the ability to defer a portion of their compensation until a later date. The deferred amounts and earnings thereon are payable to participants, or designated beneficiaries, at specified future dates upon retirement, death or termination from the Company. The deferred compensation liability, which is classified as other liabilities, was approximately $282 million and $234 million at December 28, 2013 and December 29, 2012, respectively.
	Defined Benefit Plans: The Company has funded and unfunded defined benefit plans for employees in certain countries outside the United States. The Company had an accrued liability totaling $17 million and $16 million at December 28, 2013 and December 29, 2012, respectively, which approximated the actuarial calculated unfunded liability. The amount of funded plan assets and the amount of pension expense was not material. In connection with the legacy cardiac rhythm management restructuring actions (see Note 9), the Company elected to terminate its defined benefit pension plan in Sweden and made a lump sum settlement payment of $31 million during the fourth quarter of 2011 and recognized a pension settlement charge of $13 million.

Fair_Value_Measurements_And_Fi

Fair Value Measurements And Financial Instruments	12 Months Ended
	Dec. 28, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements And Financial Instruments	'
	FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS
	The fair value measurement accounting standard, codified in ASC Topic 820, Fair Value Measurement (ASC Topic 820), provides a framework for measuring fair value and defines fair value as the price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. The standard establishes a valuation hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on independent market data sources. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available. The valuation hierarchy is composed of three categories. The categorization within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement.
	The categories within the valuation hierarchy are described as follows:

	•	Level 1 – Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.

	•	Level 2 – Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.

	•	Level 3 – Inputs to the fair value measurement are unobservable inputs or valuation techniques.
	Assets and Liabilities that are Measured at Fair Value on a Recurring Basis
	The fair value measurement standard applies to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). These financial assets and liabilities include money-market securities, trading marketable securities, available-for-sale marketable securities and derivative instruments. The Company continues to record these items at fair value on a recurring basis and the fair value measurements are applied using ASC Topic 820. The Company does not have any material nonfinancial assets or liabilities that are measured at fair value on a recurring basis. A summary of the valuation methodologies used for the respective financial assets and liabilities measured at fair value on a recurring basis is as follows:
	Money-market securities: The Company’s money-market securities include funds that are traded in active markets and are recorded at fair value based upon the quoted market prices. The Company classifies these securities as level 1.
	Trading securities: The Company’s trading securities include publicly-traded mutual funds that are traded in active markets and are recorded at fair value based upon quoted market prices of the net asset values of the funds. The Company classifies these securities as level 1.
	Available-for-sale securities: The Company’s available-for-sale securities include publicly-traded equity securities that are traded in active markets and are recorded at fair value based upon the closing stock prices. The Company classifies these securities as level 1.
	Derivative instruments: The Company’s derivative instruments consist of foreign currency exchange contracts and interest rate swap contracts. The Company classifies these instruments as level 2 as the fair value is determined using inputs other than observable quoted market prices. These inputs include spot and forward foreign currency exchange rates and interest rates that the Company obtains from standard market data providers. The fair value of the Company’s outstanding foreign currency exchange contracts was not material at December 28, 2013 or December 29, 2012.
	Contingent Consideration: In connection with certain business combinations or purchases of intellectual property the Company may agree to provide future contingent consideration payments. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels, achieving product development targets or receiving regulatory approvals to market products. Contingent consideration is recognized on the acquisition date at the estimated fair value of the contingent milestone payment(s). The acquisition date fair value is measured based on the consideration expected to be transferred (probability-weighted), discounted back to present value. The discount rate used is determined at the time of measurement in accordance with accepted valuation methods. The fair value of the contingent consideration is remeasured to its estimated fair value at each reporting period with the change in fair value recognized in selling, general and administrative expense in the Company's Consolidated Statements of Earnings. The Company measures the liability on a recurring basis using Level 3 inputs including projected revenues or cash flows, growth rates, discount rates, probabilities of payment and projected payment dates. Projected revenues are based on the Company's most recent internal operating budgets and long-term strategic plans. Increases or decreases to any of the inputs may result in significantly higher or lower fair value measurements.
	A summary of assets and liabilities measured at fair value on a recurring basis at December 28, 2013 and December 29, 2012 is as follows (in millions):


		Balance Sheet	December 28, 2013				Quoted Prices				Significant		Significant
		Classification					In Active				Other		Unobservable
							Markets				Observable		Inputs
							(Level 1)				Inputs		(Level 3)
											(Level 2)
	Assets

	Money-market securities	Cash and cash equivalents	$	875			$	875			$	—	$	—

	Available-for-sale securities	Other current assets	35				35				—		—

	Trading securities	Other assets	279				279				—		—

	Total assets		1,189				1,189				—		—


	Liabilities
	Contingent consideration	Other liabilities	195				—				—		195

	Total liabilities		$	195			$	—			$	—	$	195




		Balance Sheet	December 29, 2012				Quoted Prices				Significant		Significant
		Classification					In Active				Other		Unobservable
							Markets				Observable		Inputs
							(Level 1)				Inputs		(Level 3)
											(Level 2)
	Assets

	Money-market securities	Cash and cash equivalents	$	964			$	964			$	—	$	—

	Available-for-sale securities	Other current assets	41				41				—		—

	Trading securities	Other assets	231				231				—		—

	Total assets		$	1,236			$	1,236			$	—	$	—


	The recurring Level 3 fair value measurements of our contingent consideration liability include the following significant unobservable inputs (in millions):


	Contingent Consideration Liability	Fair Value as of December 28, 2013			Valuation Technique		Unobservable Input		Range

Endosense regulatory-based milestone	$	139		Probability Weighted Discounted Cash Flow		Discount Rate		1.15%	-	1.59%

						Probability of Payment				90%
						Projected Year of Payment				2014

Nanostim regulatory-based milestone	56			Probability Weighted Discounted Cash Flow		Discount Rate				5.00%

						Probability of Payment				100%
						Projected Years of Three Annual Payments		2016, 2017, 2018
Total contingent consideration liability	$	195


Additionally, the following table provides a reconciliation of the beginning and ending balances of the Company's contingent consideration liability associated with its Endosense acquisition subsequent to August 19, 2013 and its Nanostim acquisition subsequent to October 11, 2013, as of December 28, 2013 (in millions):



	Endosense			Nanostim			Total
Balance as of December 29, 2012	$	—		$	—		$	—

Purchase price contingent consideration	132			56			188

Change in fair value of contingent consideration	1			—			1

Foreign currency translation	6			—			6

Balance as of December 28, 2013	$	139		$	56		$	195

The Company also had $498 million and $230 million of cash equivalents invested in short-term deposits and interest and non-interest bearing bank accounts at December 28, 2013 and December 29, 2012, respectively.
Assets and Liabilities that are Measured at Fair Value on a Nonrecurring Basis
The fair value measurement standard also applies to certain nonfinancial assets and liabilities that are measured at fair value on a nonrecurring basis. A summary of the valuation methodologies used for the respective nonfinancial assets and liabilities measured at fair value on a nonrecurring basis is as follows:
Long-lived assets: The Company reviews the carrying amount of its long-lived assets other than goodwill and indefinite-lived intangible assets for potential impairment whenever events or changes in circumstance include a significant decrease in market price, a significant adverse change in the extent or manner in which an asset is being used or a significant adverse change in the legal or business climate. The Company measures the fair value of its long-lived assets, such as its definite-lived intangible assets and property, plant and equipment using independent appraisals, market models and discounted cash flow models. A discounted cash flow model requires inputs to a present value cash flow calculation including a risk-adjusted discount rate, operating budgets, long-term strategic plans and remaining useful lives of the asset or asset group. If the carrying value of the Company’s long-lived assets (excluding goodwill and indefinite-lived intangible assets) exceeds the related undiscounted future cash flows, the carrying value is written down to the fair value in the period identified.
The Company also reviews the carrying value of its goodwill and indefinite-lived intangible assets at least annually to determine if any adverse conditions exist that would indicate a potential impairment by considering qualitative factors such as macroeconomic conditions, industry and market considerations, cost factors, financial performance, entity specific events, changes in net assets and project-based performance toward regulatory approvals. During 2013, the Company performed a qualitative assessment of its indefinite-lived intangible assets by considering many of the above factors and subsequently determined that a quantitative impairment analysis was further necessary for certain CATD indefinite-lived tradename and IPR&D assets. The Company utilized a discounted cash flow model for each individual asset level under scrutiny and recognized an impairment charge of $29 million to write-down the related assets to their estimated fair value of $50 million. The impairments were due primarily to the Company's revised expectations, including an increase in the cost and length of time to bring the related products to market through U.S. regulatory approval. The fair value measurements of these intangible assets are considered Level 3 in the fair value hierarchy due to the use of unobservable inputs used to measure fair value, including the terminal growth rate, royalty rate, discount rate and projected future cash flows.
During 2012, the Company determined that certain neuromodulation purchased technology intangible assets were impaired and recognized a $23 million impairment charge to write-down the intangible assets to their estimated fair value of $3 million. The Company also determined that certain purchased technology intangible assets in the Company's CATD segment were fully impaired as the related product lines were discontinued and recognized an $8 million impairment charge as these intangible assets had no discrete future cash flows. The fair value measurements of both of these intangible assets are considered Level 3 in the fair value hierarchy due to the use of unobservable inputs to measure fair value, including the terminal growth rate, royalty rate, discount rate and projected future cash flows.
During 2011, the Company initiated restructuring actions resulting in the planned future closure of its cardiac rhythm management manufacturing facility in Sweden, resulting in the recognition of a $12 million impairment charge to write-down the facility to its estimated fair value of $13 million. The fair value measurement of the facility is considered Level 2 in the fair value hierarchy due to the use of observable inputs, specifically comparable third party sale prices for similar facilities.
During 2013, 2012 and 2011, the Company recognized $13 million, $2 million and $52 million, respectively, of intangible asset impairments primarily associated with customer relationship intangible assets acquired in connection with legacy acquisitions of businesses involved in the distribution of the Company's products. Due to the changing dynamics of the U.S. healthcare market, specifically as it relates to hospital purchasing practices, the Company determined that these intangible assets had no future discrete cash flows and were fully impaired. Refer to Note 9 for further details of these charges.
Cost method investments: The Company also holds investments in equity securities that are accounted for as cost method investments, which are classified as other assets and measured at fair value on a nonrecurring basis. The carrying value of these investments approximated $69 million and $151 million at December 28, 2013 and December 29, 2012, respectively. The fair value of the Company’s cost method investments is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of these investments. When measured on a nonrecurring basis, the Company’s cost method investments are considered Level 3 in the fair value hierarchy due to the use of unobservable inputs to measure fair value.
Fair Value Measurements of Other Financial Instruments
The aggregate fair value of the Company’s fixed-rate senior notes at December 28, 2013 (measured using quoted prices in active markets) was $2,236 million compared to the aggregate carrying value of $2,304 million (inclusive of the terminated interest rate swap). The fair value of the Company’s variable-rate debt obligations at December 28, 2013 approximated their aggregate $1,276 million carrying value due to the variable interest rate and short-term nature of these instruments.

Derivative_Financial_Instrumen

Derivative Financial Instruments	12 Months Ended
Derivative Financial Instruments	Dec. 28, 2013
General Discussion of Derivative Instruments and Hedging Activities [Abstract]	'
Derivative Financial Instruments	'
	DERIVATIVE FINANCIAL INSTRUMENTS
	The Company follows the provisions of ASC Topic 815 in accounting for and disclosing derivative instruments and hedging activities. All derivative financial instruments are recognized on the balance sheet at fair value. Changes in the fair value of derivatives are recognized in net earnings or other comprehensive income depending on whether the derivative is designated as part of a qualifying hedge transaction. Derivative assets and derivative liabilities are classified as other current assets, other assets, other current liabilities or other liabilities based on the gain or loss position of the contract and the contract maturity date.
	Foreign Currency Forward Contracts
	The Company hedges a portion of its foreign currency exchange rate risk through the use of forward exchange contracts. The Company uses forward exchange contracts to manage foreign currency exposures related to intercompany receivables and payables arising from intercompany purchases of manufactured products. These forward contracts are not designated as qualifying hedging relationships under ASC Topic 815. The Company measures its foreign currency exchange contracts at fair value on a recurring basis. The fair value of its outstanding contracts was immaterial as of December 28, 2013 and December 29, 2012. During fiscal years 2013, 2012 and 2011 the net amount of gains (losses) the Company recorded to other expense, net for its forward currency exchange contracts not designated as hedging instruments under ASC Topic 815 were net gains of $15 million and $7 million, and a net loss of $3 million, respectively. These net gains (losses) were almost entirely offset by corresponding net (losses) gains on the foreign currency exposures being managed. The Company does not enter into contracts for trading or speculative purposes. The Company’s policy is to enter into hedging contracts with major financial institutions that have at least an “A” (or equivalent) credit rating.
	Interest Rate Swap
	In prior periods, the Company has chosen to hedge the fair value of certain debt obligations through the use of interest rate swap contracts. For interest rate swap contracts that are designated and qualify as fair value hedges, changes in the value of the fair value hedge are recognized as an asset or liability, as applicable, offsetting the changes in the fair value of the hedged debt instrument. When outstanding, the Company’s swap contracts are recorded on the consolidated balance sheets as a component of other current assets, other assets, other accrued expenses or other liabilities based on the gain or loss position of the contract and the contract maturity date. Additionally, any payments made or received under the swap contracts are accrued and recognized as interest expense. In June 2012, the Company terminated the interest rate swap it had entered into concurrent with the March 2010 issuance of the 2016 Senior Notes and received a cash payment of $24 million. The gain from terminating the interest rate swap agreement has been reflected as an increase to the carrying value of the debt and is being amortized as a reduction of interest expense resulting in a net average interest rate of 1.3% that will be recognized over the remaining term of the 2016 Senior Notes.
	Interest Rate Contracts
	During the first quarter of 2013, the Company entered into and settled treasury rate lock agreements in anticipation of issuing the $900 million principal amount of 2023 Senior Notes and the $700 million principal amount of 2043 Senior Notes. Prior to the issuance of the senior notes, the Company was subject to changes in treasury benchmark interest rates, and therefore locked into fixed-rate coupons to hedge against the interest rate fluctuations. The Company designated the treasury rate lock agreements as cash flow hedges under ASC Topic 815. Upon settlement, the $3 million gain was recognized as a component of other comprehensive income, and will be recognized as a reduction to interest expense over the life of the senior notes. The amount of hedge ineffectiveness was immaterial.

Segment_And_Geographic_Informa

Segment And Geographic Information	12 Months Ended
	Dec. 28, 2013
Segments, Geographical Areas [Abstract]	'
Segment And Geographic Information	'
	SEGMENT AND GEOGRAPHIC INFORMATION
	Segment Information
	In August 2012, the Company announced the realignment of its product divisions into two new business units (or divisions): the Implantable Electronic Systems Division (combining its legacy Cardiac Rhythm Management and Neuromodulation product divisions) and the Cardiovascular and Ablation Technologies Division (combining its legacy Cardiovascular and Atrial Fibrillation product divisions). In addition, the Company centralized certain support functions, including information technology, human resources, legal, business development and certain marketing functions. The organizational changes were part of a comprehensive plan to accelerate its growth, reduce costs and leverage economies of scale. The Company began reporting under the new organizational structure as of the beginning of fiscal year 2013. Prior period amounts in the following tables have been recast to conform to the Company's new reportable segment structure.
	The Company's principal products in each business unit are as follows: Implantable Electronic Systems Division (IESD) – tachycardia implantable cardioverter defibrillator systems (ICDs), bradycardia pacemaker systems (pacemakers) and neurostimulation products (spinal cord and deep brain stimulation devices); and Cardiovascular and Ablation Technologies Division (CATD) – vascular products (vascular closure products, pressure measurement guidewires, optical coherence tomography (OCT) imaging products, vascular plugs and other vascular accessories), structural heart products (heart valve replacement and repair products and structural heart defect devices) and AF products (EP introducers and catheters, advanced cardiac mapping, navigation and recording systems and ablation systems).
	Net sales of the Company’s reportable segments include end-customer revenues from the sale of products they each develop and manufacture or distribute. The costs included in each of the reportable segments’ operating results include the direct costs of the products sold to customers and operating expenses managed by each of the reportable segments. Certain expenses managed by the Company’s selling and corporate functions, including all stock-based compensation expense, impairment charges, certain acquisition-related charges, IPR&D charges, excise tax expense, special charges and centralized support groups' operating expenses are not recorded in the IESD and CATD reportable segments. As a result, reportable segment operating profit is not representative of the operating profit of the products in these reportable segments. Additionally, certain assets are managed by the Company’s selling and corporate functions, principally including trade receivables, inventory, cash and cash equivalents, certain marketable securities and deferred income taxes. For management reporting purposes, the Company does not compile capital expenditures by reportable segment; therefore, this information has not been presented, as it is impracticable to do so.
	The following table presents net sales and operating profit by reportable segment (in millions):


		IESD			CATD			Other			Total
	Fiscal Year 2013

	Net sales	$	3,209		$	2,292		$	—		$	5,501

	Operating profit	2,138			1,349			(2,436		)	1,051

	Depreciation and amortization expense	80			89			128			297

	Total assets	2,855			3,273			4,120			10,248

	Fiscal Year 2012

	Net sales	$	3,277		$	2,226		$	—		$	5,503

	Operating profit	2,274			1,326			(2,500		)	1,100

	Depreciation and amortization expense	73			91			120			284

	Total assets	2,320			2,967			3,984			9,271

	Fiscal Year 2011
	Net sales	$	3,453		$	2,159		$	—		$	5,612

	Operating profit	2,240			1,211			(2,336		)	1,115

	Depreciation and amortization expense	87			84			125			296

	Total assets	2,394			3,086			3,638			9,118

	Geographic Information

	The Company markets and sells its products primarily through a direct sales force. The principal geographic markets for the Company's products are the United States, Europe, Japan and Asia Pacific. The Company attributes net sales to geographic markets based on the location of the customer.

	Net sales by significant geographic market based on customer location for the respective fiscal years were as follows (in millions):


	Net Sales	2013			2012			2011
	United States	$	2,596		$	2,594		$	2,648

	International

	Europe	1,473			1,432			1,559

	Japan	567			665			641

	Asia Pacific	490			456			416

	Other	375			356			348

		2,905			2,909			2,964

		$	5,501		$	5,503		$	5,612

	The amounts for long-lived assets by significant geographic market include net property, plant and equipment by physical location of the asset as follows (in millions):


Long-Lived Assets	December 28, 2013			December 29, 2012			December 31, 2011
United States	$	1,045		$	1,036		$	1,007

International

Europe	73			82			84

Japan	28			32			31

Asia Pacific	75			82			81

Other	189			193			185

	365			389			381

	$	1,410		$	1,425		$	1,388

Quarterly_Financial_Data

Quarterly Financial Data	12 Months Ended
	Dec. 28, 2013
Quarterly Financial Data [Abstract]	'
Quarterly Financial Information [Text Block]	'
	QUARTERLY FINANCIAL DATA (UNAUDITED)


		First			Second			Third			Fourth
	(in millions, except per share amounts)	Quarter			Quarter			Quarter			Quarter

	Fiscal Year 2013:
	Net sales	$	1,338		$	1,403		$	1,338		$	1,422

	Gross profit	961			1,021			953			992

	Net earnings attributable to St. Jude Medical, Inc. (a)	223		(b)	115		(c)	262		(d)	123		(e)

	Basic net earnings per share	$	0.78		$	0.41		$	0.91		$	0.42

	Diluted net earnings per share	$	0.78		$	0.4		$	0.9		$	0.42

	Cash dividends declared per share	$	0.25		$	0.25		$	0.25		$	0.25


	Fiscal Year 2012:
	Net sales	$	1,395		$	1,410		$	1,326		$	1,372

	Gross profit	1,014			1,027			971			953

	Net earnings attributable to St. Jude Medical, Inc. (f)	212		(g)	244			176		(h)	120		(i)

	Basic net earnings per share	$	0.67		$	0.78		$	0.56		$	0.39

	Diluted net earnings per share	$	0.67		$	0.78		$	0.56		$	0.39

	Cash dividends declared per share	$	0.23		$	0.23		$	0.23		$	0.23



	(a)	Restructuring and realignment activities related to previously announced actions as the Company continues to integrate its product divisions and centralize certain support functions resulted in after-tax special charges of $32 million for the first quarter, $34 million for the second quarter, $13 million for the third quarter and $97 million for the fourth quarter of 2013.

	(b)	Includes after-tax acquisition-related charges of $29 million to adjust the carrying value of the Company's pre-existing CardioMEMS equity investment and fixed price purchase option to fair value and a $21 million income tax benefit related to extending the 2012 federal research and development tax credit, retroactive to the beginning of our 2012 tax year.

	(c)	Includes $101 million of after-tax debt retirement costs primarily associated with the make-whole redemption payments and the write-off of unamortized debt issuance costs, $14 million of after-tax special charges related to a license dispute settlement charge, $8 million related to after-tax special charges associated with intangible asset impairment charges and $3 million of after-tax acquisition-related costs.

	(d)	Includes a $15 million income tax benefit related to the settlement of domestic tax audits and $2 million of after-tax charges associated with acquisition-related costs.

	(e)	Includes $25 million of after-tax special charges associated with IESD litigation and field action costs, $19 million of after-tax special charges related to intangible asset impairment charges, $15 million of after-tax acquisition-related costs and a $15 million income tax expense charge related to prior year uncertain tax positions in foreign jurisdictions.

	(f)	Restructuring and realignment activities resulted in after-tax special charges of $29 million for the first quarter, $27 million for the second quarter, $66 million for the third quarter and $75 million for the fourth quarter of 2012.

	(g)	Includes after-tax special charges of $25 million related to a license dispute settlement charge.

	(h)	Includes after-tax special charges of $15 million for intangible asset impairment charges.

	(i)	Includes after-tax special charges of $27 million related to IESD litigation and field action costs and after-tax special charges of $11 million for intangible asset impairment charges and CATD inventory write-offs associated with discontinued product lines. Additionally, the Company recognized $46 million of additional income tax expense related to a settlement reserve for certain prior year tax positions.

Valuation_and_Qualifying_Accou

Valuation and Qualifying Accounts	12 Months Ended
	Dec. 28, 2013
Valuation and Qualifying Accounts [Abstract]	'
Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]	'
	SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTS

	(In millions)


			Balance		Additions				Deductions
	Description		at Beginning		Charged to		Other (2)		Write-offs (1)			Other (2)			Balance at
			of Year		Expense										End of Year
	Allowance for doubtful accounts:

	Fiscal year ended

	28-Dec-13		$	47	$	14	$	—	$	(16	)	$	—		$	45

	29-Dec-12		$	101	$	6	$	1	$	(61	)	$	—		$	47

	31-Dec-11		$	35	$	72	$	—	$	(3	)	$	(3	)	$	101



	-1	Uncollectible accounts written off, net of recoveries. During 2012, the Company wrote-off $55 million related to its Greek distributor, previously reserved for during the fiscal year ended December 31, 2011.

	-2	In 2012 and 2011, $1 million and $(3) million, respectively, of “other” represents the effects of changes in foreign currency translation.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies Principles of Consolidation (Policies)	12 Months Ended
	Dec. 28, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Consolidation, Policy [Policy Text Block]	'
Consolidation, Policy [Policy Text Block]	Principles of Consolidation: The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries and entities for which St. Jude Medical has a controlling financial interest. Intercompany transactions and balances have been eliminated in consolidation. For variable interest entities (VIEs), the Company assesses the terms of its interest in the entity to determine if St. Jude Medical is the primary beneficiary. Variable interests are ownership, contractual or other interests in an entity that change with increases or decreases in the fair value of the VIE's net assets exclusive of variable interests. The entity that consolidates the VIE is considered the primary beneficiary, and is defined as the party with (1) the power to direct activities of the VIE that most significantly affect the VIE's economic performance and (2) the obligation to absorb losses of the VIE or the right to receive benefits from the VIE. In the first quarter of 2013, the Company determined that CardioMEMS, Inc. (CardioMEMS) was a VIE for which the Company is the primary beneficiary and began consolidating their results effective February 27, 2013. Additionally, during the second quarter of 2013, the Company entered into a $40 million equity investment, contingent acquisition agreement and exclusive distribution agreement with Spinal Modulation, Inc. (Spinal Modulation) and determined it also was a VIE for which the Company is the primary beneficiary. The Company began consolidating Spinal Modulation's results effective June 7, 2013 (see Note 2).

Summary_of_Significant_Account2

Summary of Significant Accounting Policies Fiscal Year (Policies)	12 Months Ended
	Dec. 28, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Fiscal Period, Policy [Policy Text Block]	'
Fiscal Period, Policy [Policy Text Block]	Fiscal Year: The Company utilizes a 52/53-week fiscal year ending on the Saturday nearest December 31st. Fiscal year 2013, 2012 and 2011 consisted of 52 weeks and ended on December 28, 2013, December 29, 2012 and December 31, 2011, respectively.

Summary_of_Significant_Account3

Summary of Significant Accounting Policies Use of Estimates (Policies)	12 Months Ended
	Dec. 28, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Use of Estimates, Policy [Policy Text Block]	'
Use of Estimates, Policy [Policy Text Block]	Use of Estimates: Preparation of the Company's consolidated financial statements in conformity with accounting principles generally accepted in the United States (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Summary_of_Significant_Account4

Summary of Significant Accounting Policies Cash and cash equivalents (Policies)	12 Months Ended
	Dec. 28, 2013
Cash and Cash Equivalents [Abstract]	'
Cash and Cash Equivalents, Policy [Policy Text Block]	'
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash Equivalents: The Company considers highly liquid investments with an original maturity of three months or less to be cash equivalents. Cash equivalents are stated at cost, which approximates fair value. The Company's cash equivalents include bank certificates of deposit, money market funds and instruments and commercial paper investments. The Company performs periodic evaluations of the relative credit standing of the financial institutions and issuers of its cash equivalents and limits the amount of credit exposure with any one issuer.

Summary_of_Significant_Account5

Summary of Significant Accounting Policies Marketable securities (Policies)	12 Months Ended
	Dec. 28, 2013
Cash and Cash Equivalents [Abstract]	'
Marketable Securities, Policy [Policy Text Block]	'
	Marketable Securities: Marketable securities consist of publicly-traded equity securities that are classified as available-for-sale securities and investments in mutual funds that are classified as trading securities. On the balance sheet, available-for-sale securities and trading securities are classified as other current assets and other assets, respectively.
	The following table summarizes the components of the balance of the Company's available-for-sale securities at December 28, 2013 and December 29, 2012 (in millions):


		December 28, 2013		December 29, 2012
	Adjusted cost	$	7	$	9

	Gross unrealized gains	28		32

	Fair value	$	35	$	41


	Available-for-sale securities are reported at fair value based upon quoted market prices (see Note 13). Unrealized gains and losses, net of related incomes taxes, are recognized in accumulated other comprehensive income in shareholders' equity. Upon the sale of an available-for-sale security, the unrealized gain (loss) is reclassified out of accumulated other comprehensive income and reflected as a realized gain (loss) in net earnings. Realized gains (losses) are computed using the specific identification method and recognized as other expense, net. During both 2013 and 2012, the Company sold available-for-sale securities, recognizing pre-tax gains of $13 million and $14 million, respectively (see Note 10). There were no realized gains (losses) from the sale of available-for-sale securities recorded during fiscal year 2011. Additionally, when the fair value of an available-for-sale security falls below its original cost and the Company determines that the corresponding unrealized loss is other-than-temporary, it recognizes an impairment loss to net earnings in that period. There were no available-for-sale impairment losses recognized in fiscal years 2013, 2012 or 2011.

	The Company's investments in mutual funds are reported at fair market value based upon quoted market prices (see Note 13) and are held in a rabbi trust, which is not available for general corporate purposes and is subject to creditor claims in the event of insolvency. These investments are specifically designated as available to the Company solely for the purpose of paying benefits under the Company's deferred compensation plan (see Note 12).

Summary_of_Significant_Account6

Summary of Significant Accounting Policies Accounts receivable (Policies)	12 Months Ended
	Dec. 28, 2013
Receivables [Abstract]	'
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy	'
	Accounts Receivable: The Company grants credit to customers in the normal course of business, but generally does not require collateral or any other security to support its receivables. The Company maintains an allowance for doubtful accounts for potential credit losses. During 2013, the Company recognized a $9 million accounts receivable allowance charge in connection with a distributor termination in Europe. During 2011, the Company recognized a $57 million accounts receivable allowance charge with a distributor in the Greece market. In February 2012, an agreement was reached between the Greek government and the European Union and International Monetary Fund whereby creditors would swap existing Greek government bonds for new bonds with a significant reduction in face value, a longer term and lower interest rates. This agreement, among other macroeconomic and factors specific to the distributor, negatively impacted the solvency and liquidity of the Company's Greece distributor, raising significant doubt regarding the collectability of the Company's outstanding receivable balance. As a result, the Company recognized the $57 million accounts receivable allowance charge in the consolidated financial statements for the fiscal year ended December 31, 2011, which was subsequently written off during 2012. The Company also recognized an additional $9 million accounts receivable allowance charge in 2011 for increased collection risk associated with a customer in Europe. No significant accounts receivable allowance charges were recognized in 2012. The Company's total allowance for doubtful accounts was $45 million and $47 million at December 28, 2013 and December 29, 2012, respectively.

Summary_of_Significant_Account7

Summary of Significant Accounting Policies Inventory (Policies)	12 Months Ended
	Dec. 28, 2013
Inventory Disclosure [Abstract]	'
Inventory, Policy [Policy Text Block]	'
	Inventories: Inventories are stated at the lower of cost or market with cost determined using the first-in, first-out method. Inventories consisted of the following (in millions):



		December 28, 2013		December 29, 2012
	Finished goods	$	494	$	416

	Work in process	52		50

	Raw materials	162		144

		$	708	$	610

Summary_of_Significant_Account8

Summary of Significant Accounting Policies Property, plant and equipment (Policies)	12 Months Ended
	Dec. 28, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment, Policy [Policy Text Block]	'
Property, Plant and Equipment, Policy [Policy Text Block]	Property, Plant and Equipment: Property, plant and equipment are recorded at cost and are depreciated using the straight-line method over their estimated useful lives, ranging from 15 years to 39 years for buildings and improvements, three to 15 years for machinery and equipment, including capitalized development costs for internal-use software, and three to seven years for diagnostic equipment. Diagnostic equipment primarily consists of programmers that are used by physicians and healthcare professionals to program and analyze data from ICDs and pacemakers. Diagnostic equipment also includes other capital equipment provided by us to customers for use in diagnostic and surgical procedures. The estimated useful lives of this equipment are based on anticipated usage by physicians and healthcare professionals and the timing and impact of expected new technology platforms and rollouts by the Company. Property, plant and equipment are depreciated using accelerated methods for income tax purposes. During 2013, 2012 and 2011, depreciation expense was $218 million, $196 million, and $203 million, respectively.

Summary_of_Significant_Account9

Summary of Significant Accounting Policies Goodwill and intangible assets (Policies)	12 Months Ended
	Dec. 28, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets, Policy [Policy Text Block]	'
	Goodwill: Goodwill represents the excess of cost over the fair value of identifiable net assets of a business acquired. Goodwill for each reporting unit is reviewed for impairment at least annually. The Company assesses goodwill impairment by considering qualitative factors such as macroeconomic conditions, industry and market considerations, cost factors, financial performance, entity specific events, changes in net assets and sustained decrease in share price. If the qualitative assessment results in a determination that the fair value of a reporting unit is more-likely-than-not ("likely" meaning having a likelihood of more than 50%) greater than its carrying amount, no additional testing is considered necessary. However, if the Company determines the fair value is more-likely-than-not below the carrying value of a reporting unit, the Company performs the two-step goodwill impairment test required by the Financial Accounting Standards Board's (FASB) Accounting Standards Codification (ASC) Topic 350, Intangibles - Goodwill and Other. In the first step, the Company compares the fair value of each reporting unit, as computed primarily by present value cash flow calculations, to its book carrying value, including goodwill. If the carrying value exceeds the fair value, the goodwill of the reporting unit is potentially impaired and the Company would complete step 2 in order to measure the potential impairment loss. In step 2, the Company calculates the implied fair value of goodwill by deducting the fair value of all tangible and intangible net assets (including unrecognized intangible assets) of the reporting unit from the fair value of the reporting unit (as determined in step 1). If the implied fair value of goodwill is less than the carrying value of goodwill, the Company would recognize an impairment loss equal to the difference. During the fourth quarters of 2013, 2012 and 2011, the Company concluded that it was more-likely-than-not that the fair value was more than its carry value based on its qualitative assessment.
	Other Intangible Assets: Other intangible assets consist of purchased technology and patents, in-process research and development (IPR&D) acquired in a business acquisition, customer lists and relationships, trademarks and tradenames, licenses and distribution agreements. Definite-lived intangible assets are amortized on a straight-line basis over the estimated useful life ranging from three to 20 years. Certain trademark assets are considered indefinite-lived intangible assets and are not amortized.
	The Company's policy defines IPR&D as the value of technology acquired for which the related products have not yet reached technological feasibility and have no future alternative use. The primary basis for determining the technological feasibility of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. IPR&D acquired in a business acquisition is subject to ASC Topic 805, Business Combinations (ASC Topic 805), which requires the fair value of IPR&D to be capitalized as an indefinite-lived intangible asset until completion of the IPR&D project or abandonment. Upon completion of the development project (generally when regulatory approval to market the product is obtained), the IPR&D is amortized over its estimated useful life. If the IPR&D projects are abandoned, the related IPR&D assets would likely be impaired and written down to fair value. The purchase of certain intellectual property assets relate to technology or products without regulatory approval is considered a purchase of assets rather than the acquisition of a business. For such purchases, rather than being capitalized, any IPR&D acquired in such asset purchases is expensed immediately.
	The Company also reviews its indefinite-lived intangible assets for impairment regularly to determine if any adverse conditions exist that would indicate impairment or when impairment indicators exist. The Company assesses its indefinite-lived intangible assets for impairment similar to goodwill by considering qualitative factors such as macroeconomic conditions, industry and market considerations, cost factors, financial performance, entity specific events and project-based performance toward regulatory approvals. Similar to the goodwill impairment analysis, if the qualitative assessment results in a determination that the fair value of an indefinite-lived intangible asset is more-likely-than-not ("likely" meaning having a likelihood of more than 50%) greater than its carrying amount, no additional testing is considered necessary. However, if the Company determines the fair value of its indefinite-lived intangible assets is more-likely-than-not below the carrying value, impairment indicators exist. During 2013, the Company performed a qualitative assessment of its indefinite-lived intangible assets by considering many of the above factors and subsequently determined that a quantitative impairment analysis was further necessary for certain CATD indefinite-lived tradename and IPR&D assets. The Company utilized a discounted cash flow model for each individual asset level under scrutiny and recognized an impairment charge of $29 million to write-down the related assets to fair value. The impairments were due primarily to the Company's revised expectations, including an increase in the cost and length of time to bring the related products to market through U.S. regulatory approval. The Company recognized no impairment charges on its indefinite-lived intangible assets during fiscal year 2012 or 2011.
	The Company also reviews its definite-lived intangible assets for impairment when impairment indicators exist. When impairment indicators exist, the Company determines if the carrying value of its definite-lived intangible assets exceeds the related undiscounted future cash flows. In cases where the carrying value exceeds the undiscounted cash flows, the carrying value is written down to fair value, which the Company determines using present value cash flow calculations. During 2012, the Company recognized impairment charges of $31 million associated with purchased technology assets in the Company's IESD and CATD segments, as their future expected discounted cash flows did not exceed the carrying value of the related assets. Additionally, during 2013, 2012 and 2011, the Company recognized $13 million, $2 million and $52 million, respectively, of intangible asset impairments primarily associated with customer relationship intangible assets acquired in connection with legacy acquisitions of businesses involved in the distribution of the Company's products. Due to the changing dynamics of the U.S. healthcare market, specifically as it relates to hospital purchasing practices, these intangible assets were determined to have no future discrete cash flows and were fully impaired in the respective periods. See Note 9 for further detail regarding the intangible asset impairments recognized during fiscal years 2013, 2012 and 2011.

Recovered_Sheet1

Summary of Significant Accounting Policies Contingent Consideration (Policies)	12 Months Ended
	Dec. 28, 2013
Contingent Consideration [Abstract]	'
Contingent Consideration [Policy Text Block]	'
Contingent Consideration [Policy Text Block]	Contingent Consideration: In connection with certain business combinations or purchases of intellectual property the Company may agree to provide future contingent consideration payments. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels, achieving product development targets or receiving regulatory approvals to market products. Contingent consideration is recognized on the acquisition date at the estimated fair value of the contingent milestone payment(s). The acquisition date fair value is measured based on the consideration expected to be transferred (probability-weighted), discounted back to present value. The discount rate used is determined at the time of measurement in accordance with accepted valuation methods. The fair value of the contingent consideration is remeasured to its estimated fair value at each reporting period with the change in fair value recognized in selling, general and administrative expense in the Company's Consolidated Statements of Earnings.

Recovered_Sheet2

Summary of Significant Accounting Policies Standard product warranty (Policies)	12 Months Ended
	Dec. 28, 2013
Payables and Accruals [Abstract]	'
Standard Product Warranty, Policy [Policy Text Block]	'
	Product Warranties: The Company offers a warranty on various products, the most significant of which relate to pacemaker and ICD systems. The Company estimates the costs it expects to incur under its warranties and records a liability for such costs at the time the product is sold. Factors that affect the Company's warranty liability include the number of units sold, historical and anticipated rates of warranty claims and cost per claim. The Company regularly assesses the adequacy of its warranty liabilities and adjusts the amounts as necessary.

	Changes in the Company's product warranty liability during fiscal years 2013 and 2012 were as follows (in millions):


		2013			2012
	Balance at beginning of period	$	38		$	36

	Warranty expense recognized	3			5

	Warranty credits issued	(4		)	(3		)
	Balance at end of period	$	37		$	38

Recovered_Sheet3

Summary of Significant Accounting Policies Product liability (Policies)	12 Months Ended
	Dec. 28, 2013
Payables and Accruals [Abstract]	'
Product Liability Contingencies [Table Text Block]	'
Product Liability Contingencies [Table Text Block]	Product Liability: Based on historical loss trends and anticipated loss on products sold, the Company accrues for product liability claims through its self-insurance program in effort to adequately cover future losses. Additionally, the Company accrues for product liability claims when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Receivables for insurance recoveries from prior product liability insurance coverage are recognized when it is probable that a recovery will be realized. We are currently the subject of product liability litigation proceedings and other proceedings described in more detail at Note 5.

Recovered_Sheet4

Summary of Significant Accounting Policies Litigation policy (Policies)	12 Months Ended
	Dec. 28, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Litigation policy [Text Block]	'
Litigation policy [Text Block]	Litigation: The Company accrues a liability for costs related to litigation, including future legal costs, settlements and judgments where it has assessed that such costs are probable and an amount can be reasonably estimated.

Recovered_Sheet5

Summary of Significant Accounting Policies Revenue recognition (Policies)	12 Months Ended
	Dec. 28, 2013
Deferred Revenue Disclosure [Abstract]	'
Revenue Recognition, Policy [Policy Text Block]	'
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition: The Company sells its products to hospitals primarily through a direct sales force. In certain international markets, the Company sells its products through independent distributors. The Company recognizes revenue when persuasive evidence of a sales arrangement exists, delivery of goods occurs through the transfer of title and risks and rewards of ownership, the selling price is fixed or determinable and collectability is reasonably assured. A portion of the Company's inventory is held by field sales representatives or consigned at hospitals. For such product inventory, revenue is recognized at the time the Company is notified that the inventory has been implanted or used by the customer. For products that are not consigned, revenue recognition occurs upon shipment to the hospital or, in the case of distributors, when title transfers under the contract assuming all other revenue recognition criteria are met. The Company offers sales rebates and discounts to certain customers. The Company records such rebates and discounts as a reduction of net sales in the same period revenue is recognized. The Company estimates rebates based on customers' contracted terms and historical sales experience.

Recovered_Sheet6

Summary of Significant Accounting Policies Excise Taxes (Policies)	12 Months Ended
	Dec. 28, 2013
Accounting Policies [Abstract]	'
Excise Taxes [Policy Text Block]	'
Excise Taxes [Policy Text Block]	Excise Taxes: The Company incurs certain excise taxes in the distribution of its products, including a medical device excise tax assessed on U.S sales and an excise tax assessed on purchases from the Company's Puerto Rico manufacturing subsidiary. The U.S. medical device excise tax is imposed on the first sale in the U.S. by the manufacturer, producer or importer of a medical device to either a third party or an affiliated distribution entity. The Company capitalizes the assessment of these excise taxes as part of inventory, which is then recognized as cost of sales when the related inventory is sold to a third party customer.

Recovered_Sheet7

Summary of Significant Accounting Policies Research and development (Policies)	12 Months Ended
	Dec. 28, 2013
Research and Development [Abstract]	'
Research and Development Expense, Policy [Policy Text Block]	'
	Research and Development: Research and development costs are expensed as incurred. Research and development costs include costs of all basic research activities, including engineering and technical effort required to develop a new product or make significant improvements to an existing product or manufacturing process. Research and development costs also include pre-approval regulatory costs and clinical research expenses.

Recovered_Sheet8

Summary of Significant Accounting Policies Stock Compensation (Policies)	12 Months Ended
	Dec. 28, 2013
Accounting Policies [Abstract]	'
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-Based Compensation: The Company accounts for stock-based compensation in accordance with ASC Topic 718, Compensation - Stock Compensation (ASC Topic 718). Under the fair value recognition provisions of ASC Topic 718, the Company measures stock-based compensation cost at the grant date fair value and recognizes the compensation expense over the requisite service period, which is the vesting period, using a straight-line attribution method.
	The amount of stock-based compensation expense recognized during a period is based on the portion of the awards that are ultimately expected to vest. The Company estimates pre-vesting award forfeitures at the time of grant by analyzing historical data and revises those estimates in subsequent periods if actual forfeitures differ from those estimates. Ultimately, the total expense recognized over the vesting period will only be for those awards that vest. The Company's awards are not eligible to vest early in the event of retirement, however, the majority of the Company's awards vest early in the event of a change in control. See Note 8 for further detail on the Company's stock compensation plans.

Recovered_Sheet9

Summary of Significant Accounting Policies Earnings per share (Policies)	12 Months Ended
	Dec. 28, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share, Policy [Policy Text Block]	'
	Net Earnings Per Share Attributable to St. Jude Medical, Inc.: Basic net earnings per share is computed by dividing net earnings by the weighted average number of outstanding common shares during the period, exclusive of dilutive securities. Diluted net earnings per share is computed by dividing net earnings by the weighted average number of outstanding common shares and dilutive securities.
	The following table sets forth the computation of basic and diluted net earnings per share for fiscal years 2013, 2012 and 2011 (in millions, except per share amounts):


		2013		2012		2011
	Numerator:

	Net earnings attributable to St. Jude Medical, Inc.	$	723	$	752	$	826

	Denominator:

	Basic weighted average shares outstanding	287		313.3		324.3

	Effect of dilutive securities:

	Stock options	3.2		1.3		2.6

	Restricted stock units	0.4		0.2		0.2

	Diluted weighted average shares outstanding	290.6		314.8		327.1

	Basic net earnings per share	$	2.52	$	2.4	$	2.55

	Diluted net earnings per share	$	2.49	$	2.39	$	2.52

	Approximately 4.8 million, 18.9 million and 11.5 million shares of common stock subject to stock options and restricted stock units were excluded from the diluted net earnings per share computation because they were not dilutive during fiscal years 2013, 2012 and 2011, respectively.

Recovered_Sheet10

Summary of Significant Accounting Policies Foreign currency transaction and translation (Policies)	12 Months Ended
	Dec. 28, 2013
Foreign Currency [Abstract]	'
Foreign Currency Transactions and Translations Policy [Policy Text Block]	'
	Foreign Currency Translation: Sales and expenses denominated in foreign currencies are translated at average exchange rates in effect throughout the year. Assets and liabilities of foreign operations are translated at period-end exchange rates with the impacts of foreign currency translation recognized to cumulative translation adjustment, a component of accumulated other comprehensive income (loss). Foreign currency transaction gains and losses are included in other expense, net.

Recovered_Sheet11

Summary of Significant Accounting Policies Derivatives (Policies)	12 Months Ended
	Dec. 28, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Derivatives, Policy [Policy Text Block]	'
	Derivative Financial Instruments: The Company follows the provisions of ASC Topic 815, Derivatives and Hedging (ASC Topic 815) to account for its derivative instruments and hedging activities. ASC Topic 815 requires all derivative financial instruments to be recognized on the balance sheet at fair value. Changes in the fair value of derivatives are recognized in net earnings or other comprehensive income depending on whether the derivative is designated as part of a qualifying hedge transaction.
	The Company uses forward contracts to manage foreign currency exposures primarily related to intercompany receivables and payables arising from intercompany purchases of manufactured products. These forward contracts are not designated as qualifying hedges and therefore, the changes in the fair values of these derivatives are recognized in net earnings and classified in other expense, net. The gains and losses on these forward contracts largely offset the losses or gains on the foreign currency exposures being managed. See Note 14 for further detail on the Company's use of its derivative financial instruments.

Recovered_Sheet12

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 28, 2013
Accounting Policies [Abstract]	'
Summary Of Components Of Available-For-Sale Securities	'
	The following table summarizes the components of the balance of the Company's available-for-sale securities at December 28, 2013 and December 29, 2012 (in millions):


		December 28, 2013			December 29, 2012
	Adjusted cost	$	7		$	9

	Gross unrealized gains	28			32

	Fair value	$	35		$	41

Schedule Of Inventories	'
	Inventories are stated at the lower of cost or market with cost determined using the first-in, first-out method. Inventories consisted of the following (in millions):



		December 28, 2013			December 29, 2012
	Finished goods	$	494		$	416

	Work in process	52			50

	Raw materials	162			144

		$	708		$	610

Schedule of Product Warranty Liability	'
	Changes in the Company's product warranty liability during fiscal years 2013 and 2012 were as follows (in millions):


		2013			2012
	Balance at beginning of period	$	38		$	36

	Warranty expense recognized	3			5

	Warranty credits issued	(4		)	(3		)
	Balance at end of period	$	37		$	38

Schedule Of Computation Of Basic And Diluted Net Earnings Per Share	'
	The following table sets forth the computation of basic and diluted net earnings per share for fiscal years 2013, 2012 and 2011 (in millions, except per share amounts):


		2013			2012			2011
	Numerator:

	Net earnings attributable to St. Jude Medical, Inc.	$	723		$	752		$	826

	Denominator:

	Basic weighted average shares outstanding	287			313.3			324.3

	Effect of dilutive securities:

	Stock options	3.2			1.3			2.6

	Restricted stock units	0.4			0.2			0.2

	Diluted weighted average shares outstanding	290.6			314.8			327.1

	Basic net earnings per share	$	2.52		$	2.4		$	2.55

	Diluted net earnings per share	$	2.49		$	2.39		$	2.52

Business_Combinations_Business

Business Combinations Business Combinations - Business Combinations (Tables)	12 Months Ended
	Dec. 28, 2013
Statement [Line Items]	'
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	'

	The following table summarizes the purchase price allocation of the estimated fair values of net assets acquired and liabilities assumed as a result of the Company's acquisitions of Endosense and Nanostim during fiscal year 2013 as follows (in millions):



		Endosense			Nanostim			Total
	Assets acquired:
	Current assets	$	2		$	1		$	3

	Goodwill	258			149			407

	IPR&D	33			27			60

	Other intangible assets	20			34			54

	Other long-term assets	1			1			2

	Total assets acquired	314			212			526


	Liabilities assumed:
	Current liabilities	11			2			13

	Net assets acquired	303			210			513


	Cash paid	180			124			304

	Cash acquired	(9		)	(3		)	(12		)
	Net cash consideration	171			121			292

	Contingent consideration	132			56			188

	Fair value of St. Jude Medical, Inc.'s previously held interest	—			33			33

	Total purchase consideration	$	303		$	210		$	513

Spinal Modulation [Member]	'
Statement [Line Items]	'
Schedule of Variable Interest Entities [Table Text Block]	'
	The following table summarizes the estimated fair values of Spinal Modulation’s assets and liabilities included in St. Jude Medical's consolidated balance sheets as of the June 7, 2013 consolidation date, and as of December 28, 2013 after elimination of all intercompany balances and transactions (in millions):



		7-Jun-13			28-Dec-13
	Cash and cash equivalents	$	41		$	25

	Other current assets	9			5

	Goodwill	82			82

	IPR&D	45			45

	Other intangible assets	7			7

	Other long-term assets	1			1

	Total assets	185			165


	Current liabilities	6			5

	Deferred income taxes, net	19			19

	Total liabilities	25			24


	Non-controlling interest	$	120		$	104

Cardiomems [Member]	'
Statement [Line Items]	'
Schedule of Variable Interest Entities [Table Text Block]	'
	The following table summarizes the estimated fair values of CardioMEMS’ assets and liabilities included in St. Jude Medical's consolidated balance sheets as of the February 27, 2013 consolidation date, and as of December 28, 2013 after elimination of all intercompany balances and transactions (in millions):



		27-Feb-13			28-Dec-13
	Cash and cash equivalents	$	33		$	14

	Other current assets	2			6

	Goodwill	83			83

	IPR&D	63			63

	Other long-term assets	2			2

	Total assets	183			168


	Current liabilities	13			7

	Deferred income taxes, net	23			23

	Other liabilities	5			4

	Total liabilities	41			34


	Noncontrolling interest	$	84		$	68

Goodwill_And_Other_Intangible_1

Goodwill And Other Intangible Assets (Tables)	12 Months Ended
	Dec. 28, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule Of Changes In Carrying Amount Of Goodwill	'
	The changes in the carrying amount of goodwill for each of the Company’s reportable segments (see Note 15) for the fiscal years ended December 28, 2013 and December 29, 2012 were as follows (in millions):



		IESD			CATD		Total
	Balance at December 31, 2011	$	1,235		$	1,718	$	2,953

	Foreign currency translation and other	(6		)	14		8

	Balance at December 29, 2012	1,229			1,732		2,961

	Endosense S.A.	—			258		258

	Nanostim, Inc.	149			—		149

	Spinal Modulation, Inc.	82			—		82

	CardioMEMS, Inc.	83			—		83

	Foreign currency translation and other	(17		)	8		(9		)

	Balance at December 28, 2013	$	1,526		$	1,998	$	3,524

Schedule Of Gross Carrying Amount Of Other Intangible Assets And Related Accumulated Amortization	'
	The following table provides the gross carrying amount of other intangible assets and related accumulated amortization (in millions):


		December 28, 2013					December 29, 2012
		Gross			Accumulated		Gross			Accumulated
		Carrying			Amortization		Carrying			Amortization
		Amount					Amount
	Definite-lived intangible assets:

	Purchased technology and patents	$	986		$	393	$	947		$	336

	Customer lists and relationships	20			13		57			36

	Trademarks and tradenames	22			11		22			10

	Licenses, distribution agreements and other	4			1		6			4

		$	1,032		$	418	$	1,032		$	386

	Indefinite-lived intangible assets:

	Acquired IPR&D	$	262				$	109

	Trademarks and tradenames	35					49

		$	297				$	158

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	Actual amounts of amortization expense may differ due to actual timing of regulatory approvals, additional intangible assets acquired and foreign currency translation impacts (in millions):


														After
		2014			2015		2016			2017		2018		2018
	Amortization expense	$	90		$	95	$	101		$	93	$	87	$	410

Debt_Tables

Debt (Tables)	12 Months Ended
	Dec. 28, 2013
Debt Disclosure [Abstract]	'
Schedule Of Long-Term Debt	'
	The Company’s debt consisted of the following, including discounts and premiums (in millions):


		December 28, 2013		December 29, 2012
	Term loan due 2015	$	500	$	—

	2.50% senior notes due 2016	512		518

	3.25% senior notes due 2023	896		—

	4.75% senior notes due 2043	696		—

	3.75% senior notes due 2014 (redeemed May 2013)	—		699

	4.875% senior notes due 2019 (redeemed May 2013)	—		496

	2.20% senior notes due 2013 (retired September 2013)	—		454

	1.58% Yen-denominated senior notes due 2017	78		95

	2.04% Yen-denominated senior notes due 2020	122		149

	Yen-denominated credit facilities	62		76

	Commercial paper borrowings	714		593

	Total debt	3,580		3,080

	Less: current debt obligations	62		530

	Long-term debt	$	3,518	$	2,550

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables)	12 Months Ended
	Dec. 28, 2013
Accumulated Other Comprehensive Income [Abstract]	'
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	'
	The table below presents the changes in each component of accumulated other comprehensive income, including other comprehensive income and the reclassifications out of accumulated other comprehensive income into net earnings for fiscal years 2013, 2012 and 2011 (in millions):



		Unrealized			Unrealized			Foreign			Accumulated
		Gain (Loss) On			Gain (Loss) On			Currency			Other
		Available-for-sale			Derivative			Translation			Comprehensive
		Securities			Instruments			Adjustment			Income
	Accumulated other comprehensive income (loss), net of tax, at January 1, 2011	$	15		$	—		$	69		$	84

	Other comprehensive income (loss) before reclassifications	3			—			(71		)	(68		)

	Amounts reclassified to net earnings from accumulated other comprehensive income	—			—			—			—

	Other comprehensive income (loss)	3			—			(71		)	(68		)

	Accumulated other comprehensive income (loss), net of tax, at December 31, 2011	18			—			(2		)	16

	Other comprehensive income (loss) before reclassifications	10			—			28			38

	Amounts reclassified to net earnings from accumulated other comprehensive income	(8		)	—			—			(8		)

	Other comprehensive income (loss)	2			—			28			30

	Accumulated other comprehensive income (loss), net of tax, at December 29, 2012	20			—			26			46

	Other comprehensive income (loss) before reclassifications	5			3			—			8

	Amounts reclassified to net earnings from accumulated other comprehensive income	(8		)	—			—			(8		)

	Other comprehensive income (loss)	(3		)	3			—			—

	Accumulated other comprehensive income (loss), net of tax, at December 28, 2013	$	17		$	3		$	26		$	46

Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]	'
	The table below provides details about reclassifications out of accumulated other comprehensive income and the line items impacted in the Company's Consolidated Statements of Earnings for fiscal years 2013, 2012 and 2011 (in millions):



		Amounts reclassified from accumulated other comprehensive income
		2013			2012			2011			Statements of Earnings Classification
	Unrealized gain on available-for-sale securities:
	Gain on sale of available-for-sale securities	$	13		$	14		$	—		Other expense, net

		(5		)	(6		)	—			Income tax expense

		8			8			—			Net earnings before noncontrolling interest

		$	8		$	8		$	—		Net earnings attributable to St. Jude Medical, Inc.

Stockbased_Compensation_Stockb

Stock-based Compensation Stock-based Compenation (Tables)	12 Months Ended
	Dec. 28, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
	The Company's total stock compensation expense for fiscal years 2013, 2012 and 2011 by income statement line item was as follows (in millions):


		2013				2012				2011
	Selling, general and administrative expense	$	45			$	49			$	55

	Research and development expense	15				15				15

	Cost of sales	5				5				6

	Total stock compensation expense	$	65			$	69			$	76

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
	The following table provides the weighted average fair value of stock options granted to employees during fiscal years 2013, 2012 and 2011 and the related weighted average assumptions used in the Black-Scholes model:


		2013				2012				2011
	Fair value of options granted	$	13.83			$	7.71			$	9.17

	Assumptions:
	Expected life (years)	5.4				5.4				5.5

	Risk-free interest rate	1.6		%		0.7		%		0.9		%
	Volatility	28.6		%		31.2		%		33.9		%
	Dividend yield	1.8		%		2.5		%		2		%
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The following table summarizes stock option activity under all stock compensation plans during the fiscal year ended December 28, 2013:


									Weighted
					Weighted				Average		Aggregate
					Average				Remaining		Intrinsic
		Options			Exercise				Contractual		Value
		(in millions)			Price				Term (in years)		(in millions)
	Outstanding at December 29, 2012	28.2			$	38.05

	Granted	2.7			59.16

	Exercised	(10.6	)		39.83

	Canceled	(1.4	)		40.05

	Outstanding at December 28, 2013	18.9			$	39.94			5.3		$	422

	Vested and expected to vest	18.2			$	39.7			5.2		$	409

	Exercisable at December 28, 2013	10.6			$	37.07			4.1		$	267

Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]	'
	The following table summarizes activity for restricted stock awards and restricted stock units under all stock compensation plans during the fiscal year ended December 28, 2013:


					Weighted Average
		Restricted Stock			Grant Date
		(in millions)			Fair Value
	Unvested balance at December 29, 2012	1.6			$	36.61

	Granted	0.7			58.32

	Vested	(0.5	)		37.45

	Canceled	(0.2	)		36.96

	Unvested balance at December 28, 2013	1.6			$	45.98

Special_Charges_Tables

Special Charges (Tables)	12 Months Ended
	Dec. 28, 2013
2011 Restructuring Plan [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Summary Of Activity Related To Special Charge Restructuring Accrual	'
	A summary of the activity related to the 2011 restructuring plan accrual is as follows (in millions):


		Employee			Inventory			Fixed			Other Restructuring Costs			Total
		Termination			Charges			Asset
		Costs						Charges
	Balance at January 1, 2011	$	—		$	—		$	—		$	—		$	—

	Cost of sales special charges	9			20			9			9			47

	Special charges	73			—			17			25			115

	Non-cash charges used	—			(20		)	(26		)	(1		)	(47		)

	Cash payments	(27		)	—			—			(15		)	(42		)

	Foreign exchange rate impact	(1		)	—			—			—			(1		)

	Balance at December 31, 2011	54			—			—			18			72

	Cost of sales special charges	11			13			—			20			44

	Special charges	27			—			—			31			58

	Non-cash charges used	—			(13		)	—			(4		)	(17		)

	Cash payments	(68		)	—			—			(47		)	(115		)

	Foreign exchange rate impact	1			—			—			(1		)	—

	Balance at December 29, 2012	25			—			—			17			42

	Cost of sales special charges	—			—			—			—			—

	Special charges	5			—			1			18			24

	Non-cash charges used	—			—			(1		)	—			(1		)

	Cash payments	(21		)	—			—			(29		)	(50		)

	Foreign exchange rate impact	—			—			—			—			—

	Balance at December 28, 2013	$	9		$	—		$	—		$	6		$	15

2012 Business Realignment Restructuring Plan [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Summary Of Activity Related To Special Charge Restructuring Accrual	'
	A summary of the activity related to the 2012 business realignment plan accrual is as follows (in millions):


		Employee			Inventory			Fixed			Other Restructuring Costs			Total
		Termination			Charges			Asset
		Costs						Charges
	Balance at December 31, 2011	$	—		$	—		$	—		$	—		$	—

	Cost of sales special charges	5			17			—			2			24

	Special charges	104			—			41			16			161

	Non-cash charges used	—			(17		)	(41		)	(3		)	(61		)

	Cash payments	(52		)	—			—			(7		)	(59		)

	Foreign exchange rate impact	1			—			—			—			1

	Balance at December 29, 2012	58			—			—			8			66

	Cost of sales special charges	—			30			—			5			35

	Special charges	75			—			13			97			185

	Non-cash charges used	—			(30		)	(13		)	(4		)	(47		)

	Cash payments	(79		)	—			—			(73		)	(152		)

	Foreign exchange rate impact	—			—			—			—			—

	Balance at December 28, 2013	$	54		$	—		$	—		$	33		$	87

Other_Expense_Net_Tables

Other Expense, Net (Tables)	12 Months Ended
	Dec. 28, 2013
Other Nonoperating Income (Expense) [Abstract]	'
Schedule Of Other Expense, Net	'
	The Company’s other expense, net consisted of the following (in millions):


		2013			2012			2011
	Interest income	$	(5	)	$	(5	)	$	(4	)
	Interest expense	81			73			70

	Other	191			27			30

	Other expense, net	$	267		$	95		$	96

Income_Taxes_Income_Taxes_Tabl

Income Taxes Income Taxes (Tables)	12 Months Ended
	Dec. 28, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	'
	The Company's earnings before income taxes as generated from its U.S. and international operations are as follows (in millions):


		2013				2012				2011
	U.S.	$	(17	)		$	316			$	502

	International	801				689				517

	Earnings before income taxes and noncontrolling interest	$	784			$	1,005			$	1,019

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	'
	Income tax expense consisted of the following (in millions):


		2013				2012				2011
	Current:
	U.S. federal	$	101			$	236			$	180

	U.S. state and other	7				16				13

	International	108				78				65

	Total current	216				330				258

	Deferred	(124		)		(77		)		(65		)
	Income tax expense	$	92			$	253			$	193

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
	Deferred income taxes result from temporary differences between the amount of assets and liabilities recognized for financial reporting and tax purposes. The components of deferred tax assets and liabilities are as follows (in millions):


		2013				2012
	Deferred income tax assets:
	Net operating and capital loss carryforwards	$	402			$	236

	Tax credit carryforwards	75				70

	Inventories	136				148

	Stock-based compensation	47				78

	Compensation and benefits	123				113

	R&D expenditures, capitalized for tax	112				—

	Accrued liabilities and other	130				133

		1,025				778

	Less: valuation allowance	(368		)		(228		)
	Deferred income tax assets	657				550

	Deferred income tax liabilities:
	Unrealized gain on available-for-sale securities	(11		)		(12		)
	Property, plant and equipment	(189		)		(204		)
	Intangible assets	(352		)		(307		)
	Deferred income tax liabilities	(552		)		(523		)
	Net deferred income tax assets (liabilities)	$	105			$	27

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
	A reconciliation of the U.S. federal statutory income tax rate to the Company's effective income tax rate is as follows:


		2013			2012			2011
	U.S. federal statutory tax rate	35	%		35	%		35	%
	Increase (decrease) in tax rate resulting from:
	U.S. state income taxes, net of federal tax benefit	0.6			0.5			1.2

	International taxes at lower rates	(13.6	)		(12.1	)		(11.6	)
	Tax benefits from domestic manufacturer's deduction	(1.9	)		(2.2	)		(2.0	)
	Research and development credits	(4.6	)		(1.1	)		(2.7	)
	Puerto Rico excise tax	(3.0	)		(1.8	)		(1.7	)
	Tax settlements	(1.9	)		4.6			—

	Noncontrolling interest	3.6			—			—

	Other	(2.5	)		2.3			0.8

	Effective income tax rate	11.7	%		25.2	%		19	%
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	'
	The following table summarizes the activity related to the Company's unrecognized tax benefits (in millions):


		2013				2012				2011
	Balance at beginning of year	$	314			$	205			$	163

	Increases related to current year tax positions	74				38				33

	Increases related to prior year tax positions	33				90				16

	Reductions related to prior year tax positions	(16		)		(18		)		(1		)
	Reductions related to settlements / payments	(90		)		(1		)		(2		)
	Expiration of the statute of limitations for the assessment of taxes	—				—				(4		)

	Balance at end of year	$	315			$	314			$	205

Fair_Value_Measurements_And_Fi1

Fair Value Measurements And Financial Instruments (Tables)	12 Months Ended
	Dec. 28, 2013
Fair Value Disclosures [Abstract]	'
Summary Of Financial Assets Measured At Fair Value On A Recurring Basis	'
	A summary of assets and liabilities measured at fair value on a recurring basis at December 28, 2013 and December 29, 2012 is as follows (in millions):


		Balance Sheet	December 28, 2013				Quoted Prices				Significant		Significant
		Classification					In Active				Other		Unobservable
							Markets				Observable		Inputs
							(Level 1)				Inputs		(Level 3)
											(Level 2)
	Assets

	Money-market securities	Cash and cash equivalents	$	875			$	875			$	—	$	—

	Available-for-sale securities	Other current assets	35				35				—		—

	Trading securities	Other assets	279				279				—		—

	Total assets		1,189				1,189				—		—


	Liabilities
	Contingent consideration	Other liabilities	195				—				—		195

	Total liabilities		$	195			$	—			$	—	$	195




		Balance Sheet	December 29, 2012				Quoted Prices				Significant		Significant
		Classification					In Active				Other		Unobservable
							Markets				Observable		Inputs
							(Level 1)				Inputs		(Level 3)
											(Level 2)
	Assets

	Money-market securities	Cash and cash equivalents	$	964			$	964			$	—	$	—

	Available-for-sale securities	Other current assets	41				41				—		—

	Trading securities	Other assets	231				231				—		—

	Total assets		$	1,236			$	1,236			$	—	$	—

Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]	'
	The recurring Level 3 fair value measurements of our contingent consideration liability include the following significant unobservable inputs (in millions):


	Contingent Consideration Liability	Fair Value as of December 28, 2013			Valuation Technique		Unobservable Input		Range

	Endosense regulatory-based milestone	$	139		Probability Weighted Discounted Cash Flow		Discount Rate		1.15%	-	1.59%

							Probability of Payment				90%
							Projected Year of Payment				2014

	Nanostim regulatory-based milestone	56			Probability Weighted Discounted Cash Flow		Discount Rate				5.00%

							Probability of Payment				100%
							Projected Years of Three Annual Payments		2016, 2017, 2018
	Total contingent consideration liability	$	195

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
	Additionally, the following table provides a reconciliation of the beginning and ending balances of the Company's contingent consideration liability associated with its Endosense acquisition subsequent to August 19, 2013 and its Nanostim acquisition subsequent to October 11, 2013, as of December 28, 2013 (in millions):



		Endosense			Nanostim			Total
	Balance as of December 29, 2012	$	—		$	—		$	—

	Purchase price contingent consideration	132			56			188

	Change in fair value of contingent consideration	1			—			1

	Foreign currency translation	6			—			6

	Balance as of December 28, 2013	$	139		$	56		$	195

Segment_And_Geographic_Informa1

Segment And Geographic Information (Tables)	12 Months Ended
	Dec. 28, 2013
Segments, Geographical Areas [Abstract]	'
Schedule Of Net Sales And Operating Profit By Reportable Segment	'
	The following table presents net sales and operating profit by reportable segment (in millions):


		IESD		CATD		Other			Total
	Fiscal Year 2013

	Net sales	$	3,209	$	2,292	$	—		$	5,501

	Operating profit	2,138		1,349		(2,436		)	1,051

	Depreciation and amortization expense	80		89		128			297

	Total assets	2,855		3,273		4,120			10,248

	Fiscal Year 2012

	Net sales	$	3,277	$	2,226	$	—		$	5,503

	Operating profit	2,274		1,326		(2,500		)	1,100

	Depreciation and amortization expense	73		91		120			284

	Total assets	2,320		2,967		3,984			9,271

	Fiscal Year 2011
	Net sales	$	3,453	$	2,159	$	—		$	5,612

	Operating profit	2,240		1,211		(2,336		)	1,115

	Depreciation and amortization expense	87		84		125			296

	Total assets	2,394		3,086		3,638			9,118

Net Sales By Geographic Location	'
	Net sales by significant geographic market based on customer location for the respective fiscal years were as follows (in millions):


	Net Sales	2013		2012		2011
	United States	$	2,596	$	2,594	$	2,648

	International

	Europe	1,473		1,432		1,559

	Japan	567		665		641

	Asia Pacific	490		456		416

	Other	375		356		348

		2,905		2,909		2,964

		$	5,501	$	5,503	$	5,612

Schedule Of Long-Lived Assets By Geographic Location	'
	The amounts for long-lived assets by significant geographic market include net property, plant and equipment by physical location of the asset as follows (in millions):


	Long-Lived Assets	December 28, 2013		December 29, 2012		December 31, 2011
	United States	$	1,045	$	1,036	$	1,007

	International

	Europe	73		82		84

	Japan	28		32		31

	Asia Pacific	75		82		81

	Other	189		193		185

		365		389		381

		$	1,410	$	1,425	$	1,388

Quarterly_Financial_Data_Quart

Quarterly Financial Data Quarterly Financial Data (Tables)	12 Months Ended
	Dec. 28, 2013
Quarterly Financial Data [Abstract]	'
Schedule of Quarterly Financial Information [Table Text Block]	'
	QUARTERLY FINANCIAL DATA (UNAUDITED)


		First			Second			Third			Fourth
	(in millions, except per share amounts)	Quarter			Quarter			Quarter			Quarter

	Fiscal Year 2013:
	Net sales	$	1,338		$	1,403		$	1,338		$	1,422

	Gross profit	961			1,021			953			992

	Net earnings attributable to St. Jude Medical, Inc. (a)	223		(b)	115		(c)	262		(d)	123		(e)

	Basic net earnings per share	$	0.78		$	0.41		$	0.91		$	0.42

	Diluted net earnings per share	$	0.78		$	0.4		$	0.9		$	0.42

	Cash dividends declared per share	$	0.25		$	0.25		$	0.25		$	0.25


	Fiscal Year 2012:
	Net sales	$	1,395		$	1,410		$	1,326		$	1,372

	Gross profit	1,014			1,027			971			953

	Net earnings attributable to St. Jude Medical, Inc. (f)	212		(g)	244			176		(h)	120		(i)

	Basic net earnings per share	$	0.67		$	0.78		$	0.56		$	0.39

	Diluted net earnings per share	$	0.67		$	0.78		$	0.56		$	0.39

	Cash dividends declared per share	$	0.23		$	0.23		$	0.23		$	0.23

Summary_Of_Components_Of_Avail

Summary Of Components Of Available-For-Sale Securities (Details) (USD $)	Dec. 28, 2013	Dec. 29, 2012
In Millions, unless otherwise specified	Dec. 28, 2013	Dec. 29, 2012
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Adjusted cost	$7	$9
Available for sale securities gross unrealized gain accumulated in AOCI	28	32
Other Current Assets [Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Fair value	$35	$41

Recovered_Sheet13

Summary of Significant Accounting Policies Inventories (Details) (USD $)	Dec. 28, 2013	Dec. 29, 2012
In Millions, unless otherwise specified	Dec. 28, 2013	Dec. 29, 2012
Inventory Disclosure [Abstract]	'	'
Finished goods	$494	$416
Work in process	52	50
Raw materials	162	144
Inventory, Net	$708	$610

Recovered_Sheet14

Summary of Significant Accounting Policies Product Warranty Liability (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2013	Dec. 29, 2012
Movement in Standard Product Warranty Accrual [Roll Forward]	'	'
Balance at beginning of period	$38	$36
Warranty expense recognized	3	5
Warranty credits issued	-4	-3
Balance at end of period	$37	$38

Net_Earnings_Per_Share_Details

Net Earnings Per Share (Details) (USD $)	3 Months Ended								12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 28, 2013	Sep. 28, 2013	Jun. 29, 2013	Mar. 30, 2013	Dec. 29, 2012	Sep. 29, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Net Earnings Per Share [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net earnings attributable to St. Jude Medical, Inc.	$123	$262	$115	$223	$120	$176	$244	$212	$723	$752	$826
Basic weighted average shares outstanding	'	'	'	'	'	'	'	'	287	313.3	324.3
Diluted weighted average shares outstanding	'	'	'	'	'	'	'	'	290.6	314.8	327.1
Basic net earnings per share	$0.42	$0.91	$0.41	$0.78	$0.39	$0.56	$0.78	$0.67	$2.52	$2.40	$2.55
Diluted net earnings per share	$0.42	$0.90	$0.40	$0.78	$0.39	$0.56	$0.78	$0.67	$2.49	$2.39	$2.52
Common stock subject to stock options, restricted stock awards and restricted stock units excluded from the diluted net earnings per share computation	'	'	'	'	'	'	'	'	4.8	18.9	11.5
Employee Stock Options [Member]	'	'	'	'	'	'	'	'	'	'	'
Net Earnings Per Share [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Effect of dilutive securities	'	'	'	'	'	'	'	'	3.2	1.3	2.6
Restricted Stock Units [Member]	'	'	'	'	'	'	'	'	'	'	'
Net Earnings Per Share [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Effect of dilutive securities	'	'	'	'	'	'	'	'	0.4	0.2	0.2

Recovered_Sheet15

Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Narrative) (Details) (USD $)

12 Months Ended

In Millions, unless otherwise specified

Dec. 28, 2013

Dec. 29, 2012

Dec. 31, 2011

Dec. 28, 2013

Dec. 31, 2011

Dec. 29, 2012

Dec. 28, 2013

Dec. 29, 2012

Dec. 28, 2013

Jun. 07, 2013

Intangible Asset Charges [Member]

Purchased Technology And Patents [Member]

Customer Lists And Relationships [Member]

Minimum [Member]

Maximum [Member]

Building and Building Improvements [Member]

Machinery and Equipment [Member]

Other Capitalized Property Plant and Equipment [Member]

Spinal Modulation [Member]

Intangible Asset Charges [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Equity Security Ownership Interest And Allocated Value For Purchase Option

$33

$40

Pre-tax gain on sale of investment

Financing Receivable, Allowance for Credit Losses, Write-downs

Allowance for Doubtful Accounts Receivable, Current

Property, Plant and Equipment, Useful Life

'15 years

'39 years

'3 years

'15 years

'3 years

'7 years

Depreciation

218

196

203

Finite-Lived Intangible Asset, Useful Life

'3 years

'20 years

Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)

Impairment of Intangible Assets, Finite-lived

$52

$31

$13

Business_Combinations_Schedule

Business Combinations Schedule of Business Acquisitions, by Acquisition (Details)

12 Months Ended

In Millions, unless otherwise specified

Dec. 28, 2013

Dec. 29, 2012

Dec. 31, 2011

Dec. 28, 2013

Aug. 19, 2013

Dec. 28, 2013

Oct. 11, 2013

Dec. 28, 2013

Aug. 19, 2013

Oct. 11, 2013

Dec. 28, 2013

Aug. 19, 2013

Oct. 11, 2013

USD ($)

Endosense S.A. [Member]

Nanostim [Member]

In Process Research and Development [Member]

Patented Technology [Member]

USD ($)

CHF

USD ($)

Endosense S.A. [Member]

Nanostim [Member]

USD ($)

Endosense S.A. [Member]

Nanostim [Member]

USD ($)

Business Acquisition [Line Items]

Current Assets

Goodwill, acquired during the period

407

258

149

Indefinite-lived intangible assets, excluding goodwill

Other intangible assets

Other long-term assets

Total assets acquired

526

314

212

Current liabilities

Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net

513

303

210

Business Acquisition, Cost of Acquired Entity, Cash Paid

304

180

124

Cash Acquired from Acquisition

-12

-9

-3

Payments to Acquire Businesses, Net of Cash Acquired

292

171

160

121

Business Combination, Contingent Consideration, Liability

188

132

Equity Security Ownership Interest And Allocated Value For Purchase Option

$33

Business_Combinations_Schedule1

Business Combinations Schedule of Variable Interest Entities (Details) (USD $)

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

In Millions, unless otherwise specified

Dec. 28, 2013

Jun. 29, 2013

Dec. 28, 2013

Jun. 07, 2013

Mar. 30, 2013

Dec. 28, 2013

Feb. 27, 2013

Dec. 28, 2013

Jun. 07, 2013

Dec. 28, 2013

Jun. 07, 2013

Dec. 28, 2013

Feb. 27, 2013

Spinal Modulation [Member]

Cardiomems [Member]

Patented Technology [Member]

In Process Research and Development [Member]

Spinal Modulation [Member]

Cardiomems [Member]

Statement [Line Items]

Cash and cash equivalents

$25

$41

$14

$33

Other current assets

Goodwill, acquired during the period

407

Indefinite-lived intangible assets, excluding goodwill

Other intangible assets

Other long-term assets

Total assets

526

165

185

168

183

Current liabilities

Deferred income taxes, net

Other liabilities

Total liabilities

Noncontrolling interest

$104

$120

$68

$84

Business_Combinations_Business1

Business Combinations Business Combinations Narrative (Details)

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

In Millions, unless otherwise specified

Dec. 28, 2013

Dec. 29, 2012

Dec. 31, 2011

Dec. 28, 2013

Aug. 19, 2013

Dec. 28, 2013

Oct. 11, 2013

Sep. 28, 2013

Dec. 28, 2013

Jun. 07, 2013

Sep. 28, 2013

Mar. 30, 2013

Feb. 27, 2013

Sep. 28, 2013

Dec. 28, 2013

Aug. 19, 2013

Oct. 11, 2013

Dec. 28, 2013

Jun. 07, 2013

Dec. 28, 2013

Feb. 27, 2013

Dec. 28, 2013

Aug. 19, 2013

Dec. 28, 2013

Oct. 11, 2013

Dec. 28, 2013

Jun. 07, 2013

USD ($)

Endosense S.A. [Member]

Nanostim [Member]

Spinal Modulation [Member]

Cardiomems [Member]

In Process Research and Development [Member]

Patented Technology [Member]

USD ($)

CHF

USD ($)

CHF

USD ($)

Noncontrolling Interest [Member]

USD ($)

Noncontrolling Interest [Member]

USD ($)

Endosense S.A. [Member]

Nanostim [Member]

Spinal Modulation [Member]

Cardiomems [Member]

USD ($)

Endosense S.A. [Member]

Nanostim [Member]

Spinal Modulation [Member]

USD ($)

Payments to Acquire Businesses, Net of Cash Acquired

$292

$171

160

$121

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

167

150

Business Combination, Contingent Consideration, Liability

188

132

Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net

513

303

210

Other intangible assets

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life

'7 years

'10 years

'12 years

Indefinite-lived intangible assets, excluding goodwill

Equity Security Ownership Interest

18.00%

19.00%

Equity Interest, Total Ownership Percentage By All Other Investors

82.00%

Equity Security Ownership Interest And Allocated Value For Purchase Option

Additional Payment For Acquisition At Company Option

300

375

Variable Interest Entity, Financial or Other Support, Amount

Goodwill, Purchase Accounting Adjustments

Indefinite-lived Intangible Assets, Purchase Accounting Adjustments

Finite-Lived Intangible Assets, Purchase Accounting Adjustments

Business Combination, Provisional Information, Initial Accounting Incomplete Adjustment, Total Liabilities

Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Equity Interests

Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Loss

$29

Goodwill_And_Other_Intangible_2

Goodwill And Other Intangible Assets (Schedule Of Changes In Carrying Amount Of Goodwill) (Details) (USD $)

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

In Millions, unless otherwise specified

Dec. 28, 2013

Dec. 29, 2012

Dec. 28, 2013

Dec. 29, 2012

Dec. 28, 2013

Dec. 29, 2012

Jun. 29, 2013

Dec. 28, 2013

Mar. 30, 2013

Dec. 28, 2013

IESD [Member]

CATD [Member]

Spinal Modulation [Member]

Cardiomems [Member]

Endosense [Member]

Nanostim [Member]

IESD [Member]

CATD [Member]

IESD [Member]

CATD [Member]

IESD [Member]

CATD [Member]

IESD [Member]

CATD [Member]

Goodwill [Roll Forward]

Beginning balance

$2,961

$2,953

$1,229

$1,235

$1,732

$1,718

Foreign currency translation and other

-9

-17

-6

Goodwill, acquired during the period

407

258

149

Ending balance

$3,524

$2,961

$1,526

$1,229

$1,998

$1,732

Goodwill_And_Other_Intangible_3

Goodwill And Other Intangible Assets (Schedule Of Gross Carrying Amount Of Other Intangible Assets And Related Accumulated Amortization) (Details) (USD $)	Dec. 28, 2013	Dec. 29, 2012
In Millions, unless otherwise specified	Dec. 28, 2013	Dec. 29, 2012
Goodwill And Other Intangible Assets [Line Items]	'	'
Gross Carrying Amount	$1,032	$1,032
Accumulated Amortization	418	386
Indefinite-lived intangible assets	297	158
Acquired In Process Research And Development [Member]	'	'
Goodwill And Other Intangible Assets [Line Items]	'	'
Indefinite-lived intangible assets	262	109
Trademarks And Tradenames [Member]	'	'
Goodwill And Other Intangible Assets [Line Items]	'	'
Indefinite-lived intangible assets	35	49
Purchased Technology And Patents [Member]	'	'
Goodwill And Other Intangible Assets [Line Items]	'	'
Gross Carrying Amount	986	947
Accumulated Amortization	393	336
Customer Lists And Relationships [Member]	'	'
Goodwill And Other Intangible Assets [Line Items]	'	'
Gross Carrying Amount	20	57
Accumulated Amortization	13	36
Trademarks And Tradenames [Member]	'	'
Goodwill And Other Intangible Assets [Line Items]	'	'
Gross Carrying Amount	22	22
Accumulated Amortization	11	10
Licenses, Distribution Agreements And Other [Member]	'	'
Goodwill And Other Intangible Assets [Line Items]	'	'
Gross Carrying Amount	4	6
Accumulated Amortization	$1	$4

Goodwill_And_Other_Intangible_4

Goodwill And Other Intangible Assets Goodwill and Other Intangible Assets Schedule of Expected Future Amortization Expense (Details) (USD $)	Dec. 28, 2013
In Millions, unless otherwise specified	Dec. 28, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	$90
Finite-Lived Intangible Assets, Amortization Expense, Year Two	95
Finite-Lived Intangible Assets, Amortization Expense, Year Three	101
Finite-Lived Intangible Assets, Amortization Expense, Year Four	93
Finite-Lived Intangible Assets, Amortization Expense, Year Five	87
Finite-Lived Intangible Assets, Amortization Expense, after Year Five	$410

Goodwill_And_Other_Intangible_5

Goodwill And Other Intangible Assets Goodwill And Other Intangible Assets Narrative (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Amortization of Intangible Assets	$79	$88	$93
Intangible Asset Charges [Member]	'	'	'
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	29	'	'
Intangible asset impairment charges, Finite-li	'	'	52
Intangible Asset Charges [Member] \| Customer Relationships [Member]	'	'	'
Intangible asset impairment charges, Finite-li	$13	'	'

Debt_Schedule_Of_LongTerm_Debt

Debt (Schedule Of Long-Term Debt) (Details) (USD $)	Dec. 28, 2013	Dec. 29, 2012
In Millions, unless otherwise specified	Dec. 28, 2013	Dec. 29, 2012
Debt Instrument [Line Items]	'	'
Total Debt	$3,580	$3,080
Less: current debt obligations	62	530
Long-term debt	3,518	2,550
Term loan due 2015 [Member]	'	'
Debt Instrument [Line Items]	'	'
Total Debt	500	0
2.50% Senior Notes Due 2016 [Member]	'	'
Debt Instrument [Line Items]	'	'
Total Debt	512	518
Three point twenty-five percent Senior Notes Due Two Thousand Twenty-three [Member]	'	'
Debt Instrument [Line Items]	'	'
Total Debt	896	0
Four point seventy-five percent Senior Notes Due Two Thousand Fourty-three [Member] [Member]	'	'
Debt Instrument [Line Items]	'	'
Total Debt	696	0
3.75% Senior Notes Due 2014 [Member]	'	'
Debt Instrument [Line Items]	'	'
Total Debt	0	699
4.875% Senior Notes Due 2019 [Member]	'	'
Debt Instrument [Line Items]	'	'
Total Debt	0	496
2.20% Senior Notes Due 2013 [Member]	'	'
Debt Instrument [Line Items]	'	'
Total Debt	0	454
1.58% Yen-Denominated Senior Notes Due 2017 [Member]	'	'
Debt Instrument [Line Items]	'	'
Total Debt	78	95
2.04% Yen-Denominated Senior Notes Due 2020 [Member]	'	'
Debt Instrument [Line Items]	'	'
Total Debt	122	149
Yen Denominated Credit Facilities [Member]	'	'
Debt Instrument [Line Items]	'	'
Total Debt	62	76
Commercial paper borrowings [Member]	'	'
Debt Instrument [Line Items]	'	'
Total Debt	$714	$593

Debt_Narrative_Details

Debt (Narrative) (Details)

Dec. 28, 2013

2-May-13

Dec. 29, 2012

Dec. 28, 2013

Dec. 29, 2012

Dec. 28, 2013

Dec. 29, 2012

Jun. 30, 2012

Dec. 28, 2013

Apr. 02, 2013

Dec. 29, 2012

Dec. 28, 2013

Apr. 02, 2013

Dec. 29, 2012

Dec. 28, 2013

Jun. 29, 2013

Dec. 29, 2012

Dec. 28, 2013

Jun. 29, 2013

Dec. 29, 2012

Dec. 28, 2013

Dec. 29, 2012

Dec. 28, 2013

Dec. 29, 2012

Dec. 28, 2013

Dec. 29, 2012

Dec. 28, 2013

Dec. 29, 2012

Dec. 28, 2013

Dec. 29, 2012

Dec. 28, 2013

USD ($)

Term loan due 2015 [Member]

2.50% Senior Notes Due 2016 [Member]

Three point twenty-five percent Senior Notes Due Two Thousand Twenty-three [Member]

Four point seventy-five percent Senior Notes Due Two Thousand Fourty-three [Member] [Member]

3.75% Senior Notes Due 2014 [Member]

4.875% Senior Notes Due 2019 [Member]

2.20% Senior Notes Due 2013 [Member]

1.58% Yen-Denominated Senior Notes Due 2017 [Member]

2.04% Yen-Denominated Senior Notes Due 2020 [Member]

Yen Denominated Credit Facilities [Member]

Yen Denominated Credit Facility One [Member]

Yen Denominated Credit Facility Two [Member]

Commercial paper borrowings [Member]

Japan, Yen

United States Currency Rate

Scheduled Maturity of May 2018 [Member]

Scheduled Maturity of February 2015 [Member]

USD ($)

JPY (¥)

USD ($)

JPY (¥)

USD ($)

JPY (¥)

USD ($)

Term loan due 2015 [Member]

Credit Facility [Member]

United States Currency Rate

Credit Facility [Member]

USD ($)

Credit Facility [Member]

USD ($)

Debt Instrument [Line Items]

Expected minimum principal payments in 2014

$62,000,000

Expected minimum principal payments in 2015

500,000,000

Expected minimum principal payments in 2016

500,000,000

Expected minimum principal payments in 2017

78,000,000

Expected minimum principal payments in 2018

714,000,000

Expected minimum principal payments thereafter

1,722,000,000

Debt Instrument, Face Amount

500,000,000

900,000,000

700,000,000

500,000,000

450,000,000

78,000,000

8,100,000,000

95,000,000

122,000,000

12,800,000,000

149,000,000

Debt instrument term, years

'2 years

'5 years

'10 years

'30 years

'5 years

'10 years

'3 years

'7 years

'10 years

Debt instrument, stated percentage rate

2.50%

3.25%

4.75%

3.75%

4.88%

2.20%

1.58%

2.04%

Make-whole redemption charge

161,000,000

Debt instrument, due date

26-Jun-15

15-Jan-16

15-Apr-23

15-Apr-43

15-Sep-13

28-Apr-17

28-Apr-20

30-Jun-14

10-Mar-14

31-May-18

Debt Instrument, Description of Variable Rate Basis

'Yen LIBOR

'LIBOR

Debt instrument, effective interest rate

2.54%

3.31%

4.79%

Interest rate swap term, years

'5 years

Notional amount interest rate swap designated as a fair value hedge

500,000,000

Proceeds from termination of interest rate swap

24,000,000

Net average interest rate

1.30%

Outstanding balance under yen denominated credit facilities

62,000,000

6,500,000,000

76,000,000

Maximum borrowing capacity

11,250,000,000

Debt instrument basis spread

0.50%

0.28%

0.25%

0.80%

Unused borrowing capacity

1,500,000,000

Maximum days commercial paper program provides for the issuance of short-term, unsecured commercial paper

270

Total Debt

$3,580,000,000

$3,080,000,000

$500,000,000

$512,000,000

$518,000,000

$896,000,000

$696,000,000

$699,000,000

$496,000,000

$454,000,000

$78,000,000

$95,000,000

$122,000,000

$149,000,000

$62,000,000

$76,000,000

$714,000,000

$593,000,000

Weighted average effective interest rate

0.24%

Commitments_And_Contingencies_

Commitments And Contingencies (Narrative) (Details) (USD $)

12 Months Ended

In Millions, unless otherwise specified

Dec. 28, 2013

Dec. 29, 2012

Dec. 31, 2011

Dec. 28, 2013

Jul. 15, 2013

Apr. 29, 2013

Apr. 04, 2013

Dec. 28, 2013

Jun. 30, 2012

Dec. 28, 2013

Dec. 29, 2012

Dec. 28, 2013

Sep. 28, 2013

Dec. 28, 2013

Riata Litigation [Member]

Silzone Product Liability Insurance [Member]

Superior Court of California case for Los Angeles City and County [Member]

U.S. District Court for the Central District of California [Member]

Ontario Class Action Matters [Member]

Individual Ontario Case [Member]

VolcanoCorpvs.Lightlab [Member]

Regulatory Matters Sylmar, CA [Member]

Federal Court [Member]

State Court [Member]

Riata Litigation [Member]

Silzone Litigation [Member]

Riata Litigation [Member]

U.S. District Court for the Central District of California [Member]

U.S. District Court for the District of Minnesota [Member]

U.S. District Court for the District of South Carolina [Member]

U.S. District Court for the Northern District of New York [Member]

U.S. District Court for the Western District of New York [Member]

U.S. District Court for the Middle District of Florida [Member]

U.S. District Court for the Western District of Kentucky [Member]

U.S. District Court for the Southern District of West Virginia [Member]

Riata Litigation [Member]

Minnesota [Member]

California [Member]

Indiana [Member]

Georgia [Member]

Kentucky [Member]

Riata Litigation [Member]

Commitments And Contingencies [Line Items]

Operating Leases, Future Minimum Payments Due, Next Twelve Months

$30

Operating Leases, Future Minimum Payments, Due in Two Years

Operating Leases, Future Minimum Payments, Due in Three Years

Operating Leases, Future Minimum Payments, Due in Four Years

Operating Leases, Future Minimum Payments, Due in Five Years

Operating Leases, Future Minimum Payments, Due Thereafter

Operating Leases, Rent Expense

Number of lawsuits outstanding

Number of multi-plaintiff lawsuits outstanding, excluding class action lawsuits

Number of plaintiffs to exceed in one lawsuit to result in a multi-plaintiff case

Number of claimants in lawsuit

Number of outstanding class actions

Number of lawsuits outstanding, excluding class action lawsuits

Number of common class issues in class action suit

Minimum damage loss claimed

Remaining insurance coverage for Silzone claims

$10

days of legal notice

Number of Form 483 Observations

Shareholders_Equity_Shareholde

Shareholders' Equity Shareholders' Equity (Details) (USD $)

1 Months Ended

2 Months Ended

3 Months Ended

12 Months Ended

In Millions, except Per Share data, unless otherwise specified

Dec. 28, 2013

Jan. 17, 2014

Feb. 01, 2013

Dec. 29, 2012

Nov. 06, 2012

Aug. 29, 2011

Jan. 20, 2011

Feb. 01, 2013

Feb. 08, 2012

Mar. 29, 2014

Jan. 20, 2011

Jan. 01, 2011

Dec. 28, 2013

Dec. 29, 2012

Dec. 31, 2011

Equity [Abstract]

Stock Repurchase Program, Authorized Amount

$700

$300

$500

$1,000

$300

$600

Stock Repurchased During Period, Shares

4.4

11.1

13.9

12.9

7.7

11.7

6.6

26.8

7.1

Stock Repurchased During Period, Value

$266

$700

$542

$458

$300

$500

$275

$1,000

$300

$900

$808

$1,058

$775

Treasury Stock Acquired, Average Cost Per Share

$60.18

$63.07

$38.83

$35.60

$38.97

$42.79

$41.44

$37.27

$42.14

$40.87

Common Stock, Dividends, Per Share, Cash Paid

$0.27

$0.25

$0.23

$0.21

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income - Schedule of Accumulated Other Comprehensive Income (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011	Jan. 01, 2011
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Accumulated Other Comprehensive Income (Loss), Net of Tax	$46	$46	$16	$84
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	8	38	-68	'
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	-8	-8	0	'
Other Comprehensive Income (Loss), Net of Tax	0	30	-68	'
Accumulated Net Unrealized Investment Gain (Loss) [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Accumulated Other Comprehensive Income (Loss), Net of Tax	17	20	18	15
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	5	10	3	'
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	-8	-8	0	'
Other Comprehensive Income (Loss), Net of Tax	-3	2	3	'
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Accumulated Other Comprehensive Income (Loss), Net of Tax	3	0	0	0
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	3	0	0	'
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	0	0	0	'
Other Comprehensive Income (Loss), Net of Tax	3	0	0	'
Accumulated Translation Adjustment [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Accumulated Other Comprehensive Income (Loss), Net of Tax	26	26	-2	69
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	0	28	-71	'
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	0	0	0	'
Other Comprehensive Income (Loss), Net of Tax	$0	$28	($71)	'

Accumulated_Other_Comprehensiv3

Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income - Reclassification out of Accumulated Other Comprehensive Income (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Available-for-Sale Securities [Line Items]	'	'	'
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax	($5)	($6)	$0
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax	-8	-8	0
Other Expense [Member]	'	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Available-for-Sale Securities [Line Items]	'	'	'
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax	13	14	0
Income Tax Expense [Member]	'	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Available-for-Sale Securities [Line Items]	'	'	'
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax	-5	-6	0
Net Income (Loss) Before Noncontrolling Interest [Member]	'	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Available-for-Sale Securities [Line Items]	'	'	'
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax	8	8	0
Net Income (Loss) attributable to St. Jude Medical, Inc. [Member]	'	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Available-for-Sale Securities [Line Items]	'	'	'
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax	$8	$8	$0

Stockbased_Compensation_Stockb1

Stock-based Compensation Stock-based compensation (Total Stock Compensation Expense) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock-based compensation	$65	$69	$76
Selling General And Administrative Expense [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock-based compensation	45	49	55
Research and Development Expense [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock-based compensation	15	15	15
Cost of Sales [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock-based compensation	$5	$5	$6

Stockbased_Compensation_Stock_

Stock-based Compensation Stock Based Compensation (Assumptions Table) (Details) (USD $)	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$13.83	$7.71	$9.17
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	'5 years 4 months 24 days	'5 years 4 months 24 days	'5 years 6 months
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.60%	0.70%	0.90%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	28.60%	31.15%	33.90%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	1.75%	2.49%	2.00%

Stockbased_Compensation_Stockb2

Stock-based Compensation Stock-based Compensation (Summary of Option Activity) (Details) (USD $)	12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 28, 2013	Dec. 29, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	18.9	28.2
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$39.94	$38.05
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	'5 years 3 months 18 days	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	$422	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	2.7	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$59.16	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	-10.6	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	$39.83	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period	-1.4	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price	$40.05	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	18.2	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	$39.70	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	'5 years 2 months 12 days	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	409	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	10.6	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$37.07	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	'4 years 1 month 6 days	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	$267	'

Stockbased_Compensation_Stock_1

Stock-based Compensation Stock Based Compensation (Restricted Stock & Unit Activity) (Details) (Restricted Stock Awards and Restricted Stock Units [Member], USD $)	12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 28, 2013	Dec. 29, 2012
Restricted Stock Awards and Restricted Stock Units [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	1.6	1.6
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value	$45.98	$36.61
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	0.7	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$58.32	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	-0.5	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value	$37.45	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	-0.2	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value	$36.96	'

Stockbased_Compensation_Stockb3

Stock-based Compensation Stock-based compensation Narrative (Details) (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
	M	Dec. 29, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	15,700,000	'	'
Shares Available For Option Grants In Lieu Of Restricted Stock Grants	13,900,000	'	'
Shares Available For Restricted Stock Grants Two Thousand Seven Plan	6,200,000	'	'
Reduction In The Number Of Shares Available For Certain Grants Of Restricted Stock Units Or Awards	2.25	'	'
Shares Available For Option Grants In Lieu Of Restricted Stock Grants	100,000	'	'
Shares Available For Restricted Stock Grants	100,000	'	'
Shares Available For Only Option Grants	1,700,000	'	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	$149	'	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	'2 years 10 months 24 days	'	'
Employee Stock Purchase Plan Offering Period	12	'	'
Employee Stock Purchase Plan Employee Price Paid As A Percent Of Market Price	85.00%	'	'
Stock Issued During Period, Shares, Employee Stock Purchase Plans	900,000	900,000	900,000
Employee Stock Purchase Plan Outstanding Common Shares Available For Grant	5,800,000	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value	125	14	96
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Total Fair Value	$18	$11	$7
Restricted Stock [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$42.26	$37.63	$49.77
Restricted Stock Units [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$59.04	$35.39	$35.14
Employee Stock [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$13.06	$9.39	$10.86

Special_Charges_Narrative_Deta

Special Charges (Narrative) (Details) (USD $)

3 Months Ended

12 Months Ended

In Millions, unless otherwise specified

Mar. 31, 2012

Dec. 28, 2013

Dec. 29, 2012

Dec. 31, 2011

Dec. 28, 2013

Dec. 31, 2011

Dec. 28, 2013

Dec. 29, 2012

Dec. 28, 2013

Dec. 29, 2012

Dec. 31, 2011

Dec. 28, 2013

Dec. 29, 2012

Dec. 28, 2013

Dec. 29, 2012

Dec. 28, 2013

Dec. 29, 2012

Dec. 31, 2011

Jan. 01, 2011

Dec. 28, 2013

Dec. 29, 2012

Dec. 31, 2011

Jan. 01, 2011

Dec. 29, 2012

Dec. 31, 2011

Dec. 29, 2012

Dec. 31, 2011

Dec. 29, 2012

Dec. 31, 2011

Dec. 28, 2013

Dec. 29, 2012

Dec. 31, 2011

Jan. 01, 2011

Dec. 28, 2013

Dec. 29, 2012

Dec. 31, 2011

Jan. 01, 2011

Dec. 28, 2013

Dec. 29, 2012

Dec. 31, 2011

Jan. 01, 2011

Dec. 31, 2011

Dec. 29, 2012

Dec. 31, 2011

Dec. 28, 2013

Dec. 29, 2012

Dec. 31, 2011

Dec. 28, 2013

Dec. 29, 2012

Dec. 31, 2011

Dec. 28, 2013

Dec. 29, 2012

Dec. 28, 2013

Dec. 29, 2012

Dec. 31, 2011

Dec. 28, 2013

Dec. 29, 2012

Dec. 31, 2011

Dec. 28, 2013

Dec. 29, 2012

Dec. 31, 2011

Dec. 28, 2013

Dec. 29, 2012

Dec. 28, 2013

Dec. 29, 2012

Dec. 31, 2011

Dec. 28, 2013

Dec. 29, 2012

Dec. 31, 2011

Dec. 28, 2013

Dec. 29, 2012

Dec. 31, 2011

Dec. 28, 2013

Dec. 29, 2012

Dec. 31, 2011

Dec. 28, 2013

Dec. 29, 2012

Dec. 31, 2011

Dec. 28, 2013

Dec. 29, 2012

Dec. 28, 2013

Dec. 29, 2012

Dec. 28, 2013

Dec. 29, 2012

Dec. 28, 2013

Dec. 29, 2012

Dec. 28, 2013

Dec. 29, 2012

Dec. 28, 2013

Dec. 29, 2012

Dec. 28, 2013

Dec. 29, 2012

Dec. 31, 2011

Dec. 28, 2013

Dec. 29, 2012

Dec. 31, 2011

Dec. 28, 2013

Dec. 29, 2012

Dec. 31, 2011

Dec. 28, 2013

Dec. 29, 2012

Dec. 31, 2011

Dec. 28, 2013

Dec. 29, 2012

Dec. 31, 2011

Dec. 28, 2013

Dec. 29, 2012

Dec. 28, 2013

Dec. 29, 2012

Dec. 28, 2013

Dec. 29, 2012

Dec. 28, 2013

Dec. 29, 2012

Dec. 28, 2013

Dec. 29, 2012

Dec. 28, 2013

Intangible Asset Charges [Member]

Licensing Agreements [Member]

Other Restructuring [Member]

product quality action cost [Member]

Field Action Cost IESD [Member]

Customer Lists And Relationships [Member]

2011 Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

Operating Expense [Member]

Cost of Sales [Member]

Research agreement termination cost [Member]

CATD [Member]

Neuromodulation [Member]

Intangible Asset Charges [Member]

Other Restructuring [Member]

Contract Termination [Member]

Facility Closing [Member]

Employee Termination Costs [Member]

Inventory Charges [Member]

Fixed Asset Charges [Member]

Other Costs [Member]

Other Restructuring [Member]

Contract Termination [Member]

Employee Termination Costs [Member]

Inventory Charges [Member]

Fixed Asset Charges [Member]

Other Costs [Member]

2011 Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

Field Action Cost IESD [Member]

2011 Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

IESD [Member]

Other Restructuring [Member]

Employee Termination Costs [Member]

Inventory Charges [Member]

Fixed Asset Charges [Member]

Other Restructuring [Member]

Employee Termination Costs [Member]

Inventory Charges [Member]

Fixed Asset Charges [Member]

Other Restructuring [Member]

Employee Termination Costs [Member]

Inventory Charges [Member]

Fixed Asset Charges [Member]

Other Restructuring [Member]

Employee Termination Costs [Member]

Inventory Charges [Member]

Fixed Asset Charges [Member]

Contract Termination [Member]

Restructuring Cost and Reserve [Line Items]

Research and Development Asset Acquired Other than Through Business Combination, Written-off

Special charges

102

162

220

185

115

185

161

Severance And Benefit Costs Number Of Employees Impacted For Exit and Disposal Activities

650

Severance and benefits costs, number of employees impacted

100

550

Severance and benefit costs

109

104

Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date Percent

5.00%

Special charges, inventory obsolescence charges

Other asset impairment charges

Restructuring reserve period expense

102

Pension settlement charges

Idle facility costs

Restructuring Reserve, Settled without Cash

-1

-17

-47

-4

-1

-13

-20

-1

-26

-47

-61

-4

-3

-30

-17

-13

-41

Payments for Restructuring

-50

-115

-42

-29

-47

-15

-21

-68

-27

-152

-59

-73

-7

-79

-52

Loss Contingency, Loss in Period

Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)

Intangible asset impairment charges, Finite-li

Legal settlement charge

Purchased technology and patents

Restructuring Reserve, Translation Adjustment

-1

Restructuring Reserve

$15

$42

$72

$17

$18

$25

$54

$87

$66

$33

$54

$58

Special_Charges_Summary_Of_Act

Special Charges (Summary Of Activity Related To Special Charge Restructuring Accrual) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
2011 Restructuring Plan [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Balance at beginning	$42	$72	$0
Special charges	24	102	162
Non-cash charges used	-1	-17	-47
Cash payments	-50	-115	-42
Foreign exchange rate impact	0	0	-1
Balance at ending	15	42	72
2011 Restructuring Plan [Member] \| Employee Termination Costs [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Balance at beginning	25	54	0
Special charges, severance and benefit costs	5	38	82
Non-cash charges used	0	0	0
Cash payments	-21	-68	-27
Foreign exchange rate impact	0	1	-1
Balance at ending	9	25	54
2011 Restructuring Plan [Member] \| Inventory Charges [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Balance at beginning	0	0	0
Non-cash charges used	0	-13	-20
Cash payments	0	0	0
Foreign exchange rate impact	0	0	0
Balance at ending	0	0	0
2011 Restructuring Plan [Member] \| Fixed Asset Charges [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Balance at beginning	0	0	0
Special charges, fixed asset impairment charges	'	'	26
Non-cash charges used	-1	0	-26
Cash payments	0	0	0
Foreign exchange rate impact	0	0	0
Balance at ending	0	0	0
2011 Restructuring Plan [Member] \| Other Restructuring [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Balance at beginning	17	18	0
Special charges, other	18	51	34
Non-cash charges used	0	-4	-1
Cash payments	-29	-47	-15
Foreign exchange rate impact	0	-1	0
Balance at ending	6	17	18
2012 Business Realignment Restructuring Plan [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Balance at beginning	66	0	'
Special charges	220	185	'
Non-cash charges used	-47	-61	'
Cash payments	-152	-59	'
Foreign exchange rate impact	0	1	'
Balance at ending	87	66	'
2012 Business Realignment Restructuring Plan [Member] \| Employee Termination Costs [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Balance at beginning	58	0	'
Special charges, severance and benefit costs	75	109	'
Non-cash charges used	0	0	'
Cash payments	-79	-52	'
Foreign exchange rate impact	0	1	'
Balance at ending	54	58	'
2012 Business Realignment Restructuring Plan [Member] \| Inventory Charges [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Balance at beginning	0	0	'
Non-cash charges used	-30	-17	'
Cash payments	0	0	'
Foreign exchange rate impact	0	0	'
Balance at ending	0	0	'
2012 Business Realignment Restructuring Plan [Member] \| Fixed Asset Charges [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Balance at beginning	0	0	'
Non-cash charges used	-13	-41	'
Cash payments	0	0	'
Foreign exchange rate impact	0	0	'
Balance at ending	0	0	'
2012 Business Realignment Restructuring Plan [Member] \| Other Restructuring [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Balance at beginning	8	0	'
Special charges, other	102	18	'
Non-cash charges used	-4	-3	'
Cash payments	-73	-7	'
Foreign exchange rate impact	0	0	'
Balance at ending	33	8	'
Cost of Sales [Member] \| 2011 Restructuring Plan [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Special charges	0	44	47
Cost of Sales [Member] \| 2011 Restructuring Plan [Member] \| Employee Termination Costs [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Special charges, severance and benefit costs	0	11	9
Cost of Sales [Member] \| 2011 Restructuring Plan [Member] \| Inventory Charges [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Special charges, inventory obsolescence charges	0	13	20
Cost of Sales [Member] \| 2011 Restructuring Plan [Member] \| Fixed Asset Charges [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Special charges, fixed asset impairment charges	0	0	9
Cost of Sales [Member] \| 2011 Restructuring Plan [Member] \| Other Restructuring [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Special charges, other	0	20	9
Cost of Sales [Member] \| 2012 Business Realignment Restructuring Plan [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Special charges	35	24	'
Cost of Sales [Member] \| 2012 Business Realignment Restructuring Plan [Member] \| Employee Termination Costs [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Special charges, severance and benefit costs	0	5	'
Cost of Sales [Member] \| 2012 Business Realignment Restructuring Plan [Member] \| Inventory Charges [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Special charges, inventory obsolescence charges	30	17	'
Cost of Sales [Member] \| 2012 Business Realignment Restructuring Plan [Member] \| Fixed Asset Charges [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Special charges, fixed asset impairment charges	0	0	'
Cost of Sales [Member] \| 2012 Business Realignment Restructuring Plan [Member] \| Other Restructuring [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Special charges, other	5	2	'
Operating Expense [Member] \| 2011 Restructuring Plan [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Special charges	24	58	115
Operating Expense [Member] \| 2011 Restructuring Plan [Member] \| Employee Termination Costs [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Special charges, severance and benefit costs	5	27	73
Operating Expense [Member] \| 2011 Restructuring Plan [Member] \| Inventory Charges [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Special charges, inventory obsolescence charges	0	0	0
Operating Expense [Member] \| 2011 Restructuring Plan [Member] \| Fixed Asset Charges [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Special charges, fixed asset impairment charges	1	0	17
Operating Expense [Member] \| 2011 Restructuring Plan [Member] \| Other Restructuring [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Special charges, other	18	31	25
Operating Expense [Member] \| 2012 Business Realignment Restructuring Plan [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Special charges	185	161	'
Operating Expense [Member] \| 2012 Business Realignment Restructuring Plan [Member] \| Employee Termination Costs [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Special charges, severance and benefit costs	75	104	'
Operating Expense [Member] \| 2012 Business Realignment Restructuring Plan [Member] \| Inventory Charges [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Special charges, inventory obsolescence charges	0	0	'
Operating Expense [Member] \| 2012 Business Realignment Restructuring Plan [Member] \| Fixed Asset Charges [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Special charges, fixed asset impairment charges	13	41	'
Operating Expense [Member] \| 2012 Business Realignment Restructuring Plan [Member] \| Other Restructuring [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Special charges, other	$97	$16	'

Other_Expense_Net_Schedule_Of_

Other Expense, Net (Schedule Of Other Expense, Net) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Other Nonoperating Income (Expense) [Abstract]	'	'	'
Interest income	($5)	($5)	($4)
Interest expense	81	73	70
Other	191	27	30
Other expense, net	$267	$95	$96

Other_Expense_Net_Other_Expens

Other Expense, Net Other Expense, Net Narrative (Details) (USD $)	12 Months Ended				3 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011	2-May-13	Mar. 30, 2013	Dec. 28, 2013	Jun. 29, 2013	Dec. 28, 2013	Jun. 29, 2013
	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011	2-May-13	Cardiomems [Member]	Three point seven five percent Senior Notes Due Two Thousand Fourteen [Member]	Three point seven five percent Senior Notes Due Two Thousand Fourteen [Member]	Four point eight seven five percent Senior Notes Due Two Thousand Nineteen [Member]	Four point eight seven five percent Senior Notes Due Two Thousand Nineteen [Member]
Debt Instrument, Face Amount	'	'	'	'	'	$700	$700	$500	$500
Make-whole redemption charge	'	'	'	161	'	'	'	'	'
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Loss	'	'	'	'	29	'	'	'	'
Pre-tax gain on sale of investment	$13	$14	$0	'	'	'	'	'	'

Income_Taxes_Income_Taxes_Sche

Income Taxes Income Taxes (Schedule of Income before Income Tax, Domestic and Foreign) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
U.S.	($17)	$316	$502
International	801	689	517
Earnings before income taxes and noncontrolling interest	$784	$1,005	$1,019

Income_Taxes_Income_Taxes_Sche1

Income Taxes Income Taxes (Schedule of Components of Income Tax Expense) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
U.S. federal	$101	$236	$180
U.S. state and other	7	16	13
International	108	78	65
Current Income Tax Expense (Benefit)	216	330	258
Deferred Income Tax Expense (Benefit)	-124	-77	-65
Income tax expense	$92	$253	$193

Income_Taxes_Income_Taxes_Sche2

Income Taxes Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details) (USD $)	Dec. 28, 2013	Dec. 29, 2012
In Millions, unless otherwise specified	Dec. 28, 2013	Dec. 29, 2012
Income Tax Disclosure [Abstract]	'	'
Operating Loss And Capital Loss Carryforwards	$402	$236
Tax Credit Carryforward, Deferred Tax Asset	75	70
Deferred Tax Assets, Inventory	136	148
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost	47	78
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits	123	113
Deferred Tax Asset, Research and Development capitalized for tax purposes	112	0
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities	130	133
Deferred Tax Assets, Gross	1,025	778
Deferred Tax Assets, Valuation Allowance	-368	-228
Deferred Tax Assets, Net of Valuation Allowance	657	550
Deferred Tax Liabilities, Other Comprehensive Income	-11	-12
Deferred Tax Liabilities, Property, Plant and Equipment	-189	-204
Deferred Tax Liabilities, Intangible Assets	-352	-307
Deferred Tax Liabilities, Gross	-552	-523
Deferred Tax Assets, Net	$105	$27

Income_Taxes_Income_Taxes_Sche3

Income Taxes Income Taxes (Schedule of Effective Income Tax Reconciliation) (Details)	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
U.S. federal statutory tax rate	35.00%	35.00%	35.00%
U.S. state income taxes, net of federal tax benefit	0.60%	0.50%	1.20%
International taxes at lower rates	-13.60%	-12.10%	-11.60%
Tax benefits from domestic manufacturer's deduction	-1.90%	-2.20%	-2.00%
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent	-4.60%	-1.10%	-2.70%
Puerto Rico excise tax	-3.00%	-1.80%	-1.70%
Tax settlements	-1.90%	4.60%	0.00%
Noncontrolling interest	3.60%	0.00%	0.00%
Effective Income Tax Rate Reconciliation, Other Adjustments	-2.50%	2.30%	0.80%
Effective Income Tax Rate, Continuing Operations	11.70%	25.20%	19.00%

Income_Taxes_Income_Taxes_Sche4

Income Taxes Income Taxes (Schedule of Unrecognized Tax Benefits Rollforward) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011	Jan. 01, 2011
Income Tax Disclosure [Abstract]	'	'	'	'
Unrecognized Tax Benefits	$315	$314	$205	$163
Unrecognized Tax Benefits, Increases Related to Current Period Tax Positions	74	38	33	'
Unrecognized Tax Benefits, Increases Related to Prior Period Tax Positions	33	90	16	'
Unrecognized Tax Benefits, Reductions Related to Prior Period Tax Positions	-16	-18	-1	'
Unrecognized Tax Benefits, Reductions related to Settlements/Payments	-90	-1	-2	'
Unrecognized Tax Benefits, Expiration of the statute of limitations for the assessment of taxes	$0	$0	($4)	'

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	12 Months Ended
Income Taxes (Narrative) (Details) (USD $)	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Income Taxes [Line Items]	'	'	'
Deferred Tax Assets, Valuation Allowance	$368,000,000	$228,000,000	'
Undistributed Foreign Earnings	3,600,000,000	'	'
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense	2,000,000	22,000,000	1,000,000
Accrued interest and penalties	37,000,000	69,000,000	35,000,000
Domestic Tax Authority [Member]	'	'	'
Income Taxes [Line Items]	'	'	'
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	22,000,000	'	'
Tax Credit Carryforward, Amount	4,000,000	'	'
State and Local Jurisdiction [Member]	'	'	'
Income Taxes [Line Items]	'	'	'
Tax Credit Carryforward, Amount	71,000,000	'	'
Foreign Tax Authority [Member]	'	'	'
Income Taxes [Line Items]	'	'	'
Operating Loss Carryforwards, Foreign	$380,000,000	'	'

Retirement_Plans_Details

Retirement Plans (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Retirement Plans [Abstract]	'	'	'
Defined Contribution Plan, Cost Recognized	$26	$26	$23
Deferred Compensation Liability, Classified, Noncurrent	282	234	'
Defined Benefit Pension Plan, Liabilities, Noncurrent	17	16	'
Defined Benefit Plan, Settlements, Benefit Obligation	'	'	31
Pension settlement charges	'	'	$13

Fair_Value_Measurements_And_Fi2

Fair Value Measurements And Financial Instruments Fair Value Measurements Recurring Basis Table (Details) (USD $)	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
In Millions, unless otherwise specified	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Total assets	$1,189	$1,236	'
Fair value of acquisition contingent consideration	188	0	0
Liabilities, Fair Value Disclosure, Recurring	195	'	'
Quoted Prices In Active Markets (Level 1) [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Total assets	1,189	1,236	'
Liabilities, Fair Value Disclosure, Recurring	0	'	'
Significant Other Observable Inputs (Level 2) [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Total assets	0	0	'
Liabilities, Fair Value Disclosure, Recurring	0	'	'
Significant Unobservable Inputs (Level 3) [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Total assets	0	0	'
Liabilities, Fair Value Disclosure, Recurring	195	'	'
Contingent Consideration Liability [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Fair value of acquisition contingent consideration	195	'	'
Contingent Consideration Liability [Member] \| Quoted Prices In Active Markets (Level 1) [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Fair value of acquisition contingent consideration	0	'	'
Contingent Consideration Liability [Member] \| Significant Other Observable Inputs (Level 2) [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Fair value of acquisition contingent consideration	0	'	'
Contingent Consideration Liability [Member] \| Significant Unobservable Inputs (Level 3) [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Fair value of acquisition contingent consideration	195	0	'
Cash and Cash Equivalents [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Money Market Securities Fair Value Disclosure	875	964	'
Cash and Cash Equivalents [Member] \| Quoted Prices In Active Markets (Level 1) [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Money Market Securities Fair Value Disclosure	875	964	'
Cash and Cash Equivalents [Member] \| Significant Other Observable Inputs (Level 2) [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Money Market Securities Fair Value Disclosure	0	0	'
Cash and Cash Equivalents [Member] \| Significant Unobservable Inputs (Level 3) [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Money Market Securities Fair Value Disclosure	0	0	'
Other Current Assets [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Available-for-sale Securities, Fair Value Disclosure	35	41	'
Other Current Assets [Member] \| Quoted Prices In Active Markets (Level 1) [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Available-for-sale Securities, Fair Value Disclosure	35	41	'
Other Current Assets [Member] \| Significant Other Observable Inputs (Level 2) [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Available-for-sale Securities, Fair Value Disclosure	0	0	'
Other Current Assets [Member] \| Significant Unobservable Inputs (Level 3) [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Available-for-sale Securities, Fair Value Disclosure	0	0	'
Other Assets [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Trading Securities, Fair Value Disclosure	279	231	'
Other Assets [Member] \| Quoted Prices In Active Markets (Level 1) [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Trading Securities, Fair Value Disclosure	279	231	'
Other Assets [Member] \| Significant Other Observable Inputs (Level 2) [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Trading Securities, Fair Value Disclosure	0	0	'
Other Assets [Member] \| Significant Unobservable Inputs (Level 3) [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Trading Securities, Fair Value Disclosure	$0	$0	'

Fair_Value_Measurements_And_Fi3

Fair Value Measurements And Financial Instruments Fair Value Measurements, Fair Value Inputs, Liabilities, Quantitative Information (Details) (USD $)

Dec. 28, 2013

Dec. 29, 2012

Dec. 31, 2011

Dec. 28, 2013

Dec. 29, 2012

Dec. 28, 2013

Dec. 29, 2012

Dec. 28, 2013

Dec. 29, 2012

In Millions, unless otherwise specified

Contingent Consideration Liability [Member]

Endosense S.A. [Member]

Nanostim [Member]

Fair Value, Inputs, Level 3 [Member]

Minimum [Member]

Maximum [Member]

Contingent Consideration Liability [Member]

Fair Value, Inputs, Level 3 [Member]

Contingent Consideration Liability [Member]

Fair Value, Inputs, Level 3 [Member]

Payment Year 1 [Member]

Payment Year 2 [Member]

Payment Year 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value Inputs, Liabilities, Quantitative Information [Line Items]

Fair value of acquisition contingent consideration

$188

$195

$139

$56

Fair Value Inputs, Discount Rate

1.15%

1.59%

5.00%

Probability of Payment

90.00%

100.00%

Projected Year Of Payment

'2014

'2016

'2017

'2018

Fair_Value_Measurements_And_Fi4

Fair Value Measurements And Financial Instruments Fair Value Measurements and Financial Instruments, (Fair Value, Liabilities Measured on a Recurring Basis, Unobservable Input Reconciliation) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Contingent Consideration Liability [Roll Forward]	'	'	'
Balance as of December 29, 2012	$0	$0	'
Change in fair value of contingent consideration	1	0	0
Balance as of December 28, 2013	188	0	0
Endosense S.A. [Member] \| Fair Value, Inputs, Level 3 [Member]	'	'	'
Projected Year Of Payment	'2014	'	'
Contingent Consideration Liability [Member]	'	'	'
Contingent Consideration Liability [Roll Forward]	'	'	'
Balance as of December 28, 2013	195	'	'
Contingent Consideration Liability [Member] \| Fair Value, Inputs, Level 3 [Member]	'	'	'
Contingent Consideration Liability [Roll Forward]	'	'	'
Balance as of December 29, 2012	0	'	'
Purchase price contingent consideration	188	'	'
Change in fair value of contingent consideration	1	'	'
Foreign currency translation	6	'	'
Balance as of December 28, 2013	195	'	'
Contingent Consideration Liability [Member] \| Endosense S.A. [Member] \| Fair Value, Inputs, Level 3 [Member]	'	'	'
Contingent Consideration Liability [Roll Forward]	'	'	'
Balance as of December 29, 2012	0	'	'
Purchase price contingent consideration	132	'	'
Change in fair value of contingent consideration	1	'	'
Foreign currency translation	6	'	'
Balance as of December 28, 2013	139	'	'
Contingent Consideration Liability [Member] \| Nanostim [Member] \| Fair Value, Inputs, Level 3 [Member]	'	'	'
Contingent Consideration Liability [Roll Forward]	'	'	'
Balance as of December 29, 2012	0	'	'
Purchase price contingent consideration	56	'	'
Change in fair value of contingent consideration	0	'	'
Foreign currency translation	0	'	'
Balance as of December 28, 2013	$56	'	'

Fair_Value_Measurements_And_Fi5

Fair Value Measurements And Financial Instruments (Narrative) (Details) (USD $)

Dec. 28, 2013

Dec. 29, 2012

Dec. 28, 2013

Dec. 31, 2011

Sep. 29, 2012

Dec. 29, 2012

Dec. 31, 2011

Dec. 28, 2013

Dec. 29, 2012

Dec. 31, 2011

Dec. 28, 2013

Dec. 29, 2012

In Millions, unless otherwise specified

Intangible Asset Charges [Member]

Neuromodulation [Member]

Cardiac Rhythm Management [Member]

CATD [Member]

2011 Restructuring Plan [Member]

Customer Lists And Relationships [Member]

Intangible Asset Charges [Member]

Fixed Asset Charges [Member]

Cardiac Rhythm Management [Member]

Intangible Asset Charges [Member]

Fixed Asset Charges [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

cash equivalents at carrying value excluding money market securities

$498

$230

Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)

Other asset impairment charges

Estimated fair value after write-down

Impairment of Intangible Assets, Finite-lived

Fair Value, Estimate Not Practicable, Cost Method Investments

151

Aggregate fair value, fixed-rate debt obligations

2,236

Aggregate carrying value, fixed-rate debt obligations

2,304

Aggregate carrying value, other debt obligations

$1,276

Derivative_Financial_Instrumen1

Derivative Financial Instruments (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011	Dec. 28, 2013	Jun. 30, 2012	Apr. 02, 2013	Apr. 02, 2013
	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011	2.50% Senior Notes Due 2016 [Member]	2.50% Senior Notes Due 2016 [Member]	Three point twenty-five percent Senior Notes Due Two Thousand Twenty-three [Member]	Four point seventy-five percent Senior Notes Due Two Thousand Fourty-three [Member] [Member]
Derivatives, Fair Value [Line Items]	'	'	'	'	'	'	'
The net amount of gains/(loss) recorded to other expense, net	$15	$7	($3)	'	'	'	'
Proceeds from termination of interest rate swap	'	'	'	'	24	'	'
Net average interest rate	'	'	'	1.30%	'	'	'
Debt Instrument, Face Amount	'	'	'	500	'	900	700
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax	$3	'	'	'	'	'	'

Segment_And_Geographic_Informa2

Segment And Geographic Information (Details) (USD $)	3 Months Ended								12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2013	Sep. 28, 2013	Jun. 29, 2013	Mar. 30, 2013	Dec. 29, 2012	Sep. 29, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	$1,422	$1,338	$1,403	$1,338	$1,372	$1,326	$1,410	$1,395	$5,501	$5,503	$5,612
Operating profit	'	'	'	'	'	'	'	'	1,051	1,100	1,115
Depreciation and amortization	'	'	'	'	'	'	'	'	297	284	296
Total assets	10,248	'	'	'	9,271	'	'	'	10,248	9,271	9,118
International, Net Sales	'	'	'	'	'	'	'	'	2,905	2,909	2,964
Long-Lived Assets	1,410	'	'	'	1,425	'	'	'	1,410	1,425	1,388
International, Long-Lived Assets	365	'	'	'	389	'	'	'	365	389	381
IESD [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	3,209	3,277	3,453
Operating profit	'	'	'	'	'	'	'	'	2,138	2,274	2,240
Depreciation and amortization	'	'	'	'	'	'	'	'	80	73	87
Total assets	2,855	'	'	'	2,320	'	'	'	2,855	2,320	2,394
CATD [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	2,292	2,226	2,159
Operating profit	'	'	'	'	'	'	'	'	1,349	1,326	1,211
Depreciation and amortization	'	'	'	'	'	'	'	'	89	91	84
Total assets	3,273	'	'	'	2,967	'	'	'	3,273	2,967	3,086
Other [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	0	0	0
Operating profit	'	'	'	'	'	'	'	'	-2,436	-2,500	-2,336
Depreciation and amortization	'	'	'	'	'	'	'	'	128	120	125
Total assets	4,120	'	'	'	3,984	'	'	'	4,120	3,984	3,638
United States [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	2,596	2,594	2,648
Long-Lived Assets	1,045	'	'	'	1,036	'	'	'	1,045	1,036	1,007
Europe [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	1,473	1,432	1,559
Long-Lived Assets	73	'	'	'	82	'	'	'	73	82	84
Japan [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	567	665	641
Long-Lived Assets	28	'	'	'	32	'	'	'	28	32	31
Asia Pacific [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	490	456	416
Long-Lived Assets	75	'	'	'	82	'	'	'	75	82	81
Other Countries [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	375	356	348
Long-Lived Assets	$189	'	'	'	$193	'	'	'	$189	$193	$185

Quarterly_Financial_Data_Quart1

Quarterly Financial Data Quarterly Financial Data Table (Details) (USD $)	3 Months Ended								12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 28, 2013	Sep. 28, 2013	Jun. 29, 2013	Mar. 30, 2013	Dec. 29, 2012	Sep. 29, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
Quarterly Financial Data [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Net sales	$1,422	$1,338	$1,403	$1,338	$1,372	$1,326	$1,410	$1,395	$5,501	$5,503	$5,612
Gross Profit	992	953	1,021	961	953	971	1,027	1,014	3,927	3,965	4,079
Net earnings attributable to St. Jude Medical, Inc.	$123	$262	$115	$223	$120	$176	$244	$212	$723	$752	$826
Earnings Per Share, Basic	$0.42	$0.91	$0.41	$0.78	$0.39	$0.56	$0.78	$0.67	$2.52	$2.40	$2.55
Earnings Per Share, Diluted	$0.42	$0.90	$0.40	$0.78	$0.39	$0.56	$0.78	$0.67	$2.49	$2.39	$2.52
Cash dividends declared per share:	$0.25	$0.25	$0.25	$0.25	$0.23	$0.23	$0.23	$0.23	$1	$0.92	$0.84

Valuation_and_Qualifying_Accou1

Valuation and Qualifying Accounts (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2013	Dec. 29, 2012		Dec. 31, 2011
Movement in Valuation Allowances and Reserves [Roll Forward]	'	'		'
Allowance for doubtful accounts, balance at end of year	$45	$47		'
Effects of changes in foreign currency translation	'	1		-3
Allowance for Doubtful Accounts [Member]	'	'		'
Movement in Valuation Allowances and Reserves [Roll Forward]	'	'		'
Allowance for doubtful accounts, balance at beginning of year	47	101		35
Charged to expense	14	6		72
Other, Additions	0	1	[1]	0
Write-offs	-16	-61	[2]	-3
Other, Deductions	0	0		-3	[1]
Allowance for doubtful accounts, balance at end of year	45	47		101
Write off related to Greek distributor [Member]	'	'		'
Movement in Valuation Allowances and Reserves [Roll Forward]	'	'		'
Write-offs	'	$55		'

[1]	In 2012 and 2011, $1 million and $(3) million, respectively, of botherb represents the effects of changes in foreign currency translation.
[2]	Uncollectible accounts written off, net of recoveries. During 2012, the Company wrote-off $55 million related to its Greek distributor, previously reserved for during the fiscal year ended December 31, 2011.

Quarterly_Financial_Data_Detai

Quarterly Financial Data (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2013	Sep. 28, 2013	Jun. 29, 2013	Mar. 30, 2013	Dec. 29, 2012	Sep. 29, 2012	Jun. 30, 2012	Mar. 31, 2012
After Tax Special Charges Associated With Restructuring and Realignment Activities	$97	$13	$34	$32	$75	$66	$27	$29
Tax Adjustments, Settlements, and Unusual Provisions	15	-15	'	-21	46	'	'	'
After Tax Make-whole Redemption Charge	'	'	101	'	'	'	'	'
After Tax Special Charges For Intangible Asset Impairment Charges	19	'	8	'	11	15	'	'
Acquisition related costs, net of tax	15	2	3	'	'	'	'	'
Licensing Agreements [Member]	'	'	'	'	'	'	'	'
After-tax loss contingency expense	'	'	14	'	'	'	'	25
Field Action Cost IESD [Member]	'	'	'	'	'	'	'	'
After-tax loss contingency expense	25	'	'	'	27	'	'	'
Cardiomems [Member]	'	'	'	'	'	'	'	'
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Loss	'	'	'	$29	'	'	'	'